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Abstract 
The emergence of antibiotic-resistant strains of Staphylococcus aureus including MRSA 
and VISA demands a modification in the attack strategy of antimicrobial agents. This prompted 
the search for novel compounds and new bacterial targets to combat infectious diseases that are 
associated with this pathogen. In this study, the major bacterial secretion pathway Sec was chosen 
as a novel target, because it has been identified as being responsible for secreting most of the 
staphylococcal proteins, which act directly and indirectly in the phases of infection processes. 
Depending on their signal sequences, the Sec-dependent proteins are directed in unfolded form 
through the bacterial membrane and displayed on the cell surface or secreted into the 
environment. We developed an approach, which should allow inhibition of secretion of a Sec-
dependent protein (V8 protease). The approach utilizes chemically constructed peptides that 
represent the 29 amino acid secretion signal peptide of V8 protease 
(MKGKFLKVSSLFVATLTTATLVSSPAANA) conjugated to a cell penetrating peptide that 
facilitates the entry of the construct into bacterial cells. The signal recognition particle (SRP), the 
ATPase motor protein (SecA), and/or the signal peptidase (SpsB) were hypothesized as possible 
targets in the Sec system. Those are known to interact with the signal peptide of the secreted 
proteins, and thus may be competitively inhibited by the constructed peptides.  
To test this hypothesis, it was necessary to chemically generate the potentially Sec-
interfering peptides, and establish appropriate assays that facilitate monitoring their effect on 
inhibiting this type of secretion. For that purpose, the fluorescein-conjugated forms of three 
known cell-penetrating peptides (CPPs) were first synthesized. The uptake efficiency to these 
peptides by S. aureus was investigated using fluorescence microscopy and FACS analysis. The 
HIV-Tat derived peptide YGRKKRRQRRRC-F5M showed the most promising properties.  
Based on this result, eight further peptidic constructs were chemically synthesized. A 
subset of these peptides contain the three different N-terminal forms of the secretion signal 
peptide of V8 protease as they may be found in prokaryotes during or after translation: with 
formylated methionine, with methionine, and without methionine, conjugated to the cell 
penetrating peptide (CPP). For control purposes, another subset of three forms of the V8 protease 
secretion signal peptide was synthesized without CPP. One construct was synthesized with a 
scrambled sequence of the secretion signal conjugated to the CPP, and one peptide was 
synthesized as unconjugated CPP. These peptide constructs were investigated with respect to their 
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ability to reduce the secretion of the Sec-dependent protein V8 protease. The secretion of V8 
protease was evaluated by Western blot analysis, which provided a valid and reproducible 
quantitative detection. The investigated peptides did not show any effect on bacterial growth and 
viability. Only one peptide (KGKFLKVSSLFVATLTTATLVSSPAANAYGRKKRRQRRR-
NH2) among the different constructs showed a concentration-dependent effect in reducing the 
secretion of V8 protease, which was inhibited by up to 40% at 40 µM. This effect was not limited 
to V8 protease secretion. Inhibition of secreted hemolysins and other proteases was also observed. 
Subcellular fractionation reveiled that treatment of the staphylococcal cells with this peptide 
showed retention of V8 protease in the cell wall and periplasm fraction, which suggests an 
interference with the transport of the protease through the cell wall after its release from the 
membrane. 
Although the underlying mode of action of this peptide in inhibiting the secretion is still 
not understood, a fluorescence-dependent analysis of the subcellular fractions showed a 
localization of the fluorescein-conjugated peptides in supernatant, cell wall and periplasm 
fraction, cytosol, and the membrane, with the highest abundance in the cytosol. 
In conclusion, this study can be regarded as a preliminary positive insight that secretion 
of bacterial virulence factors can be inhibited by synthetic peptides. Although it requires further 
study, it supports the idea that such an approach may eventually provide a new strategy for 
antimicrobial intervention. 
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Zusammenfassung 
Die Entstehung von Antibiotika-resistenten Stämmen von Staphylococcus aureus wie 
MRSA und VISA erfordert eine Änderung in der Angriffstrategie der antimikrobiellen Mittel. 
Dies veranlasste die Suche nach neuartigen Substanzen und neuen bakteriellen Targets um 
Infektionskrankheiten, die mit diesem Erreger verbunden sind, weiterhin wirksam bekämpfen zu 
können. In dieser Studie wurde der bakterielle Sekretionsweg Sec als neuartiges Ziel gewählt, da 
er für die Sekretion der meisten Staphylokokken-Proteine verantwortlich ist, die direkt und 
indirekt am Infektionsprozess beteiligt sind. In Abhängigkeit ihrer Signalpeptide werden die Sec-
abhängigen Proteine in ungefalteter Form durch die bakterielle Membran transportiert und an der 
Zelloberfläche verankert oder in die Umgebung sezerniert. Wir entwickelten einen Ansatz, der 
die Hemmung der Sekretion eines Sec-abhängigen Proteins (V8-Protease) ermöglichen sollte. 
Dieser Ansatz nutzt durch chemische Synthese erzeugte Peptide, welche das aus 29 Aminosäuren 
bestehende Sekretions-Signalpeptid der V8-Protease (MKGKFLKVSSLFVATLTTATLVSSPA-
ANA) enthalten und durch Konjugation mit einem Zell-penetrierenden Peptid (CPP) den Eintritt 
in die Bakterienzellen ermöglichen. Wir stellten die Hypothese auf, dass das 
Signalerkennungspartikel (Signal Recognition Particle, SRP), das ATPase Motorprotein (SecA) 
und/oder die Signalpeptidase (SpsB) mögliche Targets innerhalb des Sec-Systems sein könnten. 
Es ist bekannt, dass diese mit dem Signalpeptid der sekretierten Proteine wechselwirken und 
folglich durch die Peptidkonstrukte kompetitiv gehemmt werden könnten. 
Um diese Hypothese zu überprüfen war es notwendig, potenziell Sec-interferierende 
Peptide chemisch herzustellen und geeignete Assays zu entwickeln, mit denen die Inhibition der 
Sekretion untersucht werden kann. Dazu wurden zunächst die Fluoreszenz-konjugierten Formen 
von drei bekannten zellpenetrierenden Peptiden (CPP) chemisch synthetisiert. Die Aufnahme-
Effizienz dieser Peptide durch S. aureus wurde mit Hilfe der Fluoreszenzmikroskopie und FACS-
Analyse ausgewertet. Das HIV-Tat Peptid YGRKKRRQRRRC(F5M)-NH2 zeigte die 
vielversprechendsten Eigenschaften. 
Auf diesem Ergebnis basierend wurden acht weitere peptidische Konstrukte chemisch 
synthetisiert. Drei Peptide davon enthielten die unterschiedlichen N-terminalen Formen des 
Sekretions-Signalpeptids der V8 Protease, wie sie in Eukaryoten während oder nach dem 
Translationsprozess vorkommen: mit formyliertem Methionin, mit Methionin und ohne 
Methioninin, jeweils konjugiert mit dem zellpenetrierenden Peptid (CPP). Für 
Kontrolluntersuchungen wurden drei weitere Formen des V8 Protease Sekretions-Signalpeptids 
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ohne CPP, ein weiteres Peptid mit einer gemischten Aminosäuresequenz des Sekretions-
Signalpeptids in Konjugation mit CPP und ein weiteres Peptid als unkonjugiertes CPP 
synthetisiert. Die Peptide wurden bezüglich ihrer Fähigkeit, die Sekretion der Sec-abhängigen 
V8-Protease zu reduzieren, untersucht. Die Sekretion der V8-Protease wurde mittels Western Blot 
Analysen untersucht, was sich als valider und reproduzierbarer quantitativer Ansatz erwies. Die 
untersuchten Peptide zeigten keine Wirkung auf das Wachstum und die Lebensfähigkeit der 
Bakterien. Nur eines der acht Peptidkonstrukte (KGKFLKVSSLFVATLTTATLVSSPAANA-
YGRKKRRQRRR-NH2) zeigte eine konzentrationsabhängige Wirkung auf die Sekretion der V8-
Protease mit einer Inhibition von bis zu 40% bei einer Konzentration von 40 µM. Dieser Effekt 
war nicht auf die V8-Protease beschränkt, sondern wurde auch bei den sezernierten Hämolysinen 
und anderen Proteasen beobachtet. In subzellulären Fraktionierungen von S. aureus zeigte sich 
eine durch das Peptidkonstrukt bewirkte Anreicherung der V8-Protease in der Zellwand und 
periplasmatischen Fraktion, was auf eine mögliche Interferenz des Transports der Protease durch 
die Zellwand nach der Ablösung des Proteins von der Zellmembran hinweist.  
Obwohl der zugrundeliegende Wirkmechanismus dieses Peptids bei der Hemmung der 
Sekretion noch nicht verstanden ist, zeigte eine Fluoreszenz-abhängige Analyse der subzellulären 
Fraktionen eine Lokalisierung der Fluorescein-konjugierten Peptidkonstrukte im 
Wachstumsmedium, in der Zellwand-Periplasma Fraktion, im Zytosol und in der Membran, 
wobei sich die größte Menge im Zytosol befand. 
Zusammenfassend kann diese Studie als positiver Ansatz für die Inhibition der Sekretion 
bakterieller Virulenzfaktoren durch synthetische Peptide gewertet werden. Auch wenn 
vertiefende Studien notwendig sind, wird die Idee bekräftigt, dass solch ein Ansatz 
möglicherweise eine neue Strategie für eine antimikrobielle Intervention darstellt. 
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1 INTRODUCTION 
1.1 Staphylococcus aureus: commensal and pathogenic species 
Staphylococcus aureus (S. aureus), a Gram-positive bacterium, can switch between two 
distinct lifestyles: commensal and pathogenic. In the commensal form Staphylococcus aureus is 
asymptomatic. This is the case for 30–40% of 
the general population. Since this species is part 
of the human normal flora, it is mostly harbored 
in the moist and sebaceous regions of the skin, 
such as the armpit and the perineum, or in the 
lining mucous layers, of mouth cavities, anterior 
nares, and pharynx. Figure 1.1 highlights the 
physiological colonizing niches of 
Staphylococcus aureus in and on the human 
body. Today, it is the leading cause of human 
infections worldwide, not only in the hospital 
environment but also in the community [1, 2].  
Figure 1.1 Major colonization and infection sites of 
Staphylococcus aureus in and on the human body. 
1.2 Staphylococcus aureus: a major human pathogen 
The pathogenic bacterium Staphylococcus aureus has the potential to cause a wide variety 
of human diseases, ranging from superficial abscesses and wound infections to deep and systemic 
infections such as osteomyelitis, endocarditis, and septicemia. This has been attributed to a large 
number of secreted toxins and digesting enzymes as well as to the bacterial surface proteins that 
bind various host molecules. These so-called virulence factors are accessory. It has been proposed 
that these are synthesized in response to the specific needs for maintaing an appropriate 
environment during the course of the infection process [3].1  
                                                     
1 The bacterial factors and mechanisms that actively cause the damage of the host tissue are referred to as 
“virulence factors”  
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1.3 Staphylococcus aureus: infection mechanisms 
Staphylococcus aureus is an adept pathogen in eluding the defense mechanisms of the host 
through its ability in orchestrating the expression of virulence factors in two major phases, 
namely the adhesion and the invasion phases. S. aureus modifies its phenotype from adhesive to 
invasive in order to disseminate within the host, and to escape from the changeable conditions 
during the phases of infection [4, 5]. The infection is established starting with bacterial adhering 
to the host tissue [6], colonizing, building biofilm, surviving the host defense mechanisms and 
ending with crossing the tissue barriers and entering the tissues [7, 8]. In the adhesion phase, S. 
aureus promotes the expression of the specific extracellular adherence protein (EAP) and 
adhesins for extracellular matrix proteins (MSCRAMMs), such as collagen, fibronectin, and 
fibrinogen that are abundant in plasma, establishing persistent-binding colonies on the tissue [9]. 
In the invasion phase, S. aureus invades deeper tissues, including bone and joints, infecting every 
tissue and organ system of the body, sometimes ending with life threatening forms of infection 
(Figure 1.2). Due to its adaptive properties to grow in blood through subversion of plasma 
proteins and the tissue extracellular matrix, S. aureus can sustain the bacteremia [10]. The 
transition between the colonization and invasion phases is believed to be through expressing 
staphylococcal proteases [11-17].  
 
Figure 1.2 Characteristics of staphylococcal infection phases. 
S. aureus is able to produce and excrete a variety of toxins, enzymes, and other extracellular or cell 
wall-associated proteins, that are required for the establishment and maintenance of an infection. 
Virulence factor expression occurs in a highly orchestrated manner. In the early stage of infection, 
the surface associated-colonization promoting factors are important, while the secreted proteins are 
up-regulated during the late stage, and are believed to be required for survival of the bacteria and 
dissemination of infection. The transition is regulated with the secretion of the proteases. 
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1.4 Virulence factors in Staphylococcus aureus 
Both surface and extracellular proteins represent the interface between the host and this 
pathogenic bacterium. Moreover, they play a key role in both colonization and subversion 
processes of the human host [18-20]. Table 1.1 summarizes the functions of the secreted 
virulence factors that have been identified in Staphylococcus aureus. 
Table 1.1 Summary of the virulence factors involved in the staphylococcal pathogenesis.  
(source: Gustafsson, Thesis [21]). 
ACTIVITY / FUNCTION  PRODUCT  GENE  
Anti-immune, antiphagocytosis  
Protein A  spa  
Polysaccharide capsule type 5  cap5  
Polysaccharide capsule type 8  cap8  
Collagen binding proteins Collagen BP  cna  
Fibronectin binding proteins Fibronectin BPA, Fibronectin BPB fnba, fnbB 
Fibrinogen binding proteins Clumping factor A, Clumping factor B  clfA, clfB 
Lactoferrin binding proteins Lactoferrin BP  lbp  
Hemolysins, cytotoxin  
α-Hemolysin, β-Hemolysin hla, hlb  
δ-Hemolysin, γ-Hemolysin hld, hlg 
Leukolysin  PVL leukocidin*  lukS/F  
Food poisoning, TSST 
Enterotoxin A, Enterotoxin B sea, seb 
Enterotoxin C, Enterotoxin D sec, sed 
Enterotoxin H  seh  
Scalded skin syndrome  
Exfoliatin A  eta  
Exfoliatin B  etb  
Toxic shock syndrome  Toxic shock toxin-1  tst  
Putative protease  Serine protease-like  splA-F  
Spreading factors, nutrition 
 
V8 protease  ssp  
Hyaluronidase  hys  
Spreading, nutrition  
Staphopain (protease II)  scp  
Glycerol ester hydrolase  geh  
Lipase (butyryl esterase)  lip  
Nutrition  Nuclease  nuc  
Fatty acid esterification  
FAME  fme  
PI-phospholipase C  plc  
Clotting, clot digestion  Coagulase  coa  
Plasminogen activator  Staphylokinase  sak  
Processing enzyme  Metalloprotease (aureolysin)  aur  
Cysteine protease  sspB  
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S. aureus like other prokaryotes depends on several protein transport pathways, among 
which the major secretory (Sec) pathway is the most well known and best described [22].  
1.5 Staphylococcus aureus: challenges of disease and control in Europe 
The methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of healthcare-
associated infections (HAIs). Over 380,000 HAIs were reported to be acquired annually in 
hospitals of the EU countries in 2008 [23]. These infections were due to selected antibiotic-
resistant bacteria, including those of the bloodstream, lower respiratory tract, skin or soft tissues 
and urinary tract. In general, MRSA is responsible for 44% (n=171,200) of these infections, 22% 
(n=5,400) of attributable extra deaths and 41% (n=1,050,000) of extra days of hospitalization 
associated with these infections. The attributable extra in-hospital costs caused by MRSA are 
estimated to reach approximately 380 million EUR annually in Europe. Moreover, the vast extent 
of MRSA infections has both evoked fear and fuelled public distrust about healthcare. For many 
healthcare consumers, this has made MRSA bloodstream infection rates an indicator of both 
quality of care and outcome [23]. 
1.6 Emergence of the antibiotic-resistant strains requires modifying of the 
antimicrobial strategy 
The development of antibiotics over the last decades was followed with a fast evolutionary 
resistance of the pathogenic bacteria. The emergence of staphylococcal antibiotic-resistant strains 
such as MRSA and VISA (Vancomycin intermediate-resistant S. aureus) demonstrates the urgent 
need for new therapeutics that are effective against multidrug-resistant bacteria (Figure 1.3). 
Although some treatment options remain, the search for new antibacterial compounds and novel 
bacterial targets is urgently needed to ensure that staphylococcal infections can be effectively 
treated in the future. The recently discovered antibacterial agents should be exploited. Moreover, 
focusing on the bacterial mechanisms and their gene products that are involved in essential cell 
functions can present novel targets [24]. 
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Figure 1.3 Timeline of antibiotic deployment and the evolution of antibiotic resistance.  
Source: Clatworthy, et al. 2007 [24]. 
1.7 Peptide constructs: novel and promising potent antibacterial agents 
Most conventional antibiotics, bacteriostatic and bactericidal, are principally designed to 
target bacterial functions or growth processes. Bacteriostatic antibiotics, such as the 
aminoglycosides, macrolides, and tetracyclines, are means for targeting protein synthesis, where 
those targeting the bacterial cell wall (penicillins, cephalosporins), or cell membrane 
(polymyxins), or interfere with essential bacterial enzymes (quinolones, sulfonamides) are usually 
bactericidal [25]. More recently, after a pause of 40 years in discovering new classes of antibiotic 
compounds, only a few new classes of antibiotics have been brought into clinical use. 
Daptomycin, as an example, is a cyclic lipopeptide used for Gram-positive infections [1, 26]. It 
has a distinct mechanism of action illustrated in disrupting multiple aspects of bacterial cell 
membrane function. It appears to bind to the membrane and cause rapid depolarization, resulting 
in a loss of membrane potential leading to inhibition of protein, DNA and RNA synthesis, which 
results in bacterial cell death [26, 27]. Recent research reveals that both cyclic peptides and the 
linear cationic peptides are potential alternatives to counteract the bacterial resistance to existing 
antibiotics [28, 29]. More than 1000 naturally occurring antimicrobial peptides have been 
described so far. These peptides are generally short (less than 50 amino acids in length), cationic, 
amphiphilic, demonstrate different three-dimensional structures, and appear to have different 
modes of actions. Some antibacterial peptides are summarized in Table 1.2.  
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Table 1.2 Selected natural cationic antimicrobial peptides. (Source: Hilpert et al., 2008 [29]). 
Name  Source  Sequence MIC 
(µg/ml)  
Gramicidin Bacillus brevis cyclo-((D)Phe-Pro-Val-Orn-Leu) 3.1 
Indolicidin Bovine neutrophil ILPWKWPWWPWRR-NH2 3.8 
Lactoferricin 
H-20 
Human, 
Lactoferrin 
KCFQWQRNMRKVRGPPVSCI 128 
Lactoferricin 
P-20 
Porcine, derived 
from Lactoferrin 
KCRQWQSKIRRTNP IFCIRR 32 
LL37 Human 
neutrophils 
epithelial cells 
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES >32 (µM) 
Magainin2 Xenopus 
Laevisskin 
GIGKFLHSAKKFGKAFVGEIMNS 64 
Bac7 Bovine 
Neutrophils 
RRIRPRPPRLPRPRPLPFPRPGPRPIPRPLPFPRPGPTPIPRPLPFPRPGPRPIPRPL-NH2 200 
Bactenecin Bovine 
neutrophils 
RLCRIVVIRVCR 32-64 
Novel peptides as therapeutics for treating infections are being exploited. The possibility 
that peptides have multiple targets, in addition to their fundamental interaction with the bacterial 
membrane, means the chances of resistance by target modification are slight, as this would 
require the complete alteration of the membrane and/or several biochemical pathways to be 
circumvented [28, 30]. Table 1.3 explains the advantages of antimicrobial peptides on 
conventional antibiotics. 
Table 1.3 Comparison of conventional antibiotics with cationic antimicrobial peptides 
(source: Marr et al, 2006 [30]). 
Property  Conventional antibiotics  Cationic antimicrobial peptides  
Spectrum of 
activity  
Bacterial infections (often selective)  Bacterial, fungal and viral infections; septicemia; and/or 
inﬂammation  
Uptake  Speciﬁc mechanisms  Relatively non-speciﬁc. Based on charge. Self-promoted 
uptake  
Targets  Usually one dominating target or class of 
targets (e.g. penicillin-binding proteins, 
topoisomerases, ribosomes) 
Relatively less speciﬁc (possibly multiple targets in any 
given cell)  
Resistance rate and 
mechanism  
Resistance development at frequencies of 
10-7 to 10 -10, or after a few passages at sub-
MIC.  
Resistance generally cannot be directly selected. Needs 
multiple passages on sub-MIC concentrations to induce 
resistance.  
 Resistance caused by mechanisms such as 
reduced uptake or increased efﬂux, chemical 
modiﬁcation or degradation of antibiotic, or 
altered target  
Resistance caused by mechanisms such as an impermeable 
outer membrane or speciﬁc proteases (can be overcome by 
incorporating D-amino acids or backbone alterations)  
Additional 
activities  
No  Include anti-endotoxic and/or boosting of innate immunity  
Pharmacokinetics  Varies but once per week antimicrobials 
under development  
Short systemic half-life owing to proteolytic degradation  
Toxicology  Antibiotics tend to be one of the safest 
groups of pharmaceuticals  
No known topical toxicities; systemic toxicity issues remain  
undeﬁned  
Manufacturing 
costs  
Can be inexpensive (e.g. $0.8 per gram for 
aminoglycosides) 
Expensive ($50–400 per gram) 
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1.8 Novel antimicrobial targets in Staphylococcus aureus 
The search for novel antibacterial targets in S. aureus has increased. Several research 
groups have e.g. investigated the possibility of inhibiting the two-component regulatory system in 
S. aureus [31, 32]. A model for novel discovered targets in S. aureus is the accessory gene 
regulatory system (Agr). Cyclic autoinducing peptides (AIPS), which have the conserved 
sequence YSTCAFIM, were considered as promising inhibitors for the transmembrane receptors 
AgrC of this regulatory system (Figure 1.4).  
 
Figure 1.4 Schematic representation of the staphylococcal quorum sensing system shows the agr locus and its 
regulatory pathways. 
The agr locus consists of two divergent operons, which is transcribed under the control of the promoters P2 and 
P3. The P2 transcript RNAII is polycistronic (agrBDCA) comprising the genes that encode proteins of a quorum 
sensing system that, at threshold concentration of the AIP, activates the transcription of P2 resulting in signal 
amplification) and P3-initiating production of the transcript RNAIII. Being the effector of the agr system, 
RNAIII initiates the transcription of genes that encode a variety of exoproteins, e.g. hla (encoding α-hemolysin), 
saeB (enterotoxin B), tst (TSST-1), ssp and spr (serine proteases), and represses the genes encoding cell surface 
proteins, e.g., spa (protein A) and fnb (fibronectin-binding protein). AIP result from the post-translational 
modification of AgrD by the membrane-bound AgrB. The AgrC-AgrA forms the crucial agr TCSTS. Source 
Chan et al., 2004 [33]. 
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Upon AgrC inhibition, the quorum sensing of the staphylococcal bacteria will be switched 
off2. This will result in down regulating the expression of virulence factors and biofilm building. 
The discovery of this mechanism in S. aureus opened the doors to find more targets in other 
Gram-positive and Gram-negative bacteria. Similarly, the staphylococcal RNAIII, which is 
responsible for expressing the virulent exoproteins, hemolysins and proteases, was found to be 
inhibited by peptide analogues of the domain YSPWTNF. Developments were tried to optimize 
the inhibitory effect of this structure. 
The peptides in the former examples are receptor-antagonists that in turn and 
consequently convey the inhibition to the gene transcription level. However, the inhibition can be 
designed to be on the protein level. Several research groups have been working on inhibiting the 
type I of the staphylococcal signal peptidase, SPsB, which is a membrane integrated peptidase 
processing the virulence factors on their N-terminus, facilitating their passage through the 
membrane from the cytoplasm to the periplasm and the cell wall [34]. 
The FtsZ, a bacterial cytoskeleton protein, which is involved in cell division, was found 
as novel target in Staphylococcus aureus. FtsZ assembles into protofilaments in a GTP-dependent 
manner, and forms a dynamic Z-ring at the mid-cell position. Haydon and others have found that 
FtsZ is a significant target for inhibitors like PC-190723. Several points were discussed 
suggesting the potential of FtsZ as a drug target for antistaphylococcal therapy [35]. Dubin and 
others have utilized hemocidin, an antibacterial peptide derived from hemoglobin and myoglobin, 
and products of enzymatic digestion of maternal proteins as specific inhibitors in targeting 
individual bacterial virulence factors, like the staphylococcal proteases [36]. Table 1.4 
summarizes the active research in developing alternative antimicrobial strategies based on 
promising peptide antibiotics and synthetic small molecules. 
  
                                                     
2 Quorum sensing is a type of decision-making process where bacteria coordinate their gene expression 
according to the local density of their population. In S. aureus the agr system, a two-component system, is 
responsible for reception of the chemical sensing in the individual components to assess the number of 
other components they interact with, and to trigger a standard response once a threshold number of 
components is detected. 
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Table 1.4 Novel targets that are essential in Staphylococcus aureus pathogenicity. 
New compounds (peptide) Novel target Effect Reference 
Cyclic-YSTCAFIM-NH2 
analogues 
Agr C inhibition of the transmembrane sensor Agr C (two 
component regulatory system) quorum quenching 
[31, 32, 37-45] 
YSPWTNF-NH2 
Analogues 
RNA III Inhibiting the biofilm building [37, 46-49]  
Decanolyl 
LTPTAKAASKIDD 
α-ketoamid analogues 
SpsB Inhibiting the Type I signal peptidase  [50, 51] 
Arylomycin SPase Inhibiting Type I signal peptidase [52] 
5-amino-thiazolo[4,5-
d]pyrimidines 
Sec A Inhibiting the ATPase Translocation motor Sec A [53] 
PC-190723 FtsZ Inhibit the Staphylococcus cell division [35] 
cis-5-phenyl proline  SrtA Inhibiting the integration of the cell wall proteins. [54, 55] 
Hemocidins 
Staphostatins  
Targeting of individual bacterial virulence factors [36] 
LBM-415 PDF Inhibit the peptide deformylase and the maturation of 
proteins 
[56] 
Thus, it is clear from the former examples that peptides can contribute in inhibiting the 
virulence factors or in intervening with the pathogenicity mechanisms if they are utilized as novel 
therapeutics. Furthermore, they can have more potential if novel pathogenicity mechanisms are 
targeted. Based on these facts, it is believed that peptides can have a multiple potential impact 
against antibiotic resistant strains. This might reduce the selective pressure of the bacterial 
multidrug resistance. Targeting the secretion pathways of virulence factors that directly cause the 
harm to the host tissue in the infection process might be a successful approach in targeting 
virulence. 
1.9 Sec pathway: a major bacterial route for secreting pathogenicity factors  
One of the main reasons why S. aureus is able to infect almost every organ and tissue in 
the human body is that S. aureus cells can produce an arsenal of virulence factors that are 
exported to the cell surface and host milieu. The secreted proteins play key role in the interaction 
of bacteria with their environment [22]. These factors include proteins that are necessary for: 1) 
adherence to cells; 2) invasion and spreading throughout the host; 3) evasion of the immune 
system; and 4) damaging host cells, thereby contributing to the symptoms of septic shock (Table 
1.1). S. aureus contains several protein secretion pathways of which the general Sec pathway 
seems to be most frequently used [57]. Other secretion pathways include the Twin arginine 
translocation (Tat) [58-60], Com and Ess pathways [61, 62]. See table 1.5. 
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Table 1.5 The major secretion pathways in staphylococci (modified based on Sibbald et al., 2006 [22]). 
Secretion 
pathway 
Major components Hallmark of the signal 
peptide 
Membrane 
translocation 
form 
Secreted proteins 
Sec-
translocase 
SecA, SecY, Sec E, 
SecG 
NHC–extension-AAxA 
motif at C-terminus 
Unfolded 
precursor protein  
Serine, cysteine-
proteases, α,β,γ-
hemolysins; most proteins 
of secretome 
Tat-translocon Tat A, TatC NHC-Extension - RR/KR 
Two consecutive arginines 
within N-terminal 
sequence 
Folded precursor 
protein 
Iron-dependent 
peroxidase FepB (Iron-
binding lipoprotein) 
ESAT-6 like 
(ESS-1) 
Esa, EssA, EssB, 
EssC 
WXG motives Folded  EsxA, EsxB, CFP10 
Sort StrA, SrtB NHC-extension and 
LPTxG, YSIR motif at C-
terminus 
Unfolded 
Anchored to CW 
FnbPA, FnbPB CnbP, 
ClfA 
It has been suggested that the Tat pathway does not play a major role in protein secretion 
in S. aureus, rather it is functional and serves to translocate the iron-dependent peroxidase FepB 
[63]. The evolutionarily conserved general secretory (Sec) system mediates the secretion of many 
virulence proteins, in both Gram-positive bacteria like S. aureus as well as Gram-negative 
bacteria [57]. In Gram-negative bacteria, the Sec system exports unfolded proteins to the 
periplasm, where they are then recognized by other specialized systems for transport across the 
outer membrane, while in Gram-positive bacteria, Sec translocates unfolded proteins directly into 
the extracellular environment (Figure 1.5). The general secretory (Sec) system is the most used 
major secretion pathway in various bacterial species [64, 65]. In general, the N-terminus of the 
secreted proteins is a tripartite domain signal peptide, and it is needed to target them co-
translationally together with the ribosome to the translocation machinery in the cytoplasmic 
membrane. After translation and channeling through the Sec complex, the N-terminal signal 
peptide will be removed by signal peptidase (SPase) and exoproteins will be either retained in an 
extracytoplasmic compartment of the cell or secreted into the extracellular milieu after its correct 
conformational folding [22]. The transport of the proteins through the Sec system occurs in a co-
translational phase. 
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Figure 1.5 Secretion pathways in Gram-positive and Gram-negative bacteria. 
The arrows indicate the taken path of the exported protein. Arrows that initiate in the periplasm indicate that 
Sec (or rarely TAT)-dependent translocation across the plasma membrane is a necessary first step for these 
systems. Bam: beta-barrel assembly machine. CU: chaperone–usher pathway. Esx: specialized secretion system 
that is found in Gram-positive bacteria (for example, mycobacteria). Fla: flagellum. HM: host cell membrane. 
LOL: lipoprotein outer-membrane localization. OM: outer membrane. Omp85: also known as YaeT. Per: 
periplasm. PM: plasma membrane. Sort: sortase. TPS: two-partner secretion. T2S: type II secretion. T3S: type-
III secretion. T4P: type IV pili T4S: type IV secretion. T5S: type V secretion (autotransportation). T6S: type VI 
secretion (Source Papanikou et al 2007, [66]). 
1.10 Stages of protein transport in the Sec system 
The protein transport through the Sec system into the cell wall and the extracellular milieu 
can be divided into three stages. These stages include (a) targeting to the membrane translocation 
machinery by secretion-specific or general ribonucleic proteins; (b) translocation across the 
membrane via the Sec YEG, a heterotrimeric membrane protein complex, with the help of Sec 
motor ATPase SecA; and (c) post-translocational folding and modification [22, 66]. 
1.10.1 Targeting the protein from the cytoplasm to the cytoplasmic membrane 
In Gram-positive bacteria, once the N-terminal signal peptide of the translated protein 
emerges from the ribosome it is recognized by a ribonucleic protein called signal recognition 
particle (SRP). The protein part of the SRP contains a homologue of the SRP 54 in eukaryotes 
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(Ffh). The hydrophobic sequence of the signal peptide is believed to bind to the M domain of the 
Ffh protein and thus the translated protein is targeted together with its ribosome to the membrane 
via the FtsY protein, which acts as a high affinity receptor for SRP [22]. This stage ends with 
docking the signal peptide of the preprotein with its ribosome to SecA (Figure 1.6). 
 
 
 
 
 
 
 
Figure 1.6 Stage 1: Preprotein targeting to the membrane in the Sec pathway of Gram-positive bacteria. 
The signal recognition particle (SRP) screens for the hydrophobic signal sequence of the nascent protein in co-
translational phase, and locks on the ribosome to target the complex (nascent chain-ribosome) to the membrane 
receptor protein FtsY. 
1.10.2 Transmembrane crossing of the preprotein through SecYEG 
Once the SRP-ribosome-nascent protein complex is bound to its receptor protein FtsY, 
the ribosome is docked on the translocation pore. Thus, the non-folded protein is transferred to 
the SecA dimer, resulting in conformational rearrangements as the ATP molecules have bound to 
SecA, that promote their insertion of the non folded preprotein into the channel of SecYEG. 
Figure 1.7 explains the transmembrane crossing of a non-folded protein after it has docked to the 
SecA dimer. Upon the ATP molecules binding to SecA, conformational rearrangements of SecA 
promote the polypeptide insertion of the nascent protein into the channel of SecYEG [64]. 
Subsequent hydrolysis of ATP causes SecA to release the preprotein, return to its original 
conformation and disassociate from the translocation channel. The translocation of a peptide 
chain consumes many molecules of ATP. The polypeptide is further translocated across the 
cytoplasmic membrane via the proton motive force which is generated by binding and hydrolysis 
cycles of ATP molecules [66]. 
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Figure 1.7 Stage 2: Translocation across the membrane in the Sec pathway of Gram-positive bacteria. 
Transmembrane crossing of the unfolded protein with the help of SecA conformational changes: After binding 
of a preprotein to a SecA dimer, the SecA molecules will bind ATP, resulting in conformational changes that 
promote their insertion together with the preprotein into the membrane-embedded translocation channel. 
Subsequent hydrolysis of ATP causes SecA to release the preprotein, return to its original conformation, and 
reinsert it into the translocation channel. 
1.10.3 Maturation and release of the translocated protein sequences 
During transmembrane crossing, the junction between the signal peptide and the mature 
part of the translocating chain undergoes a cleavage at a specific catalytic site by the membrane 
signal peptidase SPase [22]. Figure 1.8 illustrates the signal peptidase action on the N-terminal 
recognition site of the unfolded protein through this stage.  
 
 
 
 
 
 
 
 
Figure 1.8 Stage 3: Maturation and release of the translocated non-folded protein. 
The signal peptidase (Spase) recognizes the motif AxAA at the C domain of the secretion signal peptide while the 
preprotein is crossing the membrane and cleaves the protein causing the release and maturation of the 
preprotein. At this stage, another scenario might take place if the preprotein has a lipoprotein signal sequence at 
C-terminus that causes the insertion of the protein into the membrane via YidC. 
1.10.4 Protein folding catalysts 
Sec-dependent proteins that are transported across the membrane emerge at the 
extracytoplasmic membrane surface in an unfolded state. These proteins need to be rapidly and 
correctly folded into their native and protease-resistant conformation before they are degraded by 
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proteases in the cell wall or extracellular environment. PrsA is a lipoprotein, which shows 
homology to peptidyl-prolyl cis/ trans-isomerases, and is an important folding catalyst in B. 
subtilis and S. aureus [22]. Although no data have been published on S. aureus whether PrsA is 
also essential for the viability and virulence of this organism, studies on the effects of PrsA 
depletion in B. subtilis showed that the relative amounts of extracellular proteins from PrsA-
depleted cells were significantly reduced [22]. 
Other proteins that are involved in proper folding of extracellular proteins in B. subtilis 
are the membrane proteins BdbC and BdbD, which are involved in the formation of disulfide 
bonds (Figure 1.9). Both proteins have been shown to be necessary for stabilization of the 
membrane- and cell wall-associated pseudopilin ComGC [22]. 
 
Figure 1.9 Protein-folding catalysts in the interface between the cytoplasmic membrane and the cell wall of B. 
subtilis. 
Diagram shows the components of the Sec pathway and the elements involved in folding of secretory proteins 
and the degradation of misfolded proteins in Gram-positive bacteria. Two model proteins are shown: amylase 
from B. amyloliquefaciens and the alkaline phosphatase from E. coli. Source: Sarvas et al., 2004 [67]. 
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1.10.5 The role of signal peptides in targeting proteins 
In S. aureus, the Sec-system signal peptides are consensus sequences and comprise on 
average the first 25 to 32 amino acids of the preprotein, and contain three distinguishable 
domains: the N, H, and C domain [22]. Figure 1.10 illustrates the nature of information that is 
localized within the signal sequences of the Sec-dependent proteins that have to be exported to 
different destinations.  
The N-terminal domain contains positively charged amino acids, which are believed to 
interact with the secretion machinery, and/or with the negatively charged phospholipids in the 
membrane, whereas the H domain will provide the appropriate hydrophobicity to bind to the SRP, 
and will facilitate membrane insertion. Helix-breaking residues in the middle of the H domain 
may facilitate H domain looping during membrane insertion and translocation of the precursor 
protein. The subsequent unlooping of the H domain would display the SPase recognition and 
cleavage site at the extracytoplasmic membrane surface, where the catalytic domains of type I and 
type II SPases are localized. Helix breaking residues just before the SPase recognition and 
cleavage site would facilitate precursor processing by SPase I or II. Finally, the start and the end 
of C domain that includes the motif AXAA is defined by the helix breaking residues and the 
cleavage site for specific SPase, either SPase I or SPaseII [22, 68]. A conserved signal sequence, 
LPTXG, which is located at the C-terminus of the translocated sequences, sorts the proteins to be 
anchored to the cell wall by specific cell wall enzymes called sortases. In S. aureus, SrtA 
catalyzes the transpeptidation reaction that joins this LPTXG containing domain to the cell wall 
[69]. A set of about 20 surface proteins of Staphylococcus aureus were found to carry a YSIRK-
G/S motif but this motif is not essential for surface protein anchoring to the cell wall envelope. 
 
Figure 1.10 Tripartite domain of the signal peptide of the Sec-dependent proteins, comprises N, H, and C 
motives. 
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1.10.6 Destination of the virulence factors 
The secreted virulence factors can be destined to one of the following positions: (1) 
secreted to the extracellular milieu, (2) retained to the cell surface by non-covalent or covalent 
binding to the peptidoglycan moiety of the cell wall or to cell membrane after they are sorted by 
sortase. Such proteins are protein A, clumping factors, fibronectin and fibrinogen binding 
proteins. The described details about the protein export stages via the Sec system reveal the 
pivotal role that signal peptides play in determining whether the exported protein will be secreted 
into the extracellular milieu or integrated in the cell wall or the cell membrane. In the Sec 
pathway, this signal peptide is likely to be recognized by three major players in different stages. 
First, it is recognized by the signal recognition particle SRP (ribonucleoprotein) in the cytoplasm 
in the targeting stage. Second, it is docked at the ATPase motor SecA, into the cytoplasmic 
membrane at the transmembrane crossing stage. Third, it is cleaved by the signal peptidase SPase 
(type I or type II) at the recognition site, which consists of small, aliphatic residues at positions -1 
and -3 relative to the cleaved bond, and these correspondingly bind in the S1 and S3 binding sites 
of the SPase [22, 70].  
1.11 Sec-pathway: a vital target for antivirulence therapy in former studies 
The Sec pathway is considered a general pathway in Gram-positive and Gram-negative 
bacteria, through which the majority of all extracellular proteins are secreted. Most studies of the 
Sec pathway in Gram-positive bacteria have been carried out with B. subtilis Data on the S. 
aureus Sec system is scarce: SecA and SecY have been shown to be important, respectively 
essential, for growth by using antisense RNA [71]. Moreover, evidence is accumulating that 
mutation of some gene products of this pathway result in reducing the secretome in the 
supernatants associated with accumulation of some proteins in the cytoplasm. Sibbald et al. 
showed that a SecG mutant in Staphylococcus aureus results in affecting the extracellular 
accumulation of nine abundant exoproteins and seven cell wall-bound proteins, whereas deletion 
of secY2 exacerbated the secretion defects of secG mutants, affecting the extracellular 
accumulation of one additional exoprotein and one cell wall protein. Furthermore, a secG secY2 
double mutant displayed a synthetic growth defect [72]. Other research groups showed that 
deficiency in SRP affect the biosynthesis [73, 74]. Proteome analysis of B. subtilis strains 
depleted of Ffh revealed a reduction of 13 extracellular proteins in the supernatant [73]. 
On the other hand, it has been shown that SecG, SecY mutations affect the amounts of the 
exoproteins. Baars et al. has studied the role of the Sec translocon in E. coli using subproteome 
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analysis of cells depleted of the essential translocon component SecE. The analysis showed that 
upon SecE depletion (i) secretory proteins aggregated in the cytoplasm and the cytoplasmic 
sigma-32-stress response was induced, (ii) the accumulation of outer membrane proteins was 
reduced, with the exception of some proteins, and (iii) the accumulation of a surprisingly large 
number of inner membrane proteins appeared to be unaffected or increased. Some individual 
studies on E. coli showed that depletion of SecA results in abolishment of the protein export 
through the membrane and a loss of cell viability. Since the prokaryotic SecA, SRP and type I 
Spase have structures that are different from their human counterparts, inhibitors for these key 
proteins have the potential to be of a novel class of antimicrobial agents with low toxicity [75]. 
1.12 Developing a novel approach for targeting virulence is an urgent 
demand 
As described formerly, the resistance of pathogenic microorganisms like S. aureus to 
currently known antibiotics is constantly increasing due to a broad use of antimicrobials in 
medicine, animal husbandry and agriculture [36]. Yet with the exception of the recent 
development of the narrow-spectrum drugs, daptomycin and linezolid, there have been no new 
classes of clinically relevant antibiotics discovered in over 40 years. Traditional antibiotics have 
been identified for their ability to kill bacteria (bactericidal) or inhibit growth (bacteriostatic). 
They act by inhibiting bacterial functions (such as cell wall synthesis, DNA replication, RNA 
transcription and protein synthesis) that are essential for in vitro, logarithmic growth. However, 
through the use of antibiotic, lasting alterations are being made to a mutualistic relationship that 
has taken millennia to evolve: the relationship between the host and its microbiota [76]. Host–
microbiota interactions are dynamic; therefore, changes in the microbiota as a consequence of 
antibiotic treatment can result in the dysregulation of host immune homeostasis and an increased 
susceptibility to disease [76]. A better understanding of both the changes in the microbiota as a 
result of antibiotic treatment and the consequential changes in host immune homeostasis is of 
vital importance, so that these effects can be alleviated (Figure 1.11). Since the conventional 
concept of virulence is defined by the ability of a pathogen to cause disease, and the virulence 
determinants are defined as the bacterial factors and mechanisms that actively cause the damage 
of the host tissue, developing antimicrobials that have novel modes of action should be 
considered in disarming the pathogens. This can be achieved by inhibiting the secretion of 
virulence factors that cause direct harm to the host tissue [24]. Over the past few decades, 
tremendous efforts to understand how bacteria cause disease have revealed new approaches. 
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Therefore, the next period of efforts in developing novel approaches should utilize the concept of 
virulence, and consider the balance between the microbiota and the changes in host immune 
homeostasis. 
 
Figure 1.11 Interaction between pathogens and immune responses in the microbial pathogenesis. 
Hypothesis of reducing the secretions of virulence factors might contribute in delaying the pathogen mechanisms 
in setting the infection or in causing the damage to the host tissue. The diagram depicts the damage to the host 
tissues caused by both factors (red area). In the normal case (state 0), which extends along the white area, there 
is a balance between the microbes and the immune response. In case the immune response abnormally sinks, 
(state 1), normal flora can cause a disease. For some pathogens, such as paramyxovirus (state 2), the immune 
responses rather than the microbial pathogen is primarily responsible for the tissue damage. For many 
pathogens, host with normal immune response may be colonized asymptomatically, but hosts with very 
strong/weak immune responses may suffer severe damage or even death. 
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Aim of the study 
This study comes in the series of establishing alternative approaches to target functions 
essential for infection. The major bacterial secretion pathway (Sec) was put in the focus since it is 
dispensable for secreting proteins, most of which act as virulence factors in the infection process. 
The hypothesis of inhibiting or at least reducing the secretions of S. aureus carries a new 
approach that has several potential advantages including attenuating the damage caused to the 
host tissue by bacterial pathogen, expanding the repertoire of bacterial targets, preserving the host 
endogenous microbiome, and exerting less selective pressure, which may result in decreased 
resistance. Under the increasing needs to develop novel approaches and therapeutics for 
combating the infections caused by the antibiotic-resistant pathogens, several attempts have been 
made to discover novel targets in S. aureus. This pilot study aims at establishing a base for 
affecting the secretion efficiency of the bacterial virulence factors. This can be built on two major 
objectives: 
1) Targeting the Sec-pathway in Staphylococcus aureus, using peptidic inhibitors, and 
monitoring the effect of the peptidic inhibitors on the bacterial growth, viability, and 
secretion. 
2) Establishing biochemical and molecular assays that facilitate monitoring the success of 
the targeted process. 
Under these two main objectives, the features of our research strategy are determined in 
the following parts: 
 Synthesizing peptide constructs that are able to penetrate the Staphylococcus aureus cells 
and probing their extent of internalization 
 Determining the optimal secretion conditions of proteases into the bacterial culture 
supernatants with focus on the V8 protease and establishing sensitive and quantitative 
detection methods as a model for the secretion of pathogenicity factors via the Sec 
pathway. 
 Generating potential peptidic Sec-inhibitors that consist of the optimal internalizing 
sequence conjugated with the secretion signal sequence of V8 protease, including control 
sequences. 
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 Testing the effect of the peptides on the secretion through  
a. Quantifying the Sec-dependent V8 protease in the supernatant of bacterial cultures, 
and in different cellular compartments. 
b. Quantifying the total proteins in the supernatant of bacterial cultures (the secretome), 
and in different subcellular compartments to understand the mode of action of the 
peptides. 
For a deeper understanding of the methods that were employed in this investigation the basic 
principles of solid phase peptide synthesis and the development and utilization of cell penetrating 
peptides will first be elaborated in the following chapter  
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2 Technical approaches 
2.1 Solid phase peptide synthesis (SPPS) 
Since their crucial role in biological, pharmaceutical, and in medical research, peptides, 
and their syntheses on a solid phase have been the major focus in this study. Solid phase peptide 
synthesis (SPPS) offers important advantages over the synthesis in solution, in that coupling 
reactions can be performed more rapidly and nearly to completion using an excess of the 
activated amino acid derivative, which is removed at the end of the reaction by simple washing 
operations. In contrast to ribosome protein synthesis, solid-phase peptide synthesis proceeds on 
the resin at a C-terminal to N-terminal manner. The N-termini of amino acid monomers are 
normally protected by Fmoc or Boc groups. These two groups are labile in base or acidic 
conditions, respectively. In this study, the automated technique of the peptide synthesizer 
PIONEER®, which works according to the Fmoc approach, was utilized. The advantages of Fmoc 
on Boc chemistry are known that the former generates peptides of higher quality and in greater 
yield than the latter [77]. The sequence, the amino acids content, and the length of a peptide 
influence whether correct assembly and purification are feasible. These factors also determine the 
solubility of the final product. Therefore, some important points that were considered in designing 
the peptide constructs are highlighted. 
2.2 Description of the Fmoc solid-phase peptide synthesis process 
In general, Fmoc solid phase synthesis can be performed by automated synthesizers that 
generate peptides from amino acids through coupling the amino acids in cycles. Each cycle 
consist of the following major phases (Figure 2.1): 
1. Loading phase: loading of C-terminal amino acid to resin, this is only done in the first step 
2. Deprotection phase: removal of the Fmoc protecting group from the N-terminus of amino acids 
after their coupling. 
3. Activation phase: includes activating the carboxyl group of the next coupled amino acid e.g. by 
forming an uronium, phosphonium, or other onium salts. 
4. Coupling phase: coupling new carboxyl-activated amino acid to the Fmoc-deprotected amine 
of the peptide chain, and washing the peptides. 
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5. Repeating the steps 2-4 again or cleaving the completed peptide from the resin. 
The following chart depicts the major steps in the Fmoc solid-phase peptide synthesis. 
 
Figure  2.1 The steps and cycles of Fmoc solid-phase peptide synthesis. 
2.2.1 Prediction of synthetically difficult sequences 
Before starting the synthesis, a simple view at the peptide primary structure can be helpful to 
predict the degree of difficulty in coupling the amino acids along the peptide chain, especially 
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when synthesizing long peptides. For that purpose, the computer program, Peptide Companion 
from CSPS Pharmaceutical Inc, was utilized. This predictive view determines practically the 
coupling difficulties that can arise from the aggregation of some amino acids along the peptide 
chain. It additionally shows other measures, and predicts whether the coupling efficiency needs to 
be enhanced in the synthesis. 
2.2.2 Loading the first amino acid to the solid support 
Coupling the first amino acid to the resin occurs within the first cycle of synthesis. This 
requires detaching the Fmoc group from the resin in basic condition (20% piperidine), and 
activating the C-terminus of the first amino acid with coupling reagents (Figure 2.2). 
 
 
 
 
 
 
 
 
Figure  2.2 The rink-amide solid support for peptide synthesis. 
TentaGel S RAM resin from RAPP POLYMERE can be used for all amide peptide syntheses. Here, the first 
amino acid to be coupled to the resin is cysteine. 
2.2.3 Fmoc deprotection 
The Fmoc (9H-fluoren-9-ylmethoxycarbonyl) is an orthogonal protecting group and used 
as common strategy in peptide synthesis. It is normally removed from the resin linkers and from 
the amino acid units in each coupling cycle of a peptide synthesis. It can be cleaved from the N-
terminus of the peptide at the end of the synthesis process. The Fmoc protective group is 
generally labile under mild basic conditions, and stable under acidic conditions. This allows mild 
acid labile protecting groups that are stable under basic conditions, such as tert-butyl, benzyl 
oxycarbonyl (Boc) and trityl groups, to be used on the side-chains of amino acid residues of the 
target peptide. Piperidine is used for deprotecting the Fmoc from the resin when loading the first 
amino acid and, and before adding a new amino acid to the Nα-terminus of the peptide chain 
(Figure 2.3). Since the liberated fluorenyl group is a chromophore, Fmoc deprotection can be 
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monitored by UV absorbance of the overflow, a strategy that is employed in automated 
synthesizers. 
 
Figure  2.3 Mechanism of Fmoc deprotection with piperidine. 
Rink amide resin is functionalized and protected as a carbamate 1. Piperidine 2, a nucleophilic base that 
deprotonates 1 forming 3, which then decomposes into 4 and 5. Carbamide acid 5 looses carbon dioxide, yielding 
in the free amine 7. Finally, piperidine (2) as scavenger adds a nucleophile to the produced methylene fluorene 4 
yielding 6. 
2.2.4 Coupling of amino acids 
For coupling a new amino acid to the growing peptide chain in the synthesis column, the 
carboxyl group of the new amino acid needs to be activated after the Fmoc deprotection of the 
chain N-terminus. This is important for speeding up the reaction. In the last two decades 
phosphonium and uronium salts, like the reagent 2-(1-H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium tetrafluoroborate (TBTU), have been increasingly used instead of 
conventional activating groups like carbodiimides (DCC and DIC) and triazols (HOBt, HOAt). 
The activating reagents TBTU or HATU can introduce an active ester as uronium salt of a non-
nucleophilic anion. Those coupling reagents can be dissolved in DMF, allow activating the 
carboxyl group of the amino acid in the synthesis column to couple it either to the resin or to the 
unprotected N-terminus of the added amino acid. The Fmoc group of the final amino acid is 
cleaved off by treating the resin with 20% piperidine at the end of the final cycle (Figure 2.4). 
The resin is normally washed and dried before the cleavage of the crude peptide from the support. 
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Figure 2.4 Proposed mechanism of the amide bond formation through TBTU 
(source: Balalaie et al., 2007 [78]). 
2.2.5 Cleaving the synthesized peptide from the resin 
In order to obtain the peptide in the free form without protective groups, the amide linkage to 
the resin is cleaved using strongly acidic conditions such as trifluoroacetic acid (TFA). Generally, 
cocktails of TFA are used with scavengers for removing the protective groups as well (Figure 
2.5). Certain amino acids can cause problems during TFA cleavage and deprotection. These fall 
into three broad categories  
1. Amino acids, whose protecting groups are easily removed, but whose deprotected side-chains 
are especially labile in acidic conditions (e.g., Met, Cys, His, Trp).  
2. Amino acids, which need more than the normal two hours for complete removal of the side 
chain protecting groups (e.g., Arg(Pmc/Mtr), Asn/Gln(Mbh). 
3. Amino acids whose side-chain protecting groups, once removed from the side-chain, are 
extremely reactive and must be scavenged to prevent reattachment or modification of the 
deprotected side-chains (e.g., Arg(Pmc/Mtr), Asn/Gln(Tmob))  
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Figure 2.5 Deprotection of Fmoc at the N-terminus of an amino acid by 20% piperidine (basic conditions), and 
the cleavage of the side chain protective group (t-Bu) by TFA (acidic conditions). 
2.2.6 Choosing the cleavage cocktail 
The selection of the cleavage cocktail depends on (1) the nature of the cleavable linker 
attaching the peptide to the support, and (2) the nature of the protecting groups and the reactive 
properties of the unprotected side-chain. Various TFA cocktails can be prepared with chemical 
scavengers according to the presence and absence of some residues in the synthesized peptide.  
2.2.7 Post cleavage preparations 
Crude peptides should be cleaved off the resins in acidic conditions using TFA (in Fmoc 
chemistry), and then they should be further processed to obtain pure peptides. Figure 2.6 depicts 
the flow of major steps in the resin-peptide post cleavage process. 
2.2.8 Peptide isolation and precipitation 
Peptides are separated from the cleavage cocktail by precipitation. Hydrophobic and 
hydrophilic peptides that are dissolved in TFA can be isolated after evaporating the TFA by 
precipitation with the tert-butyl-methyl ether (MTBE). The resulting peptide can be isolated by 
centrifugation. Thereafter, it can be analyzed, lyophilized, and subjected to further purification 
processes (Figure 2.6). 
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Figure 2.6 Scheme of the post synthetic workup in solid phase peptide synthesis. 
2.2.9 Peptide analysis and purification techniques 
The chemistry of peptide synthesis is well known with its different side reactions, 
accordingly, impurities can be generated with the crude peptide in form of diastereomers, 
hydrolysis products of labile amide bonds, deletion sequences formed predominantly in solid-
phase peptide synthesis and insertion peptides and by-products formed during removal of 
protection groups in the final step of the synthesis. HPLC is one of the most powerful and rapid 
tools to analyze and purify peptides. The description of HPLC protocol varies according to the 
specifications of the synthesized peptides. The degree of hydrophobicity, the size, the constituent 
amino acids, the protective groups, the cyclic and linear form, and the solubility of the crude 
peptide are key determinants of the analytical and preparative HPLC-conditions. Various 
chromatography techniques can be used in large- and small scales. The majorly applied 
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techniques are reversed-phase chromatography (RPC) that is based on the hydrophobicity of the 
separated peptides, ion-exchange chromatography (IEC) that is dependent on the ionic interaction 
between the support surface and the charged group of the peptides, and gel-permeation 
chromatography (GPC) that separates the peptides primarily on the basis of size exclusion. In 
general, if the elution pattern of the peptide is unknown, a C-18 reversed phase column is used 
especially for small-to-medium-sized peptides (up to 20-30 amino acids) that are at least 
moderately hydrophilic. A shallow gradient and moderate flow rates can be used with a low 
percentage mobile organic phase (likely acetonitrile) at the start of the gradient. A polymeric 
reversed phase column C-8 or C-4 may perform better if the analyzed or the purified peptides are 
more hydrophobic or medium sized (40 amino acids). The mainly used buffers in the HPLC 
process are 0.1% TFA in water and 0.1% TFA in acetonitrile (ACN). Long peptides, or those 
having large amounts of similarly charged groups, may best be separated on either polymeric 
reversed phase or ion exchange columns. Some protecting groups, such an Mtr or Trt, absorb very 
strongly in the UV: even a small percentage of Mtr or Trt still remaining on the peptide will give 
disproportionately large peaks. Peptides, which have Mtr or Trt attached, will elute later than 
completely deprotected peptides. Peptides containing Tyr, Phe, or Trp can be monitored at 240-
260 nm, due to the strong absorbance of the aromatic ring; otherwise, monitoring at wavelengths 
closer to the absorbance of the peptide (amide) bond (210-214 nm) is applied. If the crude peptide 
is hydrophobic, DMF is used as good solvent with a subsequent dilution with the HPLC gradient 
solution. In this case, a large peak at the beginning of the gradient is expected in the 
chromatogram. An optimal separation to the peaks and isolation of the fractions that contain the 
peptide of interest, followed by mass determination by MALDI-MS or by employing online 
HPLC-MS coupling is required. The peptide can then be lyophilized and introduced to the 
bioassay. 
2.3 Cell penetrating peptides and their rules in delivering drugs into cells 
Most “information-rich” molecules, such as, genes, oligonucleotides, proteins or peptides, 
are poorly taken up by cells since they do not efficiently cross the lipid bilayer of the plasma 
membrane. This is considered to be a major limitation for their ex vivo or in vivo use in possible 
clinical applications or in essential studies. The conventional techniques to deliver such 
compounds are limited to microinjection, electroporation, association with cationic lipids, 
liposome encapsidation, or receptor-mediated endocytosis. Various problems have been 
associated with the use of these techniques such as the low transfer efficiency, complex 
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manipulation, cellular toxicity, or immunogenicity, which would prohibit their routine use in vivo 
[79]. As an alternative technique to overcome this obstacle, several peptides have been 
successfully developed and used to improve the intracellular delivery of nucleic acids or proteins. 
These peptides are known as protein transduction domains or cell penetrating peptides (CPPs). 
They include Tat, Antennapedia, and arginine-rich peptides (Table 2.1). The common feature of 
these peptides is their highly cationic nature. The cellular uptake of many peptides and proteins 
coupled to Tat, Antennapedia, or Penetratin peptides has been reported [80, 81]. The ability to 
deliver molecules into cells is not limited to peptide moieties, since oligonucleotides, peptide 
nucleic acids or other compounds or structures with low and high molecular weight such as 
liposomes, phages and nanoparticle entities have been successfully internalized. Moreover, most 
of these examples have been accompanied by the expected biological response. 
Table 2.1 Some CPPs and their physical properties. 
source: Gräslund et al., 2011 [81]. 
Peptide Sequence 
Total 
charge 
No. of 
residues 
No. of 
arginines 
No. of 
lysines 
Hydrophobicity
* 
R9 RRRRRRRRR 9+ 9 9 0 2.58 
TAT(48–60) GRKKRRQRRRPPQ 8+ 13 6 2 2.37 
Penetratin RQIKIWFQNRRMKWKK 7+ 16 3 4 1.52 
Pen-Arg RQIRIWFQNRRMRWRR 7+ 16 7 0 1.49 
pVEC LLIILRRRIRKQAHAHSK 8+ 18 4 2 1.1 
M918 MVTVLFRRLRIRRACGPPRVRV 7+ 22 7 0 0.93 
TP10 AGYLLGKINLKALAALAKKIL 4+ 21 0 4 0.53 
*Hydrophobicity calculated according to the values from von Heijne scale 
Recent studies on the mechanisms of uptake of cell-penetrating peptides (CPPs) by 
mammalian cells provide evidence that one possible pathway for peptide entry involves initial 
cell-surface binding of the peptide carrying positively charged side chains followed by 
endocytosis and cytoplasmic trafficking [82]. This endocytotic uptake mechanism has been 
verified with various techniques, such as fluorescent peptide probes, flow cytometry, and 
confocal laser scanning microscopy (CLSM). Indeed, the uncertainty regarding the mechanism of 
entry extended for a long period. Data from several groups now argue for an energy-dependent 
process of entry [82]. The entry of most of these molecules is likely to be inhibited by low 
temperature incubation or in the presence of various drugs applied to inhibit the energy-dependent 
pathway of cell entry. Moreover, the binding of the highly cationic cell penetrating peptide to 
various anionic membrane components probably initiates the first step of the cell internalization 
process [80]. On the other hand, reports demonstrated that various putative endocytosis inhibitors, 
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low temperature, or cell-energy-depletion conditions could not effectively suppress peptide 
uptake [82, 83] ; this suggests a passive direct transfer of the CPPs through the plasma membrane 
(Figure 2.7) 
 
Figure 2.7 Mechanisms of peptide uptake across the cellular membrane. 
A variety of internalization mechanisms have been proposed to explain cellular uptake of CPPs. These 
mechanisms include well-characterized energy-dependent pathways, based on vesicle formation and collectively 
referred as endocytosis, and direct translocation or cell penetration models, which involve the formation of 
hydrophilic pores or local destabilization of the lipid bilayer, (source: Trabulo et al., 2010 [82]). 
In the last two decades, CPPs have been used as successful mediators for delivering a 
number of proteins, such as β-galactosidase, eGFP, Bcl-xL, human catalase, human glutamate 
dehydrogenase, Cu, Zn-superoxide dismutase, NF-κB inhibitor srIκBα and HSP70, among others 
[82]. With the exception of Pep-1 and MPG peptides that are short amphipathic peptides able to 
form stable nanoparticles with proteins and nucleic acids respectively, CPPs are usually coupled 
to proteins through covalent bonds or through fusion constructs [84]. Moreover, other studies 
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provided evidence that CPPs are able to mediate the delivery of proteins into a wide variety of 
cells, both in vitro, and in vivo [85]. Most importantly, these studies demonstrate that CPPs 
constitute a powerful tool that could be used to facilitate the delivery of protein-based 
therapeutics in pathological conditions, such as cancer, inflammatory diseases, oxidative stress-
related disorders, diabetes and brain injury [82].  
Little was known about the uptake of CPPs by microorganisms until recently, when it was 
reported that CPPs improve drug delivery into bacteria and fungi [85]. Data are accumulating that 
CPPs themselves possess biological activity beside their potential in penetrating a wide spectrum 
of cellular barriers [86]. Rajarao et al. revealed successful peptide constructs that mediate the 
delivery of green fluorescent protein GFP into Bacillus subtilis, Escherichia coli and 
Staphylococcus aureus [87]. In the present study, the potentiality of some constructs was 
investigated in penetrating the Gram-positive bacterium, S. aureus, and accordingly their 
internalization was evaluated. 
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3 Materials and methods 
3.1 Materials 
3.1.1 Technical devices 
Peptide Synthesis, analysis and purification 
Pioneer peptide synthesizer (Applied Biosystems, USA). Analytical HPLC-system 
(Merck-HITACHI, USA) consisted of the following units, (1) C18-RP separation column, 50 x 
2.0 mm, 5 micron from Phenomenex®, (2) UV-detector of detection wavelength of 220 nm, (3) 
fraction collector and (4) a pump. The preparative HPLC system consisted of C18-RP separation 
column Nucleosil 250 x 40 mm from MACHEREY-NAGEL®, and UV-detector with detection 
wavelength of 220 nm. Ultraflex MALDI TOF MS (Bruker Daltonics, Germany), Universal 32R 
benchtop centrifuge (Hettich), a freeze-dryer (lyophilizer ALPHA 1-4 (Christ GmbH). 
Cell culture 
Incubation Shaker-Multitron 2 (INFORS HT, Switzerland), cell incubation chamber 
(Heraeus), Megafuge 3.0R™ benchtop centrifuge (Heraeus) Sterile GARD III™ work bench and 
laminar-flow cabinet (The Baker Company), Eppendorf Mixmate® vortexer (Eppendorf), 
multichannel pipettes (BioRad), blood agar plates (BD), Ultrafree-CL centrifugal filter units with 
microporous membrane 0.22μm (Millipore). 
Biochemical assays 
Spectrophotometer (HITACHI, Japan), microplate reader Biotek-FLI 600, supplied with 
different wavelength-filters (Biotek Instruments Inc, USA), Nunc 96- Microwell™ plates, 
fluorescence flat bottom (Thermo- Fischer scientific, Germany), Multichannel pipettes (BioRad, 
Germany), Optical density reader (NanoDrop 8000™ from Thermoscientific), a microplate reader 
(Fusion; PerkinElmer, USA), colonies-counting pen. Automated fluorescence microscope 
(ImageXpress microsystem®, Molecular Devices), flow cytometer (FACSCanto™, BD 
Biosciences). FluoView™ FV1000 Confocal laser scanning Microscope (Olympus, Japan). 
SDS-PAGE and Immunoblotting 
Mini-PROTEAN Tetra Cell from Bio-Rad TM, Power supply (Biometra, Germany), 
Fujifilm LAS-1000 Luminescent image analyzer system (FUJIFILM, Japan), supported with 
digital cooled CCD camera, micro lens over every pixel on CCD and UV-light table. Semi-Dry 
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Blotting Cell (Biometra), Low-voltage power supply from Biometra, X-ray BioMax™ light film 
(Kodak), X-ray film processor CURIX 60 (AGFA, Belgium), membrane exposure cassettes. 
Blotting Protran Nitrocellulose-Membrane, Typ Protran® BA85* (Whatmann); 6 pieces of 60 x 
90 mm area of WhatmannTM filter paper per gel; SDS-PAGE home-made gels for resolving 
proteins bands, and incubation trays (Invitrogen). 
Protein extraction 
NanoDrop™8000 for monitoring the bacterial growth, Sonifer 450®-Homoginizer and 
cell disruptor (Branson), Biofuge (Heraeus), and ultracentrifuge Optima L8-50 M/E (Beckman 
Coulter Inc). 
 
3.1.2 Computer programs and software 
Table 3.1 Computer programs and software used in this study. 
Computer program ( software) Source (Company) 
Peptide companion CSPS Pharmaceutical Inc 
Pioneer workstation Molecular Devices Inc 
HPLC analyzer Sigma 
flexAnalysis Data analyzer for MALDI TOF Bruker Daltonics 
metaXpress Molecular Devices 
FlowJo for Flow cytometry analysis  BD Biosciences 
FV Viewer OLYMPUS 
AIDA Advanced Image Data Analyzer Raytest, Germany 
ImageJ  Open source java software 
Adobe Photoshop CS3 Adobe 
Jalview (multiple alignment editor) University of Dundee 
W2 Clustal EMB net –Clustal server 
3.1.3 Chemicals 
All chemicals that were used in the experimental part were at least of analytical grade 
Table 3.2 Chemicals for peptide synthesis process and dyes for labeling peptides. 
Substance Source (Company) 
Tenta-Gel S-RAM resins RAPP POLYMER 
N,N-Dimethylformamide (DMF), acetonitrile, methanol, and isopropanol J. T. BAKER (Fluka) 
tert-butylmethyl ether (MTBE), Dichloromethane (DCM)  J. T. BAKER (Fluka) 
Pyridine, piperidine, and trifluoroacetic acid (TFA)  Carl Roth 
N,N-Diisopropylethylamine (DIPEA)-Hünig Base Carl Roth 
Thioanisole and dithiothreitol (DTT) Fluka 
Triisopropylsilane (TIS), phenol, and dimethylsulfoxide (DMSO) Sigma 
O-(Benzotriazol-1-yl)-N,N,',N'-tetramethyluronium tetrafluoroborat (TBTU) Sigma 
Fluorescein and fluorescein-5-maleimide (F5M) Pierce 
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Table 3.3 Fmoc protected amino acids from MultiSynTech GmbH used in peptide synthesis. 
AA-Abbreviation Fmoc-protected amino acid Molecular weight[g/mol] eq. 100µmol x4 excess [mg] 
A Fmoc-L-Ala-OH 311.3 125 
R Fmoc-L-Arg(Pbf)-OH 648.8 260 
N Fmoc-L-Asn(Trt)-OH 596.7 239 
D Fmoc-L-Asp(tBu)-OH 411.5 165 
C Fmoc-L-Cys(Trt)-OH 585.7 234 
E Fmoc-L-Glu(tBu)-OH 425.5 170 
Q Fmoc-L-Gln(Trt)-OH 610.7 244 
G Fmoc-L-Gly-OH 297.3 119 
H Fmoc-L-His(Trt)-OH 619.7 248 
I Fmoc-L-Ile-OH 353.4 141 
L Fmoc-L-Leu-OH 353.4 141 
K Fmoc-L-Lys(Boc)-OH 468.5 187 
M Fmoc-L-Met-OH 371.5 149 
F Fmoc-L-Phe-OH 387.4 155 
P Fmoc-L-Pro-OH 337.4 135 
S Fmoc-L-Ser(tBu)-OH 383.4 153 
T Fmoc-L-Thr(tBu)-OH 397.5 159 
W Fmoc-L-Trp(Boc)-OH 526.6 211 
Y Fmoc-L-Tyr(tBu)-OH 459.4 184 
V Fmoc-L-Val-OH 339.4 136 
The chemical dyes SYBR green and propidium iodide were purchased from Pierce, 
Thermo-Fischer Scientific. The fluorescein-5-maleimide was ordered from Biozol-Diganostica. 
WST-8 was purchased from Sigma-Aldrich, Germany. Most buffering salts, acids and bases were 
ordered from Carl Roth, protease inhibitors such as benzamidine (HCl), Nα-p-tosyl-L-arginine 
methyl ester HCl, PMSF protease inhibitor, leupeptin hemisulfate salt, pepstatin A, polyethylene 
glycol tert-octylphenyl ether (Triton ® X-100), polyethylene glycol sorbitan monolaurate (Tween 
20) were purchased from Sigma-Aldrich, Germany. 
3.1.4 Kits 
SuperSignal West Pico Chemiluminescent Substrate Kit (Pierce) was purchased from 
Thermo-Scientific, Germany. This kit was used to develop the enhanced chemiluminescence ECL 
on X-ray films for quantifying the Western Blotting protein bands. 
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3.1.5 Buffers 
3.1.5.1 Buffers for peptide synthesis and labeling 
Ammonium acetate buffer with isopropanol (1:1): ammonium acetate buffer (100 mM) was 
prepared by dissolving 7.708 g of ammonium acetate in 100 ml distilled H2O. The pH was 
adjusted to 7.2. This buffer was mixed with isopropanol (1:1). 
Phosphate buffered saline (10x PBS pH 7.0): 80 g NaCl, 2.0 g KCl, 14.4 g Na2HPO4, and 2.4 g 
KH2PO4 were dissolved in 800 ml distilled H2O, the pH was adjusted to 7.4, the volume was 
completed to 1000 ml, and the buffer was sterilized by autoclaving. The 1xPBS buffer can be 
prepared by diluting the stock buffer with distilled H2O (1:10) and then autoclaving. 
3.1.5.2 Buffers for enzymatic assays 
Phosphate buffer pH 7.8: 5.44 g of potassium phosphate, monobasic, anhydrous was dissolved 
in 300 ml distilled H2O; pH was adjusted to 7.8 with 1 N KOH, diluted to 400 ml. 
TRIS/HCl buffer pH 8.0: prepared by dissolving (12.1 g Tris base (MW 121.14) in 100 ml H2O, 
pH was adjusted with concentrated HCl to 8.0. 
HEPES buffer pH 7.2: prepared by dissolving 1.19 g of Hepes (N-(2-hydroxyethyl)-piperazine- 
N´-2-ethane sulfonic acid), Mw 238.3 g/mol) in 100 ml H2O and adjusting the pH to 7.3 with 1 N 
KOH. 
3.1.5.3 Buffers for subcellular fractionation and protein extraction 
Lysis buffer L: 20 μg/ ml lysostaphin from S. aureus (Genmedics) was prepared in 50 mM Tris 
buffer pH 8.0.  
Fractionation buffers: All chemicals and enzymes inhibitors were purchased from Sigma-
Aldrich, Germany. 
Buffer A:  
Substance Concentration In 100 ml 
Tris-HCl pH 8.1 40 mM 0.630g 
NaCl 100 mM 0.585g 
Sucrose 27%w/v 27g 
MgCl2 20 mM 0.191g 
PMSF protease inhibitor 2 mM 0.035g 
Benzamidine (HCl) 1 mM 0.016 
Nα-p-Tosyl-L-arginine methyl ester HCl 0.2 mM 0.0075g 
Leupeptin hemisulfate salt 10 μg/ ml 0.001g 
Pepstatin A 10 μg/ ml 0.001g 
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Buffer B:  
Substance Concentration In 100 ml 
Tris-HCl pH 9.5 40 mM 0.630g 
Benzamidine (HCl) 1 mM 0.0329g 
Leupeptin hemisulfate salt 5 μg/ ml 0.5mg 
Pepstatin A 5 μg/ ml 0.5mg 
PMSF protease inhibitor 2 mM 0.035g 
Nα-p-Tosyl-L-arginine methyl ester HCl 0.2 mM 0.0075g 
Na-EDTA 2 mM 0.058 g 
Buffer C:  
Substance Concentration In 100 ml 
Tris-HCl pH 8.1 50 mM 0.788g 
NaCl 100 mM 0.585g 
MgCl2 2 mM 0.019 g 
Triton-X 0.25% 250μl (TritonX-100) 
3.1.5.4 Buffers for SDS-PAGE 
Laemmli loading buffer: was ordered from Roth, Germany, known as Roti-Load 1, contains 2% 
(w/v) SDS; 10% (v/v) mercaptoethanol, 62.5 mM Tris-HCl, pH 6.8, 10% (v/v) glycerol, 0.01% 
(w/v) bromophenol blue. 
Resolving buffer pH 8.8: 90.9 g Tris-HCl was dissolved in 500 ml distilled H2O, pH was 
adjusted. 
Stacking buffer pH 6.8: 30.2 g Tris-HCl was dissolved in 500 ml distilled H2O, pH was 
adjusted. 
10× Running buffer pH 8.6: 30 g Tris-HCl, 144 g glycine, and 10 g SDS were dissolved in 1000 
ml distilled H2O, pH was adjusted. 
Tris-buffered saline with Tween, 10× (TBS-T): 80 g NaCl, 61 g Tris-base, 2 g KCl, and 1 ml 
tween 20 were dissolved in 1 liter of distilled H2O and the pH was adjusted to 7.0 with 32% HCl. 
Polyacrylamide gels: 10.5 × 7 cm, 1.0 mm thick of mini-gels were home-prepared. Mini slab 
gels consisting of 8-10% made of polyacrylamide/ bisacrylamide resolving gel (pH 8.8), and 4% 
polyacrylamide/ bisacrylamide stacking gel (pH 6.8) were used for resolving the proteins. 
Destaining buffer: 300 ml ethanol and 100 ml acetic acid were diluted with distilled H2O to a 
volume of 1000 ml. 
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RuPBs staining buffer: was prepared by adding 10 μl of the RuBPS stock solution (20 mM) to 1 
litre of 20% ethanol. 
3.1.5.5 Buffers for immunoblotting 
Transfer buffer: 6 g Tris-HCl, 28.8 g glycine, and 400 ml methanol, completed to 2000 ml with 
distilled H2O. 
Membrane blocking buffer: 5% skimmed-milk in 1×TBS-T buffer. 
Washing buffer: 0.05% TBS-T buffer pH 7.0. 
Antibody diluting buffer: 1% bovine serum albumin in 1× TBS-T buffer. 
3.1.6 Enzymes, antibodies, substrates, and proteins 
Table 3.4 Enzymes, antibodies, substrates and proteins that were used in this study. 
Substance Usage Source 
Glu-C Endoproteinase from Staphylococcus aureus Specific Control for enzymatic assay Merck (Calbiochem) 
Glu-C Endoproteinase from Staphylococcus aureus Control protein for SDS PAGE Roche Diagnostics 
Lysostaphin from Staphylococcus simulans Cell lysis Sigma-Aldrich 
Mutanolysin from Streptomyces globisporus Cell lysis Sigma-Aldrich 
Rabbit anti serum of glutamyl-C endoproteinase Primary antibody for detecting V8 
protease 
Biogenes GmbH 
Polyclonal goat anti-rabbit immunoglobulin 
conjugated with horseradish peroxidase (HRP)  
Secondary antibody for detecting V8 
protease 
Dako Cytomation 
Biotin conjugated anti α-hemolysin Primary antibody for detecting α-
hemolysin 
Abcam® 
Streptavidin conjugated with horse reddish 
peroxidase (HRP)  
Secondary antibody for detecting α-
hemolysin 
Pierce/ Thermoscientific 
Peptide Z-Phe-Leu-Glu-pNA V8-Specific chromogenic substrate Sigma-Aldrich 
Peptide Z-LLβNA V8-Specific fluorogenic substrate Sigma-Aldrich 
Peptide ABz-AFAFEVFY(NO2)D-OH V8-Specific chromogenic substrate Synthesized in house 
Sheep erythrocytes in Alsever’s solution Hemolysis assay Fiebig-Nährstofftechnik 
Bovine serum albumin Blocking buffer Sigma-Aldrich 
Skim milk powder Blocking buffer Difco 
Precision Plus Protein Dual Color Standard Standard protein BioRad 
3.1.7 Culture media 
Luria-Bertani (LB)-Medium 
Component Weight (g) in 1 Litre Source 
Tryptone 10 g  Oxoid 
Bacto yeast extract  5 g  BD Bioscience 
Sodium chloride 10 g  Roth 
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BM-Medium 
Component Weight (g) in 1 Litre Source 
Soya peptone 10 g  Oxoid 
Bacto yeast extract ™  5 g  BD 
Sodium chloride  5 g  Carl Roth 
KH2PO4*3H2O 1 g Carl Roth 
Glucose 1 g Carl Roth 
 
Müller Hinton (MH)-Medium 
Component Weight (g) in 1 Litre Source 
Meat infusion 2 g  Carl Roth 
Casein hydrolysate 17.5 g  Carl Roth 
Starch 1.5 g  Carl Roth 
 
Trypitcase Soy Broth (TSB)-Medium 
Component Weight (g) in 1 Litre Source 
Bacto tryptone  17 g  BD Bioscience 
Bacto soy peptone  3 g  BD Bioscience 
Dextrose 2.5 g  Carl Roth 
Sodium chloride 5 g Carl Roth 
Dipotassium phosphate 2.5 g Carl Roth 
 
T-Medium 
Component Weight (g) in 1 Litre Source 
Tryptone 17 g  Oxoid 
Soya peptone neutralized  3 g  Oxoid 
Glucose 10 g  Carl Roth 
MOPS 5.24 g Carl Roth 
NaCl 5.84 g Carl Roth 
KCl 0.149 g Carl Roth 
CaCl2× 2 H2O 0.294 g Carl Roth 
 
Brain-Heart Infusion (BHI)-Medium 
Component Weight (g) in 1 Litre Source 
Calf brain infusion solid 12.5 g  Oxoid 
Beef heart infusion solid 5.0 g  Oxoid 
Protease peptone 10 g  Oxoid 
Glucose 2.0 g Oxoid 
Sodium chloride 5.0 g Oxoid 
Disodium phosphate 2.5 g Oxoid 
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Chemically defined medium for Staphylococcus aureus 
Component  Quantity per 1-Litre Component  Quantity per 1-Litre 
Aspartic acid 1.0 g  Cysteine 0.24 g 
Glutamic acid 1.0 g Phenylalanine 0.20 g 
Proline 1.0 g Tyrosine 0.18 g 
Glycine 1.0 g Methionine 0.18 g 
Serine 1.0 g Tryptophan 0.06 g 
Threonine 1.0 g Nicotinic acid 0.002 g 
Alanine 1.0 g Thiamin HCl 0.002 g 
Lysine HCl 0.6 g KH2PO4 1,34 g 
Isoleucine 0.6 g Na2HPO4 5.7 g 
Leucine 0.6 g (NH4)2SO4 6.84 g 
Histidine 0.48 g NaCl 1.0 g 
Valine 0.48 g Glucose 4.0 g  
Arginine 0.30 g MgSO4. 7 H2O 0.05 g 
This chemically defined medium was described in Bhat et al, 1993 for optimal 
production of different exoproteins in the Staphylococcus aureus secretome [88]. This medium 
was used for producing the proteases, which can be later analyzed by mass spectrometry without 
the interference of the medium contents. All culture media above were filtered through 0.22 µm 
membrane filters into sterile bottles. The pH value of BM medium was adjusted to 7.2, and the 
pH values of MH, TSB, and T medium were adjusted to 7.4. 
Preparation of 2% milk with BHI agar medium  
Milk agar plates were used for detecting the optimal secretion of proteases. For preparing 
these agar plates, 26 g of BHI agar (Difco®) was weighed and transferred into 500 ml distilled 
H2O, stirred by a magnetic stirrer. The content of the bottle was autoclaved. After autoclaving the 
agar medium, an amount of 10 g skim milk powder was added gradually, keeping stirring under 
the laminar flow cabinet (the agar medium should be hot enough in order to avoid the 
agglomeration of milk powder). 
3.1.8 Bacterial strain 
Staphylococcus aureus, V8 strain, a proteolytically hyperactive strain that was used in this 
study, was a generous gift from Dr. J. Miedozobrozki (University Krakow, Poland). He used this 
strain in a comparative study with isolated strains from atopic dermatitis patients. This strain was 
isolated by Dr. Arvidsons who reported about considerable production of V8 protease in this 
strain [89-97]. The strain was known as high-protease-producing strain from which the four major 
staphylococcal proteases (sspA, sspB, aur, and scp) were originally characterized [89-97].  
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3.2 Methods 
3.2.1 Synthesis of peptides 
14 peptides were chemically generated on a 100 µmol scale, starting from TentaGel S-
RAM resin on the Pioneer synthesizer according to Fmoc-solid phase synthesis protocols (Table 
3.5). All Fmoc-protected amino acids that were used in peptide syntheses were of the L-
configuration and were coupled in a fourfold excess (Table 3.3). The peptides were assembled 
using TBTU and DIPEA as coupling agents and 20% piperidine in DMF as Fmoc-deprotecting 
agent. 
Table 3.5 List of the chemically synthesized peptides that were utilized in this study.  
Construct Sequence Usage 
Peptide-1 VLTNENPFSDP-C(F5M)-NH2 Cell-
penetrating 
peptides 
(CPPs) 
Peptide-2 RSNNPFRAR-C (F5M)-NH2 
Peptide-3  YGRKKRRQRRR-C(F5M)-NH2 
Peptide A KGKFLKVSSLFVATLTTATLVSSPAANAYGRKKRRQRRR-NH2  Potentially 
Sec-
interfering 
peptides 
Peptide B  MKGKFLKVSSLFVATLTTATLVSSPAANAYGRKKRRQRRR-NH2  
Peptide C  formyl- MKGKFLKVSSLFVATLTTATLVSSPAANAYGRKKRRQRRR-NH2  
Peptide D  YGRKKRRQRRRC-NH2 (CPP)  
Peptide E  MKGKFLKVSSLFVATLTTATLVSSPAANA-NH2 (Signal peptide)  
Peptide F  MKGKFLKVSSLFVATLTTATLVSSPAANA-NH2 (Signal peptide)  
Peptide G  formyl-MKGKFLKVSSLFVATLTTATLVSSPAANA-NH2 (Signal peptide)  
Peptide H  AAMGNSFVLSTLTKTKPAFLTLVASASVKYGRKKQRRR-NH2 (Scrambled)  
Peptide I MKGKFLKVSSLFVATLTTATLVSSPAANAYGRKKRRQRRR-C(F5M)-NH2  Reporter 
peptides Peptide J formyl-MKGKFLTLVSSLFVATLTTATLVSSPAANAYGRKKRRQRRR-C(F5M)-NH2  
Peptide K ABz-AFAFEVFY(NO2)D-OH Substrate 
(F5M) is the chemical dye fluorescein-5-maleimide, was abbreviated (F5M) in some parts of this dissertation. 
After removal of the last N-α-Fmoc protecting group, the peptide-conjugated resins were 
transferred to filter syringes, washed three times with 3 ml dichloromethane (DCM), and left 
under the fume hood to be dried overnight. Peptides were cleaved from the resin by 
trifluoroacetic acid cocktails (Table 3.6). The resins were collected in a syringe with frit, and 
were treated with 2x 5 ml of the cocktail, with agitation over a period of 3-6 h. Then, the syringe 
was drained carefully and the filtrate was collected in a round bottom flask. The peptide-
containing filtrate was concentrated on a rotatory evaporator and finally the peptides were 
precipitated with tert-butylmethyl ether. 
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Table 3.6 Two types of cleavage cocktails with high quality TFA and fresh scavengers were prepared. 
Cleavage cocktail Content Cleavage time Cleaving from resin of  
A (TFA/H2O/triisopropylsilane) (9.5/0.3/0.2) 3-6 h Peptides 1, 2, 3 and K 
B (TFA/H2O/phenol/thioanisol/DTT) (8.25/2.5/2.5/2.5/1) 3-6 h Peptides A to J 
The suspended precipitation was transferred into 50 ml Falcon conical-centrifuge tubes, 
and centrifuged at 4500 rpm for 15 min. The ether layer was decanted and the precipitated peptide 
was dried overnight under the fume hood. The precipitated peptides were lyophilized and 
weighed to calculate their yields. The crude peptides were resuspended and analyzed by HPLC 
using various acetonitrile gradients in aqueous 0.1% trifluoroacetic acid. Masses of HPLC crude 
peaks were determined by MALDI TOF. Peptides were purified by preparative reverse phase 
HPLC. The collected fractions of the pure peptides were lyophilized and weighed to be subjected 
to the bioassay.  
3.2.1.1 Analytical and preparative HPLC 
All crude and purified peptides were analyzed using the Merck-HITACHI HPLC-system. 
An appropriate mobile phase gradient consisting of acetonitrile and water with 0.1% TFA was 
eluted with a flow rate of 0.7 ml/ min (Table 3.7). 
Table 3.7 Gradient of analytical HPLC A: H2O + 0.1 % TFA, B: MeCN + 0.1 % TFA, C: MeOH. 
Time (min) Flow rate (μl/min) % A % B % C 
0 700 95 5 0 
1 700 95 5 0 
12 700 50 50 0 
13 700 40 60 0 
14 700 0 100 0 
15 700 0 0 100 
19 700 0 0 100 
Purification of peptides were done using an HPLC- Merck-HITACHI instrument, the 
pure peptide was eluted with an appropriate gradient using a mixture of mobile phase as 
acetonitrile: water with 0.1% TFA, product peaks were eluted with a flow rate of 25 ml/min. 
Fractions were collected and analyzed by MALDI-TOF. The fractions that correspond to the 
product were isolated, frozen, lyophilized, and then weighed to be used in specific concentration 
in the microbial experiment. The mobile phase gradient I in table 3.8 was eluted to purify 
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peptides 1, 2, and 3, whereas the mobile phase gradient II in table 3.9 was eluted to purify the 
peptides A to K. 
 
Table 3.8 Gradient I of preparative HPLC A: H2O + 0.1 % TFA, B: MeCN + 0.1 % TFA, C: MeOH. 
Time(min) Flow rate (ml/min) % A % B % C 
0 25 95 5 0 
10 25 95 5 0 
70 25 50 50 0 
70.1 25 0 0 100 
80 25 0 0 100 
 
Table 3.9 Gradient II of preparative HPLC A: H2O + 0.1 % TFA, B: MeCN + 0.1 % TFA, C: MeOH. 
Time (min) Flow rate (ml/min) % A % B % C 
0 25 95 5 0 
10 25 95 5 0 
15 25 80 20 0 
75 25 40 60 0 
75.1 25 0 0 100 
85 25 0 0 100 
 
3.2.1.2 Mass determination of peptides by MALDI TOF MS analysis 
For the mass determination, 0.5 µl of the dissolved peptide mixture was analyzed by 
Ultraflex MALDI TOF MS (Bruker Daltonics) with a λ 337 nm N2 Laser, equipped with a 
reflectron and employing alpha-cyano-4-hydroxycinnamic acid as the matrix. The obtained 
masses were externally calibrated using a mixture with standard peptides angiotensin-II (Mw 
1046.54), angiotensin-I (Mw 1296.69), substance P (Mw 1347.73), bombesine (Mw 1619.82), 
ACTH clip 1–17 (Mw 2093.09) and ACTH 18–39 (Mw 2465.20), Somatostatin 28 (Burker 
Daltonics, USA). The covered mass ranges between 1000 to 5000 Da. Bruker Daltonics Ultraflex 
consists of two Time-of-Flight channels. The first separates the ions generated by laser beam on 
the basis of their molecular weights giving a mass fingerprint. The second TOF resolves the 
fragmented species generated by a collision chamber, which is present between the two TOFs.  
3.2.1.3 Labeling the cell penetrating peptides with fluorescein-5-maleimide (F5M) 
A stock solution (100 mM) of fluorescein-5-maleimide was prepared by dissolving 8.54 
mg in 200 µl DMSO. A 100 mM ammonium acetate buffer was prepared by dissolving 7.708 g of 
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ammonium acetate in 100 ml water. The pH was adjusted at 7.2. This buffer was mixed with 
isopropanol (1:1). The peptide solution was prepared by dissolving 5-10 μmol of peptide with 
available sulfhydryl in 1 ml of the isopropanol buffer (pH 7.2), this will result a 5-10 mM peptide 
solution. For labeling the peptide with the fluorescein-5-maleimide, a 10% molar excess of 
fluorescein-5-maleimide was added onto the molar amount of sulfhydryl to be coupled. The 
reaction was allowed to proceed in dark vessel overnight at room temperature. Analytical HPLC 
was performed, a shifting of the retention time in the main peaks was observed. Mass analysis for 
the labeled peptide was determined by MALDI-TOF. The labeled peptide was purified by 
preparative HPLC, and the collected fractions were isolated, lyophilized, and weighed. 
3.2.1.4 Labeling the Sec-interfering peptides with fluorescein-5-maleimide (F5M) 
The potentially Sec-interfering peptides were chemically generated with a cysteine 
residue at the C-terminus (table 3.6). Due to their low yields, the cysteine containing peptides 
were labeled with F5M and purified in one pot according to Vive’s, et al. [98]. In summary, the 
peptide was incubated with the F5M in buffer conditions, and purified by adding the acetone in 
the same reaction tube, which was kept in darkness for 18 hours. The reaction mixture was under 
vacuum evaporated, lyophilized, and analyzed. 
3.2.1.5 Fmoc-Solid phase synthesis of ABz-AFAFEVFDY(NO2)D-OH as a fluorogenic 
substrate for V8 protease 
This fluorogenic substrate was prepared according to the published procedures of Singh et 
al. [99]. Briefly, the peptide was prepared according to Fmoc chemistry, the side reaction was 
entirely prevented upon treatment of the resin bound peptide with piperidine prior to final TFA 
cleavage. After deprotection, the peptide was purified and characterized by analytical HPLC and 
MALDI-TOF spectrometry. The lyophilized pure peptide was dissolved in DMSO then diluted 
with aqueous solution to be introduced to the supernatant enzymatic assay. 
3.2.2 Bacterial strain and culture conditions 
3.2.2.1 Preparation of strains in glycerol stocks 
Glycerol stock of S. aureus V8 strain was prepared from exponentially overnight growing 
cultures in BM broth, at 37 °C with constant agitation (180 rpm) and stored in cryogenic vials in 
20% glycerol at -80°C. 
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3.2.2.2 Subculture the bacterial strain on the blood agar plate 
By means of a sterile inoculating loop, a portion from the top of the frozen glycerol stock 
was scraped off and streaked onto the blood agar plate under laminar flow hood. The agar plate 
was incubated for 24 h at 37º C. The next day, the plate was taken and wrapped with paraffin film 
keeping it sterile in low temperature 4ºC. The subcultured strains were used for up to 4 weeks 
from the date of subculture. 
3.2.2.3 Culture conditions of the S. aureus V8 strain 
Main cultures of Staphylococcus aureus V8 strain were prepared by inoculating aliquots of 
the overnight culture in 5 ml growth broth. Sterile screw-cap glass tubes of 15 ml-volume were 
used for this purpose. The optical densities of bacterial cultures were started at 0.05, measured at 
λ 600 nm. The peptides were immediately inoculated to the cell suspensions in each tube. The 
growth of staphylococcal cells was allowed at 37ºC with agitation on a shaker 180 rpm until the 
stationary phase was reached. The optical densities were monitored throughout the bacterial 
growth. 24 hours after starting the growth, the bacterial cells were harvested and equal volumes of 
supernatants were collected by filtration through 0.22 μm Millipore filter units. Pellets were 
isolated in the cups of filters. For some particular experiments, bacterial cells were resuspendend 
with phosphate buffered saline (PBS) to an optical density of 1.0. Thereafter, they were either 
undergone complete lysis for testing the cellular and extracellular protein contents, or undergone 
subcellular fractionation for testing the protein contents in different cellular compartments. The 
resulting extracellular and intracellular proteins were denatured, profiled on 8% SDS-gels. 
Western-blot was used specifically for quantifying V8 protease on the X-ray images. 
3.2.3 Investigating the entry of the cell penetrating peptides into S. aureus 
Bacterial cells of S. aureus V8 strain were cultivated in BM broth in an overnight culture. 
The cell suspension was filtered through 0.22 µm Millipore filters. The pelleted cells in the top of 
the filter were rinsed with 3× 2-ml PBS buffer. The rinsed cells were diluted with PBS buffer to 
an ODλ600 of 1.0 in three individual tubes. The fluorescein-conjugated peptides 1, 2, and 3 were 
incubated with the three bacterial suspensions at a concentration of 100 µM at 30ºC. After 1 hour 
of incubation, bacterial cells were collected by 0.22 µm Millipore filters (3500 rpm, 5 min), 
washed with 3×2-ml PBS buffer to remove extracellular fluorescent-peptides and the background 
fluorescence. After diluting the bacterial suspensions with PBS (1:10) in a black 96-well plate 
(Greiner), fluorescence microscopy measurements were performed by the automated microscope 
ImageXpress with excitation and emission wavelengths of 488 and 518 nm, respectively. The 
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images were analyzed using the Transfluor mode of the metaXpress software that can count the 
pits of the fluorescent cells and consequently calculate the average intensity of the fluorescence. 
In order to get better image-resolution to the internalized peptides, confocal laser microscopy was 
used. Rhodamine B hexyl ester (RBHE) was added in a concentration of 5µM as control to detect 
the internalization of the fluorescent-peptides. 
For quantifying the staphylococcal uptake of 100 µM fluorescent peptides, samples were 
prepared in the same previous procedures for FACS analysis with diluting the cell suspension to 
an OD600 of 0.250. Propidium iodide was supplemented into the cell suspensions to determine the 
dead cells, SYBR green was used for staining the total cells. Since the flow cytometer 
FACSCanto was equipped with variable excitation laser lines, 488 nm and 633 nm for the green 
and red fluorescence channels, respectively, it was used for counting the corresponding bacterial 
populations. The calculations were deduced by comparing the count of cells that have internalized 
the peptides to the whole cell population in each sample. 
3.2.4 Identifying the optimal medium for producing proteases 
Staphylococcus aureus V8 strain was cultivated in five different media, as described in 
the procedures under 3.2.2.3, namely MH, LB, BM, TSB, and T medium. At 24 h of growth, 
supernatants were collected by filtration through 0.22 µm Millipore filters. Plates of 2% 
skimmed-milk in brain-heart-infusion agar were used in qualitative and semi-quantitative 
evaluation of extracellular proteases. Small (3 mm diameter) sterile discs were soaked with 20 µl 
aliquots of staphylococcal supernatants. The diameters of the proteolytic zones on milk agar 
plates were measured after overnight incubation at 37°C. 
3.2.5 Quantification of V8 protease in the supernatants 
3.2.5.1 Quantification of V8 protease using the chromogenic peptide Z-FLEpNA 
The enzymatic activity in bacterial culture supernatants was assayed in procedures based 
on Yabuta et al., 1995. V8 protease activity was measured at 30ºC in a 96 well plate (Nunc-flat 
buttom), each well containing 4 mM of Z-Phe-Leu-Glu-pNA in a volume of 200 µl 50 mM TRIS-
HCl buffer (pH 8.0). Initial velocity values were determined by monitoring the absorbance of the 
released p-nitroaniline at 405 nm with a Biotek FL 600 microplate reader. Serial dilution of the 
commercially available enzyme was utilized to determine the limits of detectable activity [100]. 
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3.2.5.2 Quantification of V8 protease using the fluorogenic peptide Z-LLE-βNA 
 The enzymatic activity of the purchased V8 protease was investigated by preparing 
solutions of 0, 2.5, 5, 10, 25, and 50 µM of the substrate Z-LLE-β-NA in 100 mM of phosphate 
buffer pH 7.8. The substrate solutions were assayed with 100 ng/ml of the commercially available 
V8 protease in 96 well plates. The enzymatic activity of the bacterial supernatants was assayed 
according to the same procedure. Each assay well contained 100 µl of 100 mM phosphate buffer 
(pH 7.8), 80 µl of the substrate solution and 20 µl of supernatant. The reaction was carried out for 
30 min at 25°C. The released amount of β-naphthylamide was determined at 410 nm. A unit (U) 
of enzyme is defined as the change of the fluorescence unit per min under the given assay 
conditions. In contrast to Nickerson et al. 2007, our approach was modified in using the free 
secreted V8 protease instead of covalently immobilizing the enzyme to silicon AFM tip (ATEC-
CONT) or silicon particles via amide bonds [10]. 
3.2.5.3 Quantification of V8 protease using the synthetic fluorogenic peptide 
(ABz)AFAFEVFY(NO2)D-OH as substrate 
 The assay was performed based on intramolecular fluorescence quenching according to 
Breddam, 1992 [101]. It utilizes a 96-well plate setup and fluorescence microplate reader. In 
order to optimize the sensitivity of this method, different buffers were first investigated, namely 
HEPES at pH 7.4 and phosphate at pH 7.8. The assay was further run according to the optimal 
conditions. In summary, the commercially available V8 protease (Glu-C endoproteinase from S. 
aureus) at the concentrations 0, 0.1, 0.5, 1.0, 5.0, 10, 20 µg/ ml was assayed with a solution of 
200 µM of the synthetic substrate (ABz-AFAFEVFY(NO2)D-OH) in HEPES buffer pH 7.4 and at 
room temperature conditions. The fluorescence was read each 1 min for 60 min. The isolated 
supernatants, 24 h after growing the bacterial cultures, were assayed with the synthetic substrate 
at the same conditions. In order to get better fluorescence detection, supernatants, were diluted 
with HEPES buffer (1:10) in a volume of 100 µl. The initial rate of the enzymatic activity, which 
is dependent on the concentration of V8 protease, was measured in milli-fluorescence unit per 
min (mFU/ min), it was determined from the first 5 min of the fluorescence increase that resulted 
from the cleavage of the substrate. The emission of fluorescence was measured at 410 nm using 
the fluorescence spectrophotometer FLI-600 (Bio-Tek). 
3.2.5.4 Quantification of V8 protease using SDS-PAGE 
Different concentrations of the commercially available V8 protease, Glu-C 
endoproteinase, were prepared, (0, 2.5, 5, 10, 25, 50, and 100 μg/ml), then denatured by treatment 
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with Laemmli buffer, for 10 min at 95˚C. 10 µl of protein samples were loaded into the wells of 
home-made slab gels, which consisted of a 10% polyacrylamide/ bisacrylamide resolving gel, and 
a 4% polyacrylamide/ bisacrylamide stacking gel. SDS-PAGEs were run in a Bio-Rad 
Miniprotean electrophoresis chamber at 90 Volts for about 1 hour at room temperature. Power 
was stopped when the bromophenol blue dye was leaving the gel. Subsequently, the gels were 
incubated overnight with buffer (30% ethanol and 10% acetic acid), washed 3× with 20% ethanol 
for 30 min, stained with RuBPS in 20 % ethanol for 6 hours, and destained with 30% ethanol and 
10% acetic acid. The next day, the gel was washed with water and set on a UV plate to generate a 
photo by the CCD camera (Fujifilm, Raytest). 
3.2.5.5 Quantification of V8 protease bands by using Western blots 
For Western blot analysis, 10 μl of each supernatant was resolved by 10% sodium dodecyl 
sulfate-polyacrylamide gel and was transferred to nitrocellulose membranes (Whatmann) using a 
semi dry electroblotting apparatus (Biometra) with 20% methanol in the blotting buffer. The 
membranes were blocked with 5% skimmed milk, and incubated with the rabbit V8 protease-anti 
serum at 1:10000 (Biogene GmbH). The membranes were washed with Tris-buffered saline 
containing 0.05% Tween-20 (TBS-T), and probed with an HRP-conjugated anti-rabbit antibody 
(1:10000 Dako Cytomation). For ECL detection, the kit (SuperSignal West Pico 
Chemiluminescent Substrate, Thermo Scientific) was used. Upon the ECL activation on the 
membrane, the membrane was incubated in the dark with the X-ray film inside a film-cassette. 
The exposed X-ray film was processed and scanned to produce TIFF-format images. The resulted 
bands were quantified based on densitometry scale using AIDA image analyzer (Raytest) and 
Photoshop CS3 (Adobe), and were normalized to 10 μg/ ml of endoproteinase Glu-C from Merck 
Bioscience. 
3.2.6 Testing the effect of the peptides on bacterial growth and viability 
In order to investigate the toxicity of the utilized peptides towards the bacterial cells, the 
cell viability test can give a good estimation. In this context, two assays were performed to serve 
this purpose. (1) Counting the colonies forming units (CFU/ ml), and (2) the water-soluble 
tetrazolium WST-8 assay. 
S. aureus, V8 strain, suspensions were prepared as described above in 3.2.2.3. Bacterial 
suspensions were treated with 10 µM of peptides (A to H) in individual culture tubes. One 
bacterial culture tube was left without peptide treatment as a control. After 24h of growth, 
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bacterial cell suspensions were well homogenized by a vortexer, 1 ml of each culture suspension 
was undergone serial dilution (1:9) with phosphate saline buffer (PBS pH 7.0). At the ninth 
dilution step, 100 µl of homogenized suspension was plated on BHI agar plate, and incubated 
overnight at 37ºC. On the next day, the colonies-forming units in the plates were counted as a 
parameter representing the viable cells in the suspension 24 hours after starting the growth. 
In the WST assay, the metabolic activity of the living bacterial cells was spectroscopically 
measured using a test wavelength of 460nm and a reference wavelength of 620 nm. Bacterial 
cultures were individually treated with 10µM of peptides A to H, and one culture was left without 
peptide treatment, 24 h after the growth 1ml of each bacterial culture was serially diluted with 
PBS in 96-well plates. Aliquots of 100 µl of WST-8 solution were added to each well. After 4 h 
of incubation the absorbance was read. 
3.2.7 Investigating the peptides effect on the secretion of V8 protease 
Overnight cultures of S. aureus V8 strain were diluted in BM medium to an OD600 of 0.05, 
and treated with 10 µM of peptide A, B, and C. One culture was left without peptide treatment as 
a control. Cultures were parallel grown at 37ºC under aerobic conditions (as described in 3.2.2.3). 
To monitor the growth, samples were taken every 6 hours and the OD600 was measured. Samples 
for subsequent experiments were taken after 24 hours. Cells were separated from the medium by 
centrifugation (2 min, 3500 rpm). Proteins in the supernatant were denatured, and subsequently 
introduced to SDS-PAGE and Western blotting. Comparisons between the protein bands in lanes 
of the peptide-treated cells and the other lanes of the untreated cells were performed by the 
software AIDA from (Raytest Company). The densitometry of the protein bands was used as 
comparison parameter for the protein abundance. The secreted amounts of V8 protease in 
supernatants were standardized to the optical density parameter at 24 h of growth. 
3.2.8 Investigating the optimal peptide construct that reduces the secretion of V8 
protease 
The levels of the secreted V8 protease were analyzed using Western blotting. Briefly, S. 
aureus cultures were prepared as described in 3.2.2.3, bacterial cultures were treated with 10μM 
of peptides A to H. One bacterial culture was without peptide treatment. Supernatants were 
isolated by centrifuging the suspensions through 0.22μm Millipore filter units, and then 
introduced to the SDS-PAGE and Western blotting. The quantified amounts of the V8 protease 
were standardized to the optical density of the corresponding bacterial culture. 
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3.2.9 Investigating the effect of peptide A on the secretion of V8 protease 
As described in 3.2.2.3, bacterial cultures were individually treated with 2.5, 5, 10, 20, 30, 
and 40 μM of peptide A. One bacterial culture was left without peptide treatment. Supernatants 
and cells were isolated from the growth medium after 24h by 0.22 μm Millipore filters units. 
Bacterial cells were resuspended in cold PBS in the same volume of the suspension, and then 
incubated for 1 hour at 37 ºC with the lysis buffer L. Subsequently, cell debris was homogenized 
by ultrasonifier for 30 seconds. Cell lysates were centrifuged at 10,000× g for 20 min at 4 °C. 
Both cell lysates and supernatants were introduced to SDS-PAGE and Western blotting to 
evaluate the levels of the cellular and secreted V8 protease, respectively. 
3.2.10 Investigating the effect of peptide A on α-hemolysin 
3.2.10.1 Quantification of secreted and the cellular α-hemolysin using Western blot 
analysis 
Based on the streptavidin-biotin specific binding on Western Blot analysis, an approach 
was established using different concentrations of the commercially available α-hemolysin from S. 
aureus (Sigma) ranging between (2.5–100 μg/ml). Both standards and samples were profiled on a 
gel, and were blotted onto a nitrocellulose membrane. The membrane was blocked with 5% 
bovine serum albumin for 1 h, and subsequently treated with the biotin conjugated staphylococcal 
α-hemolysin antibody (Abcam) for 1 h, then washed 6× 5 min with Tris-buffered saline 
containing 0.05% Tween-20 (TBS-T) and probed with high sensitivity streptavidin-HRP antibody 
(Pierce). The kit (SuperSignal West Pico Chemiluminescent Substrate, Thermo Scientific) was 
used for ECL detection. The ECL TIFF-format image was developed from the X-ray film. The 
densitometry of each protein band was quantified using AIDA image analyzer (Raytest) and 
Photoshop CS3 (Adobe), and were normalized to 25 μg/ml of α-hemolysin from S. aureus 
(Sigma). 
3.2.10.2 Investigating the secreted hemolysins using the hemolysis assay 
This method estimates the content of hemolysins (Sec-dependent proteins) in supernatants, 
upon treating 3 staphylococcal cultures individually with 0, 10, and 40 µM of peptide A. The 
secreted hemolysins in the supernatants were assayed in 96 well plates with sheep erythrocytes. 
Upon the lysis of sheep erythrocytes, the absorbance was read at λ440 nm. Briefly, under aseptic 
conditions, sheep erythrocytes were washed 3× 10 ml PBS buffer and resuspended after 
centrifuging (3000× g for 5 min), the resulting red blood cells solution (2%RBC) was seeded into 
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a 96-well plate (U-bottom, Greiner). Each well in the RBC-plate contains 100 µl of RBC 
suspension. Separately, a 96-well preparative control- plate was prepared: each well of this plate 
was filled with 25 µl PBS buffer, and the first position of row A was filled with 100 µl of Triton-
X 1% (positive control), and the first position of row E in this plate was filled with 100 µl of PBS 
buffer (negative control). The first positions in rows B, C, and D in this control plate were filled 
with 100 µl of supernatants of the suspensions that treated with (0, 10, and 40 μM) of peptide A, 
respectively. Serial dilutions (3:4) with PBS buffer were made in each row by transferring the 
content from each well to the next. For the hemolysis reaction, 20 µl of the content of each well 
in the control plate was pipetted onto their counterparts in the RBC plate. The RBC plate was 
incubated for 30 min at 37ºC on agitator in order to homogenize the wells content, allowing the 
erythrocytes to be lysed. The RBC plate was centrifuged for 5 min, and the lysates were pipetted 
from the RBC plate onto a reading plate. The lysates containing plate was measured at 
wavelength λ 440 nm by a light spectrophotometer. 
3.2.11 Investigating the effect of peptide A on the supernatant and subcellular 
proteins 
Two bacterial cultures were cultivated as described in 3.2.2.3. One culture was treated with 
40µM of peptide A and the other was without peptide treatment. To quantify the proteins in 
different cellular compartments, a published fractionation protocol by Pieper et al., 2006 was 
used with slight modification [102]. In summary, after 24h of S. aureus growth, supernatants 
were isolated through the 0.22 µm Millipore filters, taken in equal volumes (3 ml), frozen and 
lyophilized to be concentrated. Cell pellets were washed with PBS and centrifuged at 6000×g for 
15 min at 20ºC. The cell pellets were resuspended at OD600 of 1.0 in buffer A. Bacterial cell walls 
were digested by incubating the cells at 37ºC in a buffer A containing the enzymes lysostaphin 
(100 mg/ ml), and mutanolysin (50 mg/ ml). Ten-microliter aliquots were removed prior to and 
following 1.5 h and 3 h incubation times to monitor the decrease in A600 indicative of cell wall 
degradation. The preparations were centrifuged at 6000×g for 20 min at 4 ºC to separate the cell 
wall digestion supernatants (CWDS) from the protoplasts. CWDS samples were collected to be 
applied to SDS-PAGE experiments. Samples were frozen at - 20ºC until further analysis. The 
intact protoplast pellets were resuspended in buffer B. Addition of the hypotonic buffer caused 
rapid protoplast lysis. Cell aggregates were homogenized by ultrasonifier for 30 seconds (5 ml, 
0.01mm clearance, ten strokes). The lysates were chilled on ice and centrifuged at 100 000×g for 
20 min at 4 ºC. The supernatants containing cytosolic proteins were centrifuged and isolated. The 
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membrane non-dissolved debris was suspended in buffer C and homogenized by the ultrasonifier 
to be analyzed by SDS-PAGE. 
3.2.12 Subcellular localization of the effective peptides 
Three bacterial cultures were prepared as described in 3.2.2.3. The cultures were individually 
supplemented with fluorescein-conjugated peptides, namely peptide -3, peptide I, and peptide J. 
The supernatants were isolated through the 0.22 µm Millipore filters, and the pellets were 
undergone subcellular fractionation as described in section 3.2.11. The distribution of the peptides 
in each fraction was determined by measuring the fluorescence intensity of each fraction using 
the Fusion fluorescence reader. The background disturbance of each buffer fraction was 
subtracted from the corresponding fluorescence value. 
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4 Results and discussion 
Since the general bacterial secretory nano-machine, Sec, is indispensable for secreting most 
of the surface and extracellular virulence factors, a major interest in this pilot study was to 
establish a solid base for targeting this system. This focuses on the generation of novel 
compounds that have a high likelihood of inhibiting this system and thus reducing the secretion of 
pathogenicity factors. The strategy in this study includes three interdependent tactics: (1) 
Synthesizing cell penetrating peptides (CPPs) that potentially penetrate the staphylococcal cells 
and subsequently evaluating this potential. (2) Synthesizing the Sec-interfering peptides 
conjugated with the optimal CPP and their variants and consequently evaluating their effect on 
the secretome level, specifically Sec-dependent proteins, like V8 protease and α-hemolysin. (3) 
Having found one or more peptides showing inhibitory activity to characterize the underlying 
modes of action by which these peptides exert their activity. The first part of the results describes 
the selection and syntheses of the CPPs emphasizing their cellular uptake by Staphylococcus 
aureus using automatic fluorescence microscopy, confocal laser scanning microscopy and 
fluorescence activated cell scanning (FACS) analysis. The second part describes the syntheses of 
both the Sec-interfering peptides and their control peptides. The third part explains the attempted 
approaches for quantifying secreted proteases into the staphylococcal growth cultures (further on 
termed ‘supernatant’). In this part, several results discuss the most effective peptide, and present 
an evidence for its capability in reducing the secretion of Sec-dependent proteins. The last part of 
the results discusses the possible mode of action of the Sec-interfering peptides through (1) 
quantifying the total proteins in the supernatant and three different subcellular fractions of 
Staphylococcus aureus, namely, the periplasm and cell wall; the cytosol; and the cytoplasmic 
membrane; and (2) quantifying the fluorescein-conjugated forms of these peptides in these 
subcellular compartments. 
4.1 Design of the utilized peptide sequences 
In this pilot study, the model of intervention with the Sec pathway utilizes peptidic 
inhibitors that mimic the signal peptide of a particular Sec–dependent protein (like V8 protease). 
Based on the described machinery and the significant role of the signal peptide in exporting 
proteins via the Sec system, these peptidic inhibitors are expected to bind competitively to at least 
one of three significant Sec members SRP, SecA, and/ or SpsB, in the same manner that the 
signal peptides of the exported native proteins do. Thus, the intervention with the secretion of the 
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Sec-dependent virulence protein can theoretically occur in the cytosol or in the cytoplasmic 
membrane in the co-translational phase. In order to facilitate their entry into the bacterial cells, 
these peptidic inhibitors can be synthesized with a transduction domain at their C-termini. These 
transduction sequences are known as cell-penetrating peptides (CPPs) and classically facilitate the 
cellular uptake of various molecular cargoes [74, 103] (see introduction, chapter II). 
The purpose in linking the internalizing sequence to the C-terminus of the signal peptide is 
to keep the N-terminus of the peptidic inhibitor exposed for competitive binding to SRP or SecA 
in the cytoplasm, and/ or to the signal peptidase SPsB in the cytoplasmic membrane and thus 
affect the secretion of one or several Sec-dependent proteins (Figure 4.1). 
Figure  4.1 The hypothesized strategy of targeting the bacterial Sec-pathway. 
A design was constructed to contain the V8-protease-secretion signal peptide conjugated with a CPP. Three 
positions in the cell are potential targets to be competitively attacked by the signal peptide imitative after 
internalization. 
This template is a unique design to mimic the signal sequences at the post-translational 
modification that occur during or after ribosomal protein synthesis in prokaryotes. In prokaryotes, 
every protein translation is initiated with formylated methionine. During expression, the formyl 
group is cleaved by specific peptide-deformylases (PDF). The methionine of the majority of the 
translated proteins is then cleaved by specific methionine aminopeptidases (AMP) [104]. Since it 
is not known yet to which form the signal recognition particle SRP binds, these three variants of 
the peptide construct were proposed. In other words, mimicking the native signal peptide in the 
cytosol and cell membrane required synthesizing three forms of this signal peptide. This includes 
(a) signal peptide without methionine at its N-terminus; this mimics the final-cleaved form of the 
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prokaryotes native preprotein, (b) signal peptide with methionine that mimics the deformylated 
prokaryotic preproteins, and (c) signal peptide with formylated methionine, which mimics the 
initiated prokaryotes preprotein in the cytoplasm. 
In this pilot study, 14 linear peptides were generated according to Fmoc chemistry. They 
vary in their lengths from 8 to 40 amino acid residues, and in their hydrophobic stretches. Each 
set of these peptides was assigned to play one of the following roles:  
(1) A set of cargo delivery peptides that is able to penetrate the cellular membranes of 
Staphylococcus aureus. Rajarao, et al. published a group of cell penetrating peptides that 
showed variable efficiency in mediating the delivery of green fluorescent protein (GFP) 
into prokaryotes, including Bacillus subtilis, Escherichia coli and Staphylococcus aureus 
[87]. These peptides were fused to green fluorescent protein (GFP) in modified plasmids, 
expressed in Escherichia coli, partially purified and incubated with growing cells (Table 
4.1).  
Table 4.1 The cell penetrating peptides that showed successful delivery of GFP into prokaryotes. 
Sequence Charge Naturally occurring proteins Reference 
VLTNENPFSDP 2- Endocytosis signal in Saccharomyces cerevisiae [87, 105] 
RSNNPFRAR 3+ EH domain affinity [87, 105] 
YGRKKRRQRRR 8+ HIV-Tat protein [74, 87] 
YKKSNNPFSD 1+ EH domain affinity [87, 105] 
CFFKDEL 1- Endoplasmic reticulum localization [87, 105] 
In our study, based on Rajarao’s findings, three of these peptides were chosen and 
chemically synthesized with an added cysteine at their C-termini that was used for 
fluorescence labelling (Table 4.2). 
Table 4.2 Chemically synthesized CPPs to investigate the uptake efficiency by S aureus. 
Construct Sequence (labeled with F5M) Molar mass (Mw*) 
Peptide-1 VLTNENPFSDPC(F5M)-amide 1760.6 
Peptide-2 RSNNPFRARC(F5M)-amide 1645.6 
Peptide-3 YGRKKRRQRRRC(F5M)-amide 2088.9 
*Mw: is the monoisotopic mass calculated by Peptide companion software.”F5M” stands for the labeling 
with fluorescein-5-maleimide.  
(2) A set of potentially Sec-interfering peptides (peptides A to C), with a subset of five 
variants (peptides D to H) that were designed as control (Table 4.3).  
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All peptides that are listed in table 4.3 were synthesized in amide form at their C-termini to avoid 
introducing a charge where there is none in the native sequence, and to minimize the influence of 
any added molecule to the peptide N and C-termini on the folding of the peptides. 
Table 4.3 Chemically synthesized peptides to serve as Sec-interfering peptides and control peptides.  
Construct  Sequence  Mw *  
Peptide A  KGKFLKVSSLFVATLTTATLVSSPAANAYGRKKRRQRRR-NH2  4361.5 
Peptide B  MKGKFLKVSSLFVATLTTATLVSSPAANAYGRKKRRQRRR-NH2  4492.6 
Peptide C  formyl-MKGKFLKVSSLFVATLTTATLVSSPAANAYGRKKRRQRRR-NH2  4520.6 
Peptide D  YGRKKRRQRRRC-NH2 (CPP)  1659.9 
Peptide E  KGKFLKVSSLFVATLTTATLVSSPAANA-NH2 (Signal sequence)  2820.6 
Peptide F  MKGKFLKVSSLFVATLTTATLVSSPAANA-NH2 (Signal sequence)  2951.7 
Peptide G  formyl-MKGKFLKVSSLFVATLTTATLVSSPAANA-NH2 (Signal sequence)  2979.6 
Peptide H  AAMGNSFVLSTLTKTKPAFLTLVASASVKYGRKKQRRR-NH2 (Scrambled)  4492.6 
*Mw: is the monoisotopic mass calculated by Peptide companion software. 
(3) A set of fluorescein-conjugated peptides (peptide I and peptide J). Both peptides end with 
a cysteine residue at their C-termini (Table 4.4). The two peptides were chemically 
generated in order to investigate their localization in the staphylococcal subcellular 
compartments. 
Table 4.4 Chemically synthesized peptides that serve as reporter peptides. 
Construct  Sequence  Mw*  
Peptide I MKGKFLKVSSLFVATLTTATLVSSPAANAYGRKKRRQRRRC(F5M)-NH2  5021.6 
Peptide J formyl-MKGKFLKVSSLFVATLTTATLVSSPAANAYGRKKRRQRRRC(F5M)-NH2  5049.6 
*Mw: is the monoisotopic mass calculated by Peptide companion software. ‘F5M’ stands for the labeling 
with fluorescein 5-maleimide. 
(4) A fluorogenic substrate (peptide K), ABz-AFAFEVFY(NO2)D-OH (Mw: 1272.1). This 
peptide was used as specific substrate to monitor the secretion of the Sec-dependent 
protein (V8 protease), and consequently assess the potentiality of the peptides in affecting 
the Sec system of Staphylococcus aureus. According to Singh, et al. the serine V8 
protease has a specific substrate consisting of nine amino acids [99]. This peptide has a 
nitrotyrosine as a fluorophore, and 4- aminobenzoic acid (ABz) as a quencher at the N-
terminus. Upon specific cleavage at the alpha-carboxyl of glutamic acid, the distance 
between the fluorophore and the quencher increases, resulting in the amplification of the 
fluorescence intensity. 
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4.2 Fmoc synthesis of the cell penetrating peptides 
Rajarao, et al., illustrated the efficiency of several peptides in delivering GFP into bacteria 
and yeasts [103, 106]. Based on this result, we chemically generated three CPPs (Table 4.5). In 
order to investigate their uptake by the staphylococcal cells, the peptides were generated with a 
cysteine residue at their C-termini. The free sulfhydryl group of the cysteine residue was 
conjugated with fluorescein-5 maleimide (F5M). The fluorescent-peptides were purified, and 
utilized to assess their uptake by S. aureus using appropriate fluorescence techniques  
Table 4.5 CPPs synthesized according to Fmoc chemistry with their yields.  
 Peptide Non-labeled sequence *Mw  Theoretical 
weight+ (mg) 
Practical 
weight 
Yield after 
purification 
Peptide-1 VLTNENPFSDPC-NH2 1332.6  167.5 30 17.9% 
Peptide-2 RSNNPFRARC-NH2 1217.6 190.2 35 18.4% 
Peptide-3 YGRKKRRQRRRC-NH2 1660.9 280.1 48 17.1% 
*Mw is the monoisotopic mass of calculated by Peptide companion software. + based on the TFA salts 
that were obtained. 
The Fmoc chemistry showed a feasible approach to synthesize these CPPs. Dimeric forms 
of the desired peptides were generated as byproducts, particularly associated with the cysteine-
containing peptides that might form disulphide bonds. Therefore, purification was necessary to 
produce peptides that were appropriate for the bioassays. The eluted peaks from the analytical and 
preparative HPLC of both crude and purified products, respectively, showed the expected masses 
of the synthesized peptides according to MALDI TOF MS. (Figure 4.2)3. 
                                                     
3 The chromatograms and MALDI determinations of peptide-3 are shown in this chapter, while that of 
peptide-1 and peptide-2 can be seen in appendix-I of this dissertation. 
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Figure 4.2 HPLC chromatogram of the purified Tat-derivative peptide before labeling with the fluorescein-5-
maleimide (F5M). 
The purified forms of the cell penetrating peptides were chemically coupled to 
fluorescein-5-maleimide according to the procedure in 3.2.1.3. Mass determinations of the crude 
peptides showed a minor peak of double labeling with the fluorescence groups due to the addition 
of the fluorescein-5-maleimide to the cysteine and probably to the amine of lysine residues or the 
free N-terminus. The analytical HPLC showed a shifting of the retention time in the main peaks 
that is due to the acquired hydrophobic properties to the molecule upon coupling the fluorescein. 
The mono-labeled peptides were purified by preparative HPLC with a reversed phase column RP-
18. See figures 4.3 and 4.4. 
 
Figure 4.3  HPLC chromatogram of the purified Tat-derivative peptide after labeling with the fluorescein-5-
maleimide (F5M). 
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Figure 4. 4 MALDI-TOF mass spectrum of the purified Tat-derivative peptide after labeling with fluorescein-5-
maleimide (F5M). 
4.3 Investigation of the uptake of the fluorescein-conjugated CPPs by 
Staphylococcus aureus V8 strain 
Following the encouraging results obtained for peptide-mediated delivery into yeasts and 
bacteria from Rajarao, our study was extended to assess the uptake of fluorescein-conjugated 
CPPs by S. aureus. Peptides have been used to carry cargo molecules into bacteria previously, as 
described in the technical approach chapter, however we do not know about attempts to use the 
peptides described here for bacterial applications, and only few data are known about delivering 
proteins into bacteria using carrier peptides. Therefore, we synthesized here these peptides 
chemically, and conjugated them with fluorescein-5 maleimide to investigate the potentiality of 
CPP uptake by S. aureus, and to facilitate later the uptake of the Sec-interfering peptides.  
In this approach, freshly grown S. aureus cells were prepared at 1.0 OD. Three cell 
suspensions were individually incubated with three fluorescein-conjugated peptides at 30 ˚C for 1 
h in PBS buffer. Following incubation, cells were rinsed and examined for fluorescein 
distribution using confocal laser microscopy. The fluorescence average intensity was quantified 
for each peptide using automated fluorescence microscopy (Figure 4.5).  
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C 
 
Figure 4.5 Fluorescence microscopy analyses of Staphylococcus aureus suspensions at 0.5 OD600. 
Bacterial cell dilutions with phosphate buffer saline (1:10) were incubated at 37°C for 1 hour with 100 µM (A) 
peptide-1, (B) peptide-2 and (C) peptide-3. Fluorescence intensity of the cells is represented as white pits. 
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In addition, the uptake efficiency of the fluorescein-conjugated CPPs by S. aureus was evaluated 
using FACS analysis (Figure 4.7). 
A 
 
Fluorescent peptide-3 
B 
 
Fluorescent peptide-3 
+ Rhodamine B hexyl ester 
C 
 
Rhodamine B hexyl ester 
Figure 4.6 Confocal laser microscopy revealed the 3D distribution of peptide-3 at a specific z-value. 
(A) Fluorescent peptide-3 in the core of Staphylococcus aureus (green filter). (B) The bacteria after incubation 
with the fluorescent peptide-3 and rhodamine B hexylester (shown in green and red, respectively). (C) The 
bacteria were incubated only with rhodamine B hexylester (red). Confocal microscopy was performed and z-
series measurements were acquired with 70-nm increments. Three-dimensional (3D) projections were created 
from stacks using OLYMPUS FV1000 Viewer software. 
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The results show the highest average intensity of fluorescence when incubating the 
bacterial cells with the internalizing peptide-3 (HIV-1 Tat transduction domain), as shown in 
Figure 4.5. 4 
A verification of the peptide-3 uptake into Staphylococcus aureus was performed by 
confocal laser microscopy (Figure 4.6). Rhodamine B hexyl ester (RBHE), which is known to 
interact with the bacterial membrane but does not internalize [107, 108] was used as a control to 
stain the cell membrane of the staphylococci. The 3D imaging, at specific z level, shows the 
distribution of the fluorescein-conjugated peptide concentrated in the core of the Staphylococcus 
aureus cells (green), where Rhodamine B, the lipophilic dye, is distributed on the cell surface, 
visualized as a ring in some views of the 3-D scan (red)5. 
Fluorescence activated cell scanning (FACS) was used as an alternative technique for 
quantifying the cellular uptake of the cell penetrating peptides. Data analysis confirmed the 
optimal cellular uptake of peptide-3 (YGRKKRRQRRRC(fluor)-NH2). Figure 4.7 shows an 
appropriate quantification of population’s count resulting from three different cultures. These 
cultures were first adjusted to OD600 = 0.250 before adding the peptides and were supplemented 
with propidium iodide (PI) and with 100 µM of fluorescent peptides-1, -2, and -3, respectively. 
For performing this quantification, SYBR green was used in a separate culture of the same 
conditions to stain the total bacterial cells (positive control). The counted population of this 
culture represents the total cell count of the live and dead cells. The FACS analysis of the gated 
area shows the population’s count of the corresponding dye. The highest count was observed in 
bacterial culture that contains peptide-3. The gated area in column B shows a clustering of the 
enhanced fluorescence which might result from aggregated counted cells when adding the 
peptide, this clustering might indicate a change of the cell morphology. The clustering is most 
strong in the presence of peptide-3, which has the highest positive charge +9 of the three peptides, 
whereas peptides 1 and 2 have the charges -1 and + 4, respectively. The aggregation of the cells 
may be due to an interaction of the cationic peptides with the anionic charges of the membrane. 
(For more details, see appendix -IV). 
                                                     
4 For more images from the confocal laser microscopy, about cellular uptake of peptide-3 see appendix-IV 
5 More images of the confocal laser microscopy that show the cellular uptake of peptide-3 
(YGRKKRRQRRRC(F5M)-NH2) can be seen in appendix-IV of this dissertation. 
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Figure 4.7 Fluorescence activated cell scanning after incubating the bacteria with fluorescein-conjugated 
peptides (Pi) and propidium iodide (PI). 
Column A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). Column B: gated populations 
from the labeled cell vs, dead cells. Column C: visual peak of the population for the counted cells in the gated 
area. The rows 1, 2, 3, and 4 represent the cells that were incubated with PI, PI+peptide-1, PI+peptide-2, and 
PI+peptide-3, respectively. All dot plots were produced by FlowJo software.  
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The fluorescence microscopy analysis of the bacterial populations, which were incubated 
with the fluorescein-conjugated CPPs, showed an average fluorescence-intensity that is 
proportional to the bacterial cell count resulted from FACS analyzer. From these data, the 
efficiency of the bacterial uptake to these three fluorescein-conjugated CPPs can be evaluated 
(Figure 4.8). 
 
Figure  4.8 The efficiency of the bacterial uptake to the fluorescein-conjugated CPPs. 
The diagram shows the efficiency of the staphylococcal uptake to the CPPs, quantified by FACS (yellow bars) 
and the average fluorescence intensity, quantified by the fluorescence microscope (green bars). Data were 
obtained from staphylococcal suspensions at OD 0.250. The three fluorescein-conjugated CPPs were incubated 
with S. aureus at a concentration of 100 µM for 2 hours, the quantification was done for the 3× washed bacterial 
cultures. 
In Rajarao’s publication, the three investigated CPPs have already shown successful 
delivery of the green fluorescent protein GFP into prokaryotes and yeasts [87]. Furthermore, the 
three peptides had shown efficient internalization into S.aureus, and the peptide VLTNENPFSDP 
has shown an efficient deliverey of GFP into Candida albicans and Staphylococcus aureus, while 
YKKSNNPFSD has been most efficient for Bacillus subtilis and CFFKDEL for Escherichia coli. 
In the present study, data analysis from the automatic fluorescence microscope and FACS 
revealed the successful uptake of these three fluorescein-conjugated peptides with the highest 
uptake of peptide-3 (YGRKKRRQRRRC(F5M)-NH2) by Staphylococcus aureus. This 
observation gives further evidence of the influence of the delivered cargo on the internalization 
process, and is in excellent agreement with the other cell-based assays performed in studies that 
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utilized peptide-3 with other cellular species [74]. The higher uptake of this peptide compared to 
the other two CPPs can be due to the unique arginine-rich primary structure of peptide-3, which 
promote the cationic properties in initiating the penetration of the anionic cell walls and 
membrane components. Furthermore, peptide-3 mimics the transduction domain of the HIV-1 
transcriptional activator protein (Tat) with a similarity of 8 basic amino acids RKKRRQRRR. 
This unique structure was already used for a successful entry of different cargoes, ranging from 
small particles to proteins, peptides, and nucleic acids [74, 79, 109]. The mode of action of this 
and other CPPs is still discussed and investigated, but data from different researches argue for an 
energy-dependent process of entry [80, 103]. Therefore, the incubation of the labeled penetrating 
peptides with the staphylococcal cells was conducted at 37˚C. The addition of agents that are 
known to inhibit energy-dependent uptake pathways like omeprazole which inhibits the ATPase, 
or adding endocytosis inhibitors like wortmannin, cytochalasin, colchinine, nocodazole, taxol, 
brefeldin A, and chloroquine [110] was not investigated. Since the scope of these experiments 
was concentrated on finding a specific tool for delivering the Sec-interfering peptides the mode of 
action of the delivery peptides was not addressed. Based on the published data about the entry of 
the HIV-1 Tat conjugated proteins, this transduction domain was synthetically coupled to the C-
terminus of the secretion signal sequence of the V8 protease, conveying the cell penetrating 
properties to the Sec-interfering peptides. As a summary, incubating the three fluorescein-
conjugated peptides individually with the staphylococcal cells for 2 hours indicated the entry of 
all three of these peptides into the cells. Measuring the fluorescence properties by fluorescence 
microscopy and FACS analysis showed best results with uptake of the HIV-1 Tat mimetic, 
peptide-3. 
4.4 Fmoc syntheses of the potentially Sec-interfering peptides and their 
control peptides 
The Sec-dependent protein, V8 protease is a significant target in this study because there 
are several known pathogenic aspects associated with its secretion throughout the transition phase 
of the infection process. It plays a key role in moderating the adhesion to fibronectin by degrading 
cell surface fibronectin-binding proteins, and it regulates pathogenesis in controlling the 
microbial adhesion to the host cells [16, 96]. Moreover, V8 protease plays a key role in eluding 
phagocytosis by eliminating protein A, which is recognized by immunoglobulins (IgG) of the 
host [16, 111]. Furthermore, V8 protease is also participating indirectly in the pathogenicity, by 
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activating other bacterial cysteine proteases like SspB and Scp that are needed in cell homeostasis 
and the destruction of foreign or target cell proteins, thereby promoting bacterial invasion [12]. 
V8 protease also degrades neutrophil defensins, IgG and α-1-antichymotrypsin [112], in addition 
to its role in altering the αl-proteinase inhibitor that keeps neutrophil elastase balance in blood 
[113, 114]. In S. aureus culture supernatants, the pore-forming α-toxin is cleaved also by the 
coexpressed V8 protease and aureolysin [17, 115]. Figure 4.9 illustrates the cascade role of the 
staphylococcal proteases. 
 
Figure 4.9 Role of protease expression in staphylococcal pathogenicity. 
The four types of proteases that are found in V8 strain contribute directly and indirectly in the pathogenicity. 
The figure was established based on published results [12, 19, 97]. 
Another important reason for choosing this enzyme was the expectation to develop an 
easy peptide based assay, which facilitates evaluating the outcome of the secretion when treating 
S. aureus with the Sec-interfering peptides. The staphylococcal serine protease, V8 protease, is 
well known with its action to specifically cleave peptide bonds at the carboxyl group of the acidic 
amino acid residues aspartic acid and glutamine acid. Therefore, fluorogenic substrates were 
procured and generated to evaluate the secretion of V8 protease at specific conditions. 
In this pilot study, the secretion signal sequence of the staphylococcal glutamyl 
endoproteinase (V8 protease) was chemically synthesized to play the inhibitor role for the Sec-
system. It consists of the 29 amino acid sequence MKGKFLKVSSLFVATLTTATLVSSPAANA 
[111, 116]. Since the interference with the Sec-system is expected to be co-translational in S. 
aureus, the Sec-interfering peptides should principally contain two domains, the C-terminal 
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domain (11 amino acids of peptide-3, based on the previous results) for transport into the cell, and 
the N-terminal domain: the secretion signal peptide of V8 protease (29 amino acid stretch). Since 
we do not know which, if any, form of the V8 protease-secretion signal peptide can optimally 
perform interference, three forms of the V8 protease signal peptide were generated. (Table 4.3, 
peptides A, B, and C): 
1. The formylated methionine form: this is a common preprotein form, which is found in the 
prokaryotic cytosol, and is observed upon the emergence of the preprotein from the 
ribosome (peptide C). 
2. The methionine form: normally found in the cytoplasm in prokaryotes after they are 
processed by the peptide deformylase (PDF) (peptide B). 
3. The final cleaved form (without methionine): commonly exists in prokaryotes after the 
signal peptides processed by the PDF and the amino-methionine peptidase AMP for protein 
maturation (peptide A). 
Another subset of peptides was synthesized as controls. They consist of the transduction 
domain (peptide D), the V8 protease secretion signal peptide (three forms, peptides E, F and G), 
and in addition a scrambled sequence of the V8 secretion signal sequence with the transduction 
sequence (peptide H). Table 4.6 shows the molecular mass of the peptides and their determined 
MALDI masses of the obtained peaks. The purpose of probing these control peptides is to study 
the effect of the structure activity relationship (SAR) of any of these peptides upon the inhibition 
of secretion. 
Table 4.6 List of the Sec-interfering peptides and the control peptides with their molecular masses. 
Construct Sequence Monoisotopic 
mass [M] 
MALDI mass 
[M+H]+ 
Peptide A KGKFLKVSSLFVATLTTATLVSSPAANA-YGRKKRRQRRR-NH2 4362.5 4362 
Peptide B MKGKFLKVSSLFVATLTTATLVSSPAANA-YGRKKRRQRRR-NH2 4492.6 4493 
Peptide C For-KGKFLKVSSLFVATLTTATLVSSPAANA-YGRKKRRQRRR-NH2 4520.6 4521 
Peptide D YGRKKRRQRRRC-NH2 1659.9 1662 
Peptide E KGKFLKVSSLFVATLTTATLVSSPAANA-NH2 2820.6 2821 
Peptide F MKGKFLKVSSLFVATLTTATLVSSPAANA-NH2 2951.7 2951 
Peptide G For-KGKFLKVSSLFVATLTTATLVSSPAANA-NH2 2979.6 2980 
Peptide H AAMGNSFVLSTLTKTKPAFLTLVASASVK-YGRKKRRQRRR-NH2 4492.6 4494 
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Fmoc syntheses of the Sec-interfering and control peptides were successful. Figures 4.10 
and 4.11 represent the obtained data from the synthesis and analysis of peptide A, namely the 
analytical HPLC chromatogram for the purified peptide; and the mass determination spectrum for 
the pure peptide, respectively.6  
 
Figure 4.10 HPLC chromatogram of the purified peptide A shows a single peak. 
 
 
Figure 4.11 MALDI-TOF mass spectrum shows a corresponding mass of the purified peptide A. 
A double charged mass detection [M+2H]
2+
 appears at m/z 2181.84. 
                                                     
6 The analytical data (chromatograms and mass spectra) of all synthesized peptides can be seen in the 
appendix II and III. 
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The solid phase syntheses of all peptides according to Fmoc chemistry were feasible by 
employing the automated Pioneer synthesizer, but with low yields of the purified products 
ranging between 3-10%. These results could be due to the aggregation of the hydrophobic 
residues along the peptide chains, which plays a motive force for peptide folding, resulting in 
difficulties by HPLC purification, especially for peptide E, peptide F and peptide G, where the 
preparative HPLC was not efficient enough for separating these highly hydrophobic folded 
structures. Nevertheless, several batches were prepared after the consumption of the peptide in the 
biochemical assay. Sometimes, the quality of the newly synthesized peptide was not high, like 
peptide C that showed deviated results in the second batch (Table 4.7). Therefore, optimizations 
of the Fmoc-solid phase syntheses was necessary, this was achieved by doubly coupling the 
amino acids where the hydrophobic aggregates are increased, especially for all peptides that 
contain the secretion signal sequence of V8 protease. The double coupling of the amino acids 
starts mainly after coupling the 6th amino acid where the adjacent hydrophobic residues are 
found. Synthesis optimization strategies were based on predictions of difficult couplings from the 
analysis of the sequences by the software program Peptide Companion. 
Table 4.7: List of the synthesized Sec-interfering peptides and the control peptides with their yields. 
Construct Sequence Theoretical 
wt+ TFA* 
Practical 
wt 
Yield 
after 
purificat
ion % 
Peptide A KGKFLKVSSLFVATLTTATLVSSPAANA-YGRKKRRQRRR-NH2 584.5 mg 68 mg 11.6 
Peptide B MKGKFLKVSSLFVATLTTATLVSSPAANA-YGRKKRRQRRR-NH2 597.6 mg 55 mg 9.2 
Peptide C For-M KGKFLKVSSLFVATLTTATLVSSPAANA-YGRKKRRQRRR-NH2 589.1 mg 24 mg 4.1 
Peptide D YGRKKRRQRRRC-NH2 280.1 mg 48 mg 17.1 
Peptide E KGKFLKVSSLFVATLTTATLVSSPAANA-NH2 339.1 mg 19 mg 5.6 
Peptide F MKGKFLKVSSLFVATLTTATLVSSPAANA-NH2 352.1 mg 15 mg 4.3 
Peptide G For-MKGKFLKVSSLFVATLTTATLVSSPAANA-NH2 343.6 mg 16 mg 4.7 
Peptide H AAMGNSFVLSTLTKTKPAFLTLVASASVK-YGRKKRRQRRR-NH2 597.5 mg 23 mg 3.9 
* At each free N-terminus and at every arginine, histidine, and lysine residues, peptide has a trifluoroacetic acid 
(TFA) as a counter ion of a mass 114 g/mol. These were considered in the theoretical weights. 
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4.5 Identifying the optimal medium for inducing S. aureus protease activity 
on milk agar plates 
It is reported that S. aureus secretes four types of proteases; they are namely, serine 
proteases, cysteine proteases, metalloproteinases, and papain proteases [10, 12]. A milk agar 
assay was assigned to evaluate the total secreted proteases: The action of supernatant proteases on 
milk casein substrate, has been generally used to quantify the proteolytic activity of the secreted 
proteases of S. aureus [89, 117]. When 10 µl of supernatants of the cultured bacteria were applied 
on 3 mm sterile discs, proteolysis took place on the agar plate, resulting a white precipitation 
surrounded by a transparent zone (halo). This zone is generated by the action of extracellular 
proteases, which degrade insoluble casein of the medium into soluble peptides and insoluble 
substances that precipitate around the disc. The extent of proteolysis exhibited by the supernatants 
is represented by the type and size of the transparent zone, whereas the white zone of 
precipitation represents the first stage of casein breakdown that mainly consists of insoluble para-
κ-casein around the disc [89, 118, 119]. 
S. aureus V8 strain was cultivated in five different media, BHI, BM, LB, T, and TSB 
respectively. The supernatants were collected 24 h after starting the culture, and were investigated 
on 2% milk agar plates. The investigated supernatant that was isolated from bacterial culture in 
BM medium showed the largest proteolytic zone (Figure 4.12). 
 
 
 
 
 
 
Figure 4.12 Proteolytic activities on milk agar plates (milk was used as substrate for the staphylococcal 
proteases). 
The isolated supernatants after 24 h of culturing S. aureus (V8 strain) in 5 different media were assayed on 2% 
milk-agar plates to investigate the optimal conditions for secreting the proteases. 
This finding agrees with the finding of Coleman et.al., who found that glucose was essential for 
expressing the proteins in V8 strain, whereas a high concentration of glucose (> 1%) suppressed 
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the production of extracellular proteins [117]. Based on this result, BM medium with less than 1% 
glucose, was used as optimal medium for producing the proteases in the culture media. In 
addition to the milk agar plates, casein agar plates were utilized. However, the results with milk 
plates had better resolution than the casein plates. Furthermore, in all cases the proteolytic zones 
showed white precipitation, which was due to the cleavage of casein into insoluble κ-casein [89, 
118, 119]. 
 On the same milk agar plate, applying 10 µl of V8 protease up to a concentration of 100 
µg/ml did not show any proteolytic zone (figure 4.12 the disc in the middle). This might be due to 
an insufficient concentration of this protease, or the protein contents in milk are not cleaved by 
the V8 protease. Consequently, this method cannot be used for quantifying the secreted V8 
protease at this concentration. However, this assay can be utilized as a semi-quantitative 
determination of the optimal medium for expressing the total staphylococcal proteases that are 
secreted into the supernatant. 
4.6 Testing growth and viability of the staphylococcal cells 
Two assays were performed to check the viability of the cells 24 h after treating the 
bacterial suspensions with 10 µM of the peptides, (1) colony forming unit (CFU) assay, and (2) 
water soluble tetrazolium (WST) assay. 
S. aureus, V8 strain, suspensions were treated with 10 µM of peptides A to H in individual 
culture tubes. One bacterial culture tube was left without peptide treatment as a control and 
another tube was treated with 0.05 µg/ml of V8 protease. The homogenized 24 h-cell suspensions 
were serially diluted with PBS (up to 1:109). 100 µl of the resulted suspensions were plated on 
BHI agar plates, and incubated overnight at 37ºC to count the colony forming units (CFU/ml) that 
resulted from the viable cells. Comparing the colonies count of the peptide-treated cells with the 
one of the non-treated cells presents an evaluation for the effect of the peptides on bacterial 
viability. 
In the water-soluble tetrazolium assay (WST), the metabolic activity of the living cells can 
be spectroscopically measured using a test wavelength of 460 nm and a reference wavelength of 
620 nm. Incubating the bacterial suspensions with WST-8 will cause the bioreduction of 2-(2-
methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium by cellular 
dehydrogenases to an orange formazan product that is soluble in the cell culture medium 
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(Appendix VII). The amount of formazan produced is directly proportional to the number of 
living cells [120]. Data from the WST assay were similar to that from the CFU-count assay. In 
addition to that, the CFU test showed stable values even when treating the bacterial cultures with 
40 µM of the peptides. Up to this concentration, no toxic effect was observed on bacterial 
viability. On the other hand, the lowest growth and CFU values were observed when treating the 
staphylococcal cells at the early growth phase with 0.05 µg/ml of the commercially available V8 
protease (Figures 4.13 and 4.14). 
 
Figure 4.13 The effect of peptides A to H and external V8 protease on bacterial growth at different time points. 
Cell suspensions were treated with 10 μM of peptides A to H. One cell suspension was left without peptide 
treatment, and an extra suspension was treated with 0.05 μg/ ml of V8 protease (Glu-C Endoproteinase). 
This observation is in excellent agreement with McGavin’s results that showed a sensitivity of the 
staphylococcal fibronectin binding proteins (FnbP) and a limited number of other high-molecular-
weight cell surface proteins to V8 protease [16, 96, 121]. Published data showed that both 
adhesive phenotype and cell surface protein profile of S. aureus could be modified by V8 
protease activity [16] 7. Our result suggests that the early addition of the activated V8-protease to 
                                                     
7 V8 protease and other proteins are reported to be secreted and activated in the late exponential phase of 
growth. In this study, supernatants of bacterial suspensions were isolated at different time points of growth, 
then profiled by SDS-PAGE. An evidence introduced in this study (appendix-II) indicates that some 
proteins are expressed after 12 hours of growth, which corresponds to the late exponential phase. 
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the bacterial culture affects the adhesins and binding of bacteria to each other and to the 
environmental biomaterials [16]. The specific action of the V8 protease on the glutamyl and 
aspartyl residues at their Cα-carboxyl probably disturbs the adhesion of the bacterial cells to each 
other, which consequently affects the bacterial density in the culture medium. In addition, the 
result shown in Figure 4.14 suggests another mechanism for V8 protease: it seems to suppress 
growth. 
  
Figure 4.14 The effect of peptides A to H and V8 protease on cell viability after 24 h of growth. 
Toxicity of the peptides was determined at a concentration of 10 µM and later at 20, 30, and 40µM of peptide A 
(data not shown). 
In summary, the optical density at λ 600 nm was used to monitor the cellular growth. On 
average, the apparent optical density values were 10% higher in the presence of the peptides than 
in their absence. This was due to the limited solubility of the peptides, which contributed to the 
turbidity at higher concentrations. However, this slight change in the optical density can be 
neglected when standardizing the secretion-amounts to the parameter of colonies forming units, 
which represents the intact and viable bacterial cells. In all experiments, no toxic impact was 
observed when incubating the peptides up to a concentration of 40 µM. Both bacterial growth and 
bacterial cell viability parameters remained stable in the presence and absence of the peptides. 
Based on this fact, the quantified secretome was standardized to the optical density parameter at 
the time of harvesting the bacterial cells and isolating the secretome. 
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4.7 Quantifying the Sec-dependent protein, V8 protease, in bacterial growth 
media 
To investigate the impact of the peptides on the secretion of Staphylococcus aureus 
proteins, a precise quantitative determination of the secreted V8 protease and the Sec-dependent 
proteins was required. Since the amounts of the synthesized peptides were limited, the secretome 
was investigated in culture volumes of 5 ml. Several approaches were experimented to quantify 
the secreted proteins, and especially V8 protease in culture supernatants of 5ml-volume. Among 
the secretome of S. aureus, several extracellular proteases with proposed roles in virulence were 
described. The major proteolytic enzymes secreted by S. aureus consist of a metalloproteinase 
(aureolysin, Aur), a serine glutamyl endopeptidase (V8 serine protease, SspA) and two related 
cysteine proteinases referred to as staphopain (ScpA) and the cysteine protease (SspB) [12]. V8 
protease is secreted in a pro-form, which is proteolytically cleaved to produce a mature and 
functional enzyme, possibly in an Aur dependent manner [10, 92] (Figure 4.9). In addition to its 
important role in pathogenicity, V8 protease possesses the potential advantage of its convenient 
detection and quantification by utilizing chromo- and fluorogenic substrates. V8 protease 
specifically cleaves the Cα-carboxyl of glutamic acid or aspartic acid under specific conditions 
(buffers of pH 7.4-7.8). 
In order to estimate the secretion status of this Sec-dependent protease among other 
proteases, the activity of the secreted V8 protease was assayed with synthesized or commercially 
available peptides. These peptides in general contain a glutamic acid residue and carry either a 
chromogenic group or a fluorogenic group with a quencher at an appropriate intramolecular 
distance, which make them specific substrates to V8 protease. When the V8 protease is secreted 
to the supernatant, it specifically cleaves the Cα-carboxyl of the glutamyl residue. Consequently, 
the quenching effect is reduced causing an amplification of absorbance or fluorescence. Based on 
this principle, the following assays were used to serve this purpose. 
4.7.1 Chromogenic assay of the secreted V8 protease 
Supernatants were first assayed with the commercially available substrate 
benzyloxycarbonyl-Phe-Leu-Glu-p-nitroaniline (Z-Phe-Leu-Glu-pNA), the release of the p-
nitroaniline causes an intensive absorbance at λ405 nm [122]. The chromogenic assays in the 
present investigation failed due to a low sensitivity of the method, and due to the interference 
caused by the supernatant components that has an absorbance at the same wavelength. 
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4.7.2 Fluorogenic assays of the secreted V8 protease 
Two fluorogenic assays were experimented to detect the secreted V8 protease within the 
supernatant. The first assay utilized a trimeric peptide, benzyloxycarbonyl-Leu-Leu-Glu-βNA (Z-
LLE-βNA, which contains a glutamic acid residue attached to the fluorophore β-naphthylamine 
(ßNA) at the C-terminus [123]. This commercial substrate was incubated with the supernatant to 
principally release the fluorophore β-naphthylamine, which can be measured at the emission 
wavelength 410 nm upon excitation at λ 345 nm (Figure 4.15). Assaying the secreted V8 protease 
with this substrate was expected to give better results, but the detection of fluorescence was 
disturbed by the supernatant contents. This issue was investigated by diluting the supernatants 
with PBS ten times until a better fluorescence was detected. 
 
Figure 4.15 Z-LLE-βNA as a fluorogenic substrate for detecting the secreted V8 protease. 
The second fluorogenic assay utilized a synthetic fluorogenic peptide that carries a 
fluorophore (3-nitrotyrosine) close to the C-terminus, and a quencher (N-terminal anthraniolyl 
group) in an appropriate intramolecular distance (Figure 4.16). This Glu-Xaa-containing substrate 
previously showed specificity to different enzymes from Staphylococcus aureus (V8), Bacillus 
licheniformis and Streptomyces griseus [101]. 
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.  
Figure 4.16 A fluorogenic substrate was synthesized for detecting the secreted V8 protease. 
The cleavage product of this substrate produces increased fluorescence. 
The hydrolysis of such substrates has been fluorometrically monitored and Glu-Xaa 
peptide bonds showed approximately 1000-fold faster cleavage than Asp-Xaa bonds, where a 
decrease in intramolecular quenching was associated with the resulting hydrolysis [101]. 
Based on these findings, the fluorogenic substrate ABz-AFAFEVFFY(NO2)D-OH was 
chemically synthesized in the Glu-Xaa form and assayed with the secreted V8 protease. 
The fluorogenic assay with ABz-AFAFEVFDY(NO2)-D-OH showed a sensitive detection 
of V8 protease (detection limit 0.352 µg/ ml) only in HEPES buffer and not in any culture 
medium, because the components of the culture medium were likely contributing in inhibiting the 
secreted V8 protease.8 This conclusion was drawn after diluting the enzymatic supernatants by 
HEPES buffer; accordingly, the assay showed better increase in the fluorescence and the V8 
protease reactivity was optimally detectable after a dilution (1:9) with HEPES buffer. Despite our 
expectation about the efficiency in evaluating the secreted V8 protease in supernatants, the 
previous assays in general showed shortcomings due to the low sensitivity, and the interfering-
effect of the culture medium. 
                                                     
8 More evidences about the inhibitory effect to the secreted V8 protease by medium-contents can be seen in 
the appendix V of this dissertation, in addition to several non-reproducible results of the fluorogenic assay. 
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Several precipitation trials failed in isolating the proteins of interest from the culture 
supernatant due to the low culture volumes, and due to the co-precipitation of the nutrition 
medium content. A chemically defined medium was also used to eliminate the effects of the 
medium and the co-precipitation, but the concentration of the secreted proteases was too low to 
be detected by the fluorogenic assay. Therefore, an SDS-PAGE approach was experimented to 
have a better quantification of the V8 protease. The stain Ruthenium (II) tris (bathophenantroline 
disulfonate) (RuBPS) was utilized to visualize bands of the secretome on gels, which were 
subsequently quantified by densitometry. In general, ruthenium complexes offer the possibility 
for very sensitive detection. Despite this fact, V8 protease could not be detected in a 
concentration below 30 µg/ ml. 
Further SDS-PAGE experiments revealed a valid and robust quantification of other 
secreted proteins only after concentrating the supernatants by lyophilization, and recover them 
with fewer amounts of aqueous buffers. 
For these reasons, and to reduce the experimental errors in quantifying the V8 protease, a 
Western blot approach was further investigated. Accordingly, a polyclonal antibody for V8 
protease was generated from two rabbits by the company Genmedics, and experimented for 
optimal results. The rabbit-antiserum of V8 protease was used as primary antibody, and the 
commercial antibody, horseradish peroxidase (HRP)-conjugated to goat-anti-rabbit IgG, was used 
as secondary antibody. The detection limits in this approach can be promoted depending on the 
enhanced chemiluminescence resulting from activating the V8 protease bands. With this approach 
the V8 protease was linearly detectable in the range between 0.5 – 20 µg/ ml. Table 4.8 
summarizes the direct and indirect quantitative approaches that were experimented for 
quantifying the secreted V8 protease on a µg scale. 
On the other side, further investigations for quantifying V8 protease in the supernatants by 
WB proved the validity and reproducibility of the method even without concentrating the 
supernatants. The quantification was made for the collected supernatants 24 h after growing the 
cells in culture media containing the tested peptides (according to culture procedures 3.2.2.3). The 
quantified secreted proteins were standardized to the optical density of the respective culture. The 
supernatant of the 24 h culture without peptides was used as a control for quantifying the other 
assays. 
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Table 4.8 Biochemical assays for detecting the secreted V8 protease in the supernatants.  
Assay Substrate Detection method Reference 
Milk agar plates Milk  visible transparent zone [89, 119] 
Chromogenic Z-FLE-pNA absorbance λ 405 nm [122] 
Fluorogenic  Z-LLEβNA fluorescence λ 410 nm [123] 
Fluorogenic  ABz-AFAFEVFDY(NO2)D-OH fluorescence λ 410 nm [101] 
SDS-PAGE  RuBPS staining visible illuminated bands [124] 
Western blot Rabbit anti serum of V8 protease  enhanced chemiluminescence on X-ray film [125] 
4.8  Quantification of V8 protease on Western blots by the enhanced 
chemiluminescence signals (ECL) approach 
The success of quantifying the V8 protease bands by Western blotting depends on 
calibrating signals from the chemiluminiscent labels in a simple and reproducible manner over a 
usable range of protein concentrations. This quantification approach depends on the sensitive 
chemiluminescence detection, by means of the Horseradish peroxidase-conjugated secondary 
antibody, that gives a hard copy image on X-ray film. An accurate quantification of this signal 
can be obtained upon densitometry scanning of the V8 protease bands. Chemiluminescent 
systems based on horseradish peroxidase (HRP) offer rapid highly sensitive results with excellent 
signal-to-noise ratio. Since the ECL images were developed on a film, it was important that 
several exposure times were taken to ensure that the signal from the blot falls within the dynamic 
range of the film. A concentration gradient of the commercial V8 protease (Glu-C endoproteinase 
from Calbiochem®) ranging from 2.5 to 100 µg/ ml was investigated on the Western blot to 
determine the dynamic range of the ECL image. Subsequently to the immunodetection and 
imaging, the results were analyzed using AIDA and Adobe Photoshop CS3® to determine the 
pixel intensities of the bands by integration. With the data a standard curve was generated, which 
was used for the quantification of the secreted V8 protease from the bacterial cultures (Figure 
4.17). All Western blot experiments showed a detectable concentration of the secreted V8 
protease within the dynamic range of the ECL image, particularly below 12 µg/ ml, whereas the 
corresponding bands were not detectable on the SDS-PAGE gel after RuBPS staining due to 
insufficient sensitivity of this method. 
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Figure 4.17 ECL dependencies on the concentration of V8 protease (Glu-C endoproteinase) standard. 
The dynamic range of the ECL images that resulted from V8 protease (Glu-C) standard is broad enough to 
quantify the light output of the V8 protease bands in a concentration between 0- 60 µg/ ml. 
The detection limit of the V8 protease by Western blot using the ECL reagents is in the range of 
µg/ml. 
4.9 Standardizing parameters to quantify the secretions of V8 protease 
For optimal quantification of the secreted V8 protease, it is important to standardize the 
secreted V8 protease to an associated-parameter such as the colonies forming units (CFU), 
the optical density (OD), total secreted proteins, or to any other appropriate parameter. In 
this study, values were normalized to the optical density unit of the culture suspension at 
24 h. 
4.10 Efficiency of peptide A and peptide C in reducing the secretion of the 
Sec-dependent protein V8 protease 
Upon treating the staphylococcal cultures with 10 µM of the early batches of the peptides 
A, B, and C, the supernatants were collected after 24 hours of growth, and profiled by Western 
blot analysis. A reproducible effect of peptide A and peptide C in reducing the secreted amount of 
V8 protease was observed in three different experiments (Figures 4.18 and 4.19). 
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Figure 4.18 Western blot analysis of secreted V8 protease in four bacterial cultures of three individual 
experiments. 
Supernatants were collected after 24 h of growth. The lanes No represent the supernatants of the non-treated 
bacterial cells. The lanes A, B, and C represent three supernatants of bacterial cells treated with 10 µM of 
peptide A, B and C, respectively; lane V8 represents a standard of 10 µg/ml V8 protease. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19 Effect of the Sec interfering peptides A, B, and C on the secretion of V8 protease. 
The diagram shows error bars taken from the standard deviation of three individual experiments. 
The early batches of the experimented peptides A, B, and C showed no impact on bacterial 
growth and viability, and a small to moderate impact on reducing the secretion of V8 protease 
into the supernatants. The strongest effect was observed for peptide A and peptide C (the mean 
values of reduction were 12% and 13% respectively). These findings suggest that conjugating V8 
protease signal sequence with the HIV-1 transduction domain may be a promising tool in 
reducing the secretion of V8 protease. 
4.11 Effect of peptide A in reducing the secretion of V8 protease 
Beside the three peptidic constructs A, B and C, another five control constructs were 
examined in parallel to determine whether the two-domain structure of the peptide is essential for 
reducing the secretion of V8 protease from Staphylococcus aureus. Briefly, 8 staphylococcal 
cultures were treated with 10 µM of the peptides A to H and one culture was without peptide 
treatment. The amount of secreted V8 protease that resulted from 24 h culture supernatants was 
analyzed by Western blotting (WB; Figure 4.20). Densitometry of the bands was used for 
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quantifying the secreted proteins and then normalized to the optical density parameter (cell mass) 
of the culture (Figure 4.21). 
 
Figure 4.20 WB analysis of the secreted V8 protease in 9 individual bacterial culture supernatants. 
The ten positions on the blot represent the bacterial supernatants that were treated with: (1) no peptide, (2) 
peptide A, (3) peptide B, (4) peptide C, (5) peptide D, (6) peptide E, (7) peptide F, (8) peptide G and (9) peptide H 
at 10 µM each. Lane (0) contains 10 µg/ml of Glu-C endoproteinase (V8 protease). 
 
Figure 4.21 Diagram of the quantified V8 protease in the supernatants. 
The error bars were taken from the standard deviation of six individual experiments. 
In six individual experiments, peptide A showed a fluctuating impact in reducing the 
secretion of V8 protease (the reduction was fluctuating between 12– 38%). This finding, in 
principle, asserts that the main structure of the effective peptide should contain the signal peptide 
domain and the transduction domain. The control peptides D to H did not reduce the secretion of 
V8 protease in the staphylococcal supernatant. 
When the second batch of peptide C was tested (Figure 4.21), it did not show the same 
effect in reducing the secretion of V8 protease. This may be due to a poorer quality of this batch 
in which the synthesis was carried out without using a double coupling of amino acids. Therefore, 
it resulted with more purifying difficulties, and consequently with higher content of impurities 
and lower peptide quality than the first batch (figure 4.19). Because of the lower quality of 
peptide C as compared to peptide A, further experiments were carried out only with peptide A. 
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Peptides containing formylated methionine at their N-terminus, as peptide C, are known to be 
strong inducers of inflammation and stimulators of the human innate immune responses [126, 
127]. For these reasons, we continued probing the effect of peptide A, correlating the reduction of 
the secreted V8 protease with the concentration of peptide A. 
4.12 The concentration-dependent effect of peptide A in reducing the 
secretion of V8 protease 
For further investigations on the effect of peptide A, five individual culture tubes of V8 
strain were started as described in 3.2.2.3. At an optical density of 0.05 OD, the five tubes were 
supplemented with 0, 10, 20, 30 and 40 µM of peptide A, respectively. No effect was observed on 
the growth or on the viability of the bacteria over the tested concentration range. The secreted V8 
protease in the supernatants was profiled and quantified on WB. The quantified amounts of the 
V8 protease were standardized to the optical density of the cultures after 24 h of growth (Figure 
4.22 and 4.23). 
 
Figure 4.22 WB profile of the secreted V8 protease in supernatants. 
The cell cultures were treated with different concentrations of peptide A: position (1) No peptide, position (2) 5 
µM, position (3) 10 µM, position (4), 20 µM, position (5) 30 µM, position (6) 40 µM, position (+) shows the 
commercial V8 protease at a concentration of 10 µg/ml. 
 
Figure  4.23 Concentration-dependent effect of peptide A in reducing the secretion of V8 protease. 
The diagram represents the relative abundance of V8 protease in the supernatants. The percentage was 
calculated as a ratio of the V8 protease secreted by the peptide-treated cells to the V8 protease from non-treated 
cells. This diagram shows the values of quantified V8 protease bands after standardization to their respective 
optical densities at 24 h (A/OD600). 
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The IC50 value for reducing the secretion of V8 protease is approximately 25 µM. Furthermore, 
SDS-PAGE analysis of these supernatants showed that treating the bacterial cultures with higher 
concentrations of peptide A was associated with less secretions not only of V8 protease, rather of 
the supernatant proteins that have masses between 20-50 kD, and this reduction was observed in a 
concentration-dependent manner (Figure 4.24) 
.  
Figure 4.24 SDS-PAGE analysis of supernatants isolated from 24 h staphylococcal cultures. 
Bacterial cultures were treated with different concentrations of peptide A. Position (1) with 40 µM, (2) with 30 
µM, (3) with 20 µM, (4) with 10 µM, (5) with 5 µM, (6) without peptide A, (7) control of mixture of α-hemolysin 
and V8 protease (100 μg/ ml each). 
The concentration-dependent effect of peptide A was also investigated on the secretion of 
all proteases by milk agar assay. 10 µl of supernatants that were isolated from cultures treated 
with increasing amounts of peptide A (0, 20, and 40 µM) showed proteolytic clearance zones of 
15.5, 11.5, and 9.5 mm, respectively (Figure 4.25). 
 
Figure  4.25 Effect of peptide A on the secreted amounts of staphylococcal proteases. 
Cleavage zones on milk agar plates of supernatants isolated from cultures that have been treated with 0, 20, and 
40 µM peptide A. 
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When treating the bacterial cultures at the start of growth with peptide A, the secretion of 
V8 protease and probably of other proteases into the extracellular matrix showed to be reduced in 
a concentration-dependent manner. In contrast, the successive additions of peptide A at different 
time points after the start of growth, namely, at 3, 6, 9, and 12 hours at a concentration of 10 μM 
each did not show any further reduction of the secretion compared to that found with a single 
initial dose (data are not shown). This observation suggests that peptide A is likely to be effective 
only in the early exponential phase of staphylococcal growth. 
4.13 Quantification of cellular and extracellular V8 protease after treatment 
of the staphylococcal cultures with different concentrations of peptide A 
In order to verify the ability of peptide A to affect the secretion of V8 protease, it was 
necessary to extend investigation specifically to the cellular V8 protease. To this end, V8 protease 
was determined in a Western blot. The distribution between the secreted and the cellular form 
was determined by analyzing both supernatant and lysed cell pellet fractions. Three individual 
bacterial cultures were grown in the presence of 0, 10, and 20 µM of peptide A. After 24 hours of 
growth, supernatants and bacterial cells were separated by centrifugation, and the cells were lysed 
by lysostaphin. Both supernatants and lysates were subjected to SDS-PAGE and WB analysis. 
The two figures 4.26 and 4.27 show the quantified bands of the extracellular and intracellular V8 
protease. 
 
Figure  4.26 WB analysis of V8 protease from cell lysates and supernatants, respectively. 
Positions 1, 2, and 3 represent the cellular V8 protease from the cell pellet lysates. Positions 4, 5 and 6 represent 
the secreted V8 protease in the supernatants. Positions 1 and 4: no peptide was added to the bacterial culture. 
Positions 2 and 5: 10 µM of peptide A was added. Positions 3 and 6: 20 µM of peptide A was added. Position 7: 
10 μg/ ml of a commercially available V8 protease. 
Chapter IV  RESULTS AND DISCUSSION 
  84  
 
 
Figure 4.27 Effect of peptide A on the cellular and extracellular V8 protease. 
Two bacterial cultures were treated with 10 and 20 µM peptide A, and one culture was without peptide 
treatment. The supernatant and the lysate were collected from 24 h cultures. The blue columns represent the 
cellular V8 protease (cell lysates), and the red columns represent the extracellular V8 protease (supernatants). 
Peptide A showed a concentration-dependent reduction of the secretion of V8 protease and 
correspondingly a concentration dependent retention of the V8 protease inside the bacterial cells. 
However, this presentation shows only the secreted V8 protease and the total cell-bound V8 
protease in general, V8 protease from subcellular compartments is still not addressed. Therefore, 
this observation is not a sufficient evidence for the interference of peptide A with the secretion 
process, because there are still more possibilities that suggest a retention of the V8 protease in the 
membrane or in the cell wall. This issue requires addressing the V8 protease in subcellular 
compartments e.g. the cytosol, the cytoplasmic membrane, and the cell wall. This might give a 
better understanding to the underlying mode of action. 
4.14 The effect of peptide A on the secretion of α-hemolysin 
In order to probe whether the effect of peptide A has specificity to the Sec-system in 
general, it was necessary to investigate further Sec-dependent proteins as well. α-Hemolysin is 
another major S. aureus pathogenicity factor that is also transported through the bacterial 
membrane via the Sec pathway [22, 123]. Besides the successful quantification of the V8 
protease, a similar Western blot approach was developed to investigate the effect of peptide A on 
α-hemolysin. For that purpose, a Western blot experiment was established based on streptavidin-
biotin specific binding. The biotin conjugated anti α-hemolysin from S. aureus was utilized as 
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primary antibody, and streptavidin conjugated with horseradish peroxidase (HRP) was used for 
detection. The secretion of α-hemolysin was investigated in 24 h-culture supernatants that had 
been treated with/without peptide A. Standard solutions (2.5, 5, 10, 25, 50, and 100 µg/ml) of α-
hemolysin were prepared, and analyzed together with cellular/secreted α-hemolysin by WB 
(Figure 4.28). 
[22, 128]Figure 4.28 WB analysis and quantification of cellular and extracellular α-hemolysin. 
Positions 1 to 5 contain commercially purchased α-hemolysin (2.5, 5, 10, 25, 50 and 100 µg/ml), respectively. 
Positions 6 and 7 contain the supernatants of cultures that were treated with 0 and 40 µM peptide A, 
respectively. Positions 8 and 9 contain the isolated and lysed cell pellets of cultures that were treated with 0 and 
40 µM peptide A, respectively. The rectangles show the areas that were integrated densitometrically. 
Three major bands were recognized for the commercial α-hemolysin, whereas four bands 
were recognized for the secreted α-hemolysin. This observation can be explained through the 
possible action of enzymes (V8 protease and aureolysin) that might participate in activating α-
hemolysin in the supernatants to help it in a self-oligomerization process that is needed to 
promote the formation of the pore-forming α-hemolysin [112]. The observed amounts of the 
secreted α-hemolysin were limited between 5 and 25 µg/ml in all experiments. 
 
Figure 4.29 ECL dependencies on the concentrations of α-hemolysin. 
The dynamic range of the ECL images that resulted from α-hemolysin standard allows the quantification of α-
hemolysin bands on the Western blots in a concentration between 0-100 µg/ml. 
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A comparative WB analysis for the secreted and cellular α-hemolysin between the non-
treated cultures and cultures that were treated with 40 µM of peptide A shows a concentration-
dependent effect similar to the one that was observed for V8 protease. In other words, peptide A 
showed a concentration-dependent reduction of the secretion of α-hemolysin and correspondingly 
a concentration dependent retention of α-hemolysin inside the bacterial cells (Figure 4.30).  
 
Figure 4.30 Effect of peptide A on the secretion of α-hemolysin in bacterial cultures after 24 hours of growth. 
The percentages of the extracellular and the cellular α-hemolysin were taken as a ratio of the peptide-treated 
cultures to the non-treated cultures. 
In order to substantiate those results, a hemolysis assay was developed based on the 
hemolytic effect on erythrocytes as an alternative in quantifying the total secreted hemolysins 
instead of α-hemolysin. 
As an independent control experiment, the total hemolysins that were secreted by the bacteria 
were estimated with a hemolysis assay that is based on a literature procedure with slight 
modification [129]. In summary, the staphylococcal supernatants were isolated 24 hours after 
treating the cultures with peptide A at concentrations of 0, 10, and 40 µM, and assayed in 96-well 
plates with sheep erythrocytes (2% suspension). Fifty microliters of supernatant from each growth 
culture was transferred to a flat-bottom 96-well microplate and the absorbance of the released 
hemoglobin in the wells supernatants was determined at 440 nm. Zero hemolysis (blank) and 
100% hemolysis controls were determined using erythrocytes suspended in PBS medium and in 
1% Triton X-100, respectively. A standard curve was established by assaying solutions of 
commercially available α-hemolysin with the erythrocyte suspension (Figure 4.31). 
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Figure 4.31 The standard curve represents the functionality of the hemolysis assay to the concentration of α-
hemolysin  
The standard solutions of α-hemolysin (0, 5.6, 7.5, 10, 13, 18, 24, 32, 42, 56, 75, and 100 µg/ml), and 
staphylococcal supernatants of cultures that were treated with different concentrations of peptide A were 
assayed with a suspension of 2% sheep erythrocytes. 
Assaying the supernatants of bacterial cultures that were treated with different concentrations of 
peptide A showed a concentration-dependent effect of peptide A on lysis of the sheep 
erythrocytes (Figure 4.32). 
 
Figure 4.32 Hemolysis assay with sheep erythrocytes after the addition of growth culture supernatants with and 
without peptide A. 
Triton X-100 and PBS buffer were used as positive and negative controls, respectively. 
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Hemoglobin-lysate measurements showed a maximum absorbance of 0.420 at 440 nm. 
The absorbance value for the supernatant without peptide A is higher than the absorbance value 
of supernatant with 10 µM of the compound, and these are higher than the absorbance value of 
the culture with 40µM of peptide A. Correlating this data to the concentration of α-hemolysin in 
the standard curve, and to the WB data, we can deduce that a concentration-dependent effect of 
peptide A on the secretion of this toxin might happen, i.e. the higher the concentration of peptide 
A, the less α-hemolysin is secreted. 
In order to answer the question if this reduction in the secretion is based essentially on an 
interference of peptide A with the Sec-system, the investigation of the secretion of Sec-
independent proteins should be addressed. No commercial antibody for known Sec-independent 
proteins was available and in the time frame of the present investigations it could not be 
generated. 
4.15 Determining the effect of peptide A on the concentration of V8 protease 
in different cell compartments 
In order to obtain a better understanding of the underlying mode of action of peptide A, 
and to address if the intervention of peptide A occurs within the membrane, the cell wall, or 
within the cytosol, a comparative analysis of the staphylococcal V8 protease and the proteome in 
different cellular fractions was carried out. If peptide A blocked one of the Sec components: SRP, 
SecA, or SpsB, an accumulation of the Sec-traslocated protein would be observed in the 
corresponding cellular compartment. To this end, two staphylococcal cultures containing 0 and 40 
µM of peptide A were grown for 24 h followed by a subcellular fractionation. Based on published 
procedures [102], the successive subcellular fractionation was performed using three buffers of 
specific contents and specific pH values to keep the physiological conditions for the extracted 
proteins optimal, and to keep the fraction content intact (Figure 4.34). 
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Figure 4.33 Schematic representation of the cell fractionation procedure. 
S, CW, CYT and M represent culture supernatant, cell wall with periplasmic space, cytoplasm and membrane, 
respectively. Membrane fragments were dissolved later in buffer C. 
Moreover, it was important to keep the lysis process of the pellets under mild conditions: 
supplementing the lysis buffer with a cocktail of protease-inhibitors, keeping the protoplast intact, 
and generating a precise determination of the protein content of the cytoplasm and the 
cytoplasmic membrane. Lysostaphin (25kD) was used in this procedure as a lysis factor due to its 
known specificity in digesting the staphylococcal pentaglycine bridges of the cell wall. According 
to Park et al. [130] EDTA and an alkaline medium function as inhibitor for the zinc-
metalloproteinase (lysostaphin). Therefore, EDTA was supplemented to further buffers as an 
inhibitor for lysostaphin. Furthermore, a cocktail of protease inhibitors was utilized to inhibit the 
action of the existing proteases. Triton X was used as a detergent that is well known to solubilize 
membrane proteins and to separate them from hydrophilic proteins via phase partitioning at 
physiological temperature. The membrane fraction was isolated from the cytosol by 
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ultracentrifugation at 100,000× g. This approach resulted in four different fractions; they are 
namely, the supernatant, the cell wall/ periplasm, the cytoplasm, and the cytoplasmic membrane. 
The resulting four fractions were introduced to SDS-PAGE and WB analysis to develop the ECL 
images and subsequently quantify the extracellular and subcellular V8 protease bands (Figures 
4.34 and 4.35). 
 
Figure 4.34 WB analyses for V8 protease in different subcellular fractions and culture supernatant. 
Position (1) 10 μg/ml of V8 protease, positions 2 and 3: V8 protease of supernatants. Positions 4 and 5: V8 
protease of the cell wall and periplasm. Positions 6 and 7: V8 protease of cytosol. Positions 8 and 9: V8 protease 
of membrane fractions. Positions 2, 4, 6, and 8 were of the non-treated cells, while positions 3, 5, 7, and 9 were of 
the cells that were treated with 40 µM peptide A. The supernatants were standardized to an OD600 of 5.0, while 
the subcellular fractions were standardized to OD600 of 1.0. 
 
Figure 4.35 Effect of peptide A on V8 protease accumulation in supernatant and subcellular compartments of 
staphylococcal cells. 
The values from the culture with peptide A were related to the values from the culture without peptide addition. 
 Since the protein is co-translationally secreted through the membrane, and based on 
results that revealed the reduction of V8 protease amounts in the supernatant when using peptide 
A, an accumulation of V8 protease would be expected to be found in cytosol or cytoplasmic 
membrane when Sec system is blocked. A comparative study of V8 protease in different fractions 
was performed for the peptide treated cells and the non-treated cells. Western blot analysis 
showed that less V8 protease was secreted into the supernatant than without peptide treatment, 
and more retained in the periplasm/ cell wall of the peptide-treated cells, while only very small 
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amounts of V8 protease in the cytoplasm and the cytoplasmic membrane can be detected. A 
possible explanation to this finding might be that the matured or non-matured protein that was 
secreted into the periplasmic space during the 24 h of growth is only slowly released from the 
membrane, possibly after completion of maturation. In addition, it would be expected that nascent 
protein would be degraded in the cytoplasm. These findings are so far in agreement with peptide 
A interfering with secretion during the co-translational phase, whereby peptide A may also be 
either blocking or slowing the transport or migration through the cell wall. 
4.16 Determining the effect of peptide A on the cellular proteome in different 
cell compartments 
For a better understanding of the underlying mode of action of the peptide construct, and to 
address if the peptide A has a general effect on accumulating other proteins in cellular 
compartments, an analysis of the total staphylococcal secreted and subcellular proteins was 
carried out. For that purpose, a comparative SDS-PAGE analysis of the total proteins was 
performed in parallel under two conditions, with/ without peptide treatments. The staphylococcal 
cells were grown according to procedure 3.2.2.3, supernatants were obtained by filtering the cell 
suspensions, pellets were resuspended in the original culture volume, and undergone a 
fractionation according to procedure 3.3.7. The cellular fractions were collected in equal volumes 
to allow quantitative comparison of the proteins in each fraction and thus, get a comprehensive 
analysis of all proteins. Since the sensitivity of SDS-PAGE analysis is not as high as WB 
analysis, the supernatant and the membrane fraction were of high importance to be detected. 
Therefore, it was found advantageous to carry out a concentration enhancement before the 
electrophoretic separation, which was achieved by lyophilizing a defined aliquot of the solution 
and redissolving the solid remainder in a smaller amount of water. The supernatants were 
concentrated 6-fold this way and the membrane fractions 2-fold. Samples were profiled on large 
8% SDS-PAGE gels (Figure 4.36). 
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Figure 4.36 SDS PAGE profile of total proteins in four fractions with/ without peptide A treatments. 
Protein contents of four fractions were profiled on 8% SDS-PAGE, namely supernatants and the 3 subcellular 
fractions cell wall, cytosol, and cytoplasmic membrane. Using the lyophilization approach, supernatants were 6 
fold concentrated, while the membrane fractions were 2 fold concentrated. Lanes 1-2: supernatant fractions, 
lanes 3-4: cell wall fractions, lanes 5-6: cytoplasmic fractions, lanes 7-8: membrane fractions, lanes 9-10 are 
controls of 100 µg/ ml of commercial V8 protease and α-hemolysin, respectively. Lanes marked with A represent 
the fractions resulting from cells treated with 40 µM peptide A. Staining with RuBPS. 
 The comparative analysis of the supernatants and cellular compartments of the peptide-
treated/ non-treated cultures showed a general reducing effect on the secretion of proteins. In 
general, proteins that are transported across the membrane in a Sec-dependent manner emerge at 
the extracytoplasmic membrane surface in an unfolded state. These proteins need to be rapidly 
and correctly folded into their native and protease-resistant conformation in order to protect them 
from cleavage by proteases in the cell wall or extracellular environment [67]. The highest 
abundance of proteins was observed in the periplasm and cell wall and the cytosolic fractions in 
this experiment. 
Upon treating the bacterial cells with 40 µM of peptide A, no effect was observed on bacterial 
growth, or on cell viability, but a substantial effect in reducing the amounts of secretions into the 
supernatant and the periplasm/ cell wall. In comparison with WB analysis of the quantified V8 
protease in four fractions, treating the bacterial cultures with peptide A lead to a reduction in the 
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secreted amounts of V8 protease and to an accumulation of V8 protease in cell wall. This 
accumulation of V8 protease in the cell wall compartment can be detected by WB but not by 
SDS-PAGE approach. This may be due to the retention of the Sec-dependent proteins in the 
periplasm and the cell wall compartment, which are secreted as non-folded proteins and are 
folded to form the mature proteins. Although SDS-PAGE analysis is still insufficient tool to 
detect low concentrations of the V8 protease and other Sec-dependent proteins in comparison to 
WB analysis, it showed a reduction of the amounts of some proteins in cell wall compartments 
associated with the bacterial culture treatments with peptide A. Moreover, a slight enhancement 
of some proteins was observed in the membrane at ca. 28 and 48 kD regions. This latter finding 
calls for further investigations to determine whether these proteins (28 and 48 kD) are Sec-
dependent proteins. Not all membrane proteins use SecYEG for insertion, rather a small subset of 
integral membrane proteins are targeted to YidC where they are inserted into the membrane in a 
Sec independent manner [131, 132].  
4.17 Investigating the subcellular targeting of the potentially Sec-interfering 
peptides 
Based on the previous findings, our research interest was stimulated towards investigating 
the possible targets of the peptide constructs and their subcellular localizations in S. aureus. A 
preliminary experiment was established to serve this purpose. Three fluorescein-conjugated 
constructs were chemically synthesized, namely peptide-3, peptide I, and peptide J. (Tables 4.2 
and 4.4). These peptides were incubated with the bacterial cultures for 24 h. The supernatants 
were isolated and the bacterial cells were collected and fractionated into four fractions as 
described above. The fractions were collected in equal volumes to facilitate an optimal evaluation 
of the measured fluorescence in each fraction. This evaluation can serve as a preliminary map of 
the potential subcellular targets that can be interfered by these peptides. The fluorescence 
properties were measured in supernatant, cell wall, cytosol, and membrane fractions (Figure 
4.37). 
The fluorescence was observed in all cellular compartments (Figure 4.37). This asserts the 
potential entry of the peptide into the staphylococcal cells. The highest fluorescence value for the 
bacterial compartments was observed in the cytoplasm fraction. However, it is still yet not known 
if a potential intervention of these peptides with one of the cytoplasmic or membrane components 
has occurred. Therefore, the binding affinity of these peptides to the signal recognition particle 
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SRP, to the molecular motor SecA, and to the signal peptidase SpsB in the cytoplasmic 
membrane should be investigated in future studies. This may be addressed by utilizing peptide or 
protein microarrays. The array requires preparing a piece of glass on which different expressions 
of the SRP or SecA proteins have been affixed at separate locations in an ordered manner thus 
forming a microscopic array. The known expressed sequences of the staphylococcal SRP, or 
SecA protein are used as capture molecules to detect any specific binding to the labeled peptide 
A. This approach is still limited because no enough libraries of such proteins are commercially 
available at the time of this study. Therefore, it would be much easier to establish an ELISA-type 
assay or use SPR-based methods (e.g. the Biacore instrument) if only a few proteins and their 
interaction with peptide A are to be investigated.  
 
 
Figure 4.37 Relative distribution of fluorescein conjugated peptides in supernatants and in different subcellular 
fractions. 
The sum of fluorescence in all fractions was considered as 100%, and accordingly the distribution was 
evaluated. 
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5 Conclusions and recommendations 
These studies were initiated in the face of an urgent unmet need to develop novel approaches 
to combat the infections caused by antibiotic-resistant bacteria. Specifically the problem was 
approached to find novel active compounds and targets in S. aureus. This study investigated 
establishing a base for affecting the secretion efficiency of the bacterial virulence factors. Our 
study presents new peptides that play a double role. On one side, they penetrate the 
staphylococcal cells. On the other side, they were designed to interfere with the secretion of 
specific Sec-dependent proteins that might act in the pathogenesis of infection. Little data has so 
far been accumulated with respect to developing antimicrobial agents as specific inhibitors fo the 
signal peptidase SpsB, and Sortase A in Staphylococcus aureus [50, 51, 54, 55, 69]. These trials 
in interfering with the secretion of the cell wall integrated proteins were novel at that time. In this 
work, the general secretion pathway Sec was put on the focus due to its essential role in secreting 
most virulence factors through the cell membrane. Based on the description of this pathway in 
Gram-positive bacteria, it is believed that the signal recognition particle SRP, the secretory motor 
Sec A, and the signal peptidase SpsB play the key role in interacting with the signal peptide of the 
secreted preprotein, and thereby translocating unfolded virulence proteins from the cytoplasm 
into the extracellular milieu. Therefore, this study hypothesized that these three Sec- components 
can be significant targets to synthetic peptides, which potentially compete with the secretion 
signal sequence of a Sec-dependent protein (V8 protease). In order to internalize these peptides 
into S. aureus, three cell-penetrating peptides (CPPs) were chemically generated, and investigated 
whether they are efficient in delivering fluorescein-5-maleimide into S. aureus. Fluorescence-
based methods revealed an optimal cellular uptake of the peptide YGRKKRRQRRR. Based on 
this finding, potentially Sec-interfering peptides were chemically generated by Fmoc chemistry. 
These peptides consist mainly of two domains, the signal peptide mimetic of the V8 protease (29 
amino acids), and the transduction domain mimetic of the HIV-1 Tat protein (11 amino acids). 
Another subset of control peptides was chemically synthesized. Their potential in affecting the 
secretion of Sec-dependent proteins was investigated. 
The experimental work in this study proved that the Fmoc solid-phase synthesis was a 
feasible approach for generating the required peptide constructs, despite the relatively low yields 
of the pure products. As discussed before, automated synthesizers can chemically regenerate 
these 40mer constructs. Both quality and yields of these long peptides might be improved if 
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newer synthetic strategies and techniques were utilized, e.g. synthesizing nona- or decapeptides 
and subsequently ligating them chemically as longer peptide might be a good alternative to 
improve the yield, since this synthesis strategy might bypass the aggregation of the 
hydrophobicity along the synthesized chain and give higher yields and purity of the final products 
[133]. Another possibility is the utilization of pseudoproline (dipeptide) building blocks in the 
synthesis process. Dipeptides are known to minimize the aggregation in the peptide chain through 
providing the temporary side-chain protection especially for Ser, Thr, and Cys on one hand, and 
providing the fast solubilized building blocks leading to increase the solvation and the coupling 
rates of the peptide synthesis on the other hand [134]. This strategy might improve the yield of 
the syntheses through promoting the coupling efficiency. Microwave-assisted peptide synthesis 
technique could be another way to improve that quality and yield of the peptides because this 
approach is known to keep the long synthesized peptides receiving homogenous microwave 
energy field, providing them with optimal temperature for coupling of the amino acids with lower 
racemization degrees [135, 136]. These techniques can be successful alternatives to the 
conventional technique if they were applied in this study. 
Investigating the staphylococcal uptake of three cell-penetrating peptides showed optimal 
properties for the HIV-Tat protein derivative, YGRKKRRQRRR. Three techniques were used in 
parallel to investigate this phenomenon: automatic fluorescence microscopy to quantify the 
internalization of the fluorescently labeled peptides, FACS analysis to quantify the uptake of the 
fluorescent peptides into the Staphylococcus aureus cells, and the fluorescence quantification of 
four different subcellular fractions. 
One of the major objectives in this study was to establish robust assays for both 
qualitative and quantitative determinations of Sec-dependent proteins and total secreted proteins. 
This was set to facilitate evaluating the state of secretion upon the peptide treatments. The 
quantified amounts of Sec-dependent proteins were correlated in each experiment to the bacterial 
growth and viability parameters. 
The semi-quantitative determination on milk agar plates showed the BM medium as 
optimal growth medium for inducing the secretion of the staphylococcal proteases. Therefore, it 
was used in all experiments to cultivate the V8 strain in this study. The attempted quantitative 
determination of the secreted V8 protease in the supernatant by using colorimetric and 
chromogenic assays with special peptide substrates was not useful due to the low sensitivity of 
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the approaches. Therefore, this technical approach was replaced by alternative experimental 
settings. Gel electrophoresis followed by Western blot was found to be an optimal and valid tool 
for quantifying the secretion of the Sec-dependent proteins V8 protease and α-hemolysin. 
Investigating eight generated peptides showed a reproducible impact of peptide A 
(KGKFLKVSSLFVATLTTATLVSSPAANAYGRKKRRQRRR) in reducing the secretion of 
two Sec-dependent proteins, V8 protease, and α-hemolysin, and on the hemolysis properties of 
bacterial growth supernatants. This finding was not limited to these two Sec-dependent proteins, 
rather it includes other proteases and probably additional proteins 9. 
Investigating the secretion of Sec-independent proteins could not be addressed explicitly 
because no commercial antibody for known Sec-independent proteins was available or could be 
generated in the time frame of the present investigations. Therefore, this issue was left 
unanswered. Nevertheless, we developed a comparative approach, comparing specific protein 
contained in cellular fractions of non-treated and peptide-treated cells. This was expected to 
provide a better understanding on how the peptide constructs affect the secretion of V8 protease 
in different fractions, namely; the supernatant; the periplasm and cell wall; the cytosol; and the 
cytoplasmic membrane. 
Based on these results, an incomplete picture emerged which left many questions still 
open. A comparative secretome study of the supernatants and probably also of the different cell 
compartments in the presence and absence of peptide A should yield a more complete picture but 
was considered to be beyond the present scope of this study. This approach can be built on two-
dimensional gel electrophoresis and mass spectrometry, where the spots of the secretome, from 
the supernatants or cell compartments, can be identified by mass spectrometry and quantified. 
This approach will reveal a comprehensive view about all Sec-dependent and independent 
proteins and other cell components. 
The fluorescein-conjugated form of peptide A was distributed in all subcellular compartments. 
The high abundance of the fluorescein-conjugated peptide in the cytosol fraction calls to a further 
investigation whether the mode of action of this peptide was based upon a competitive binding to 
one of the cytosolic components, in particular SRP and/ or SecA. However, further studies are 
                                                     
9 The effect of this construct in reducing the secretion of this number of proteins could be due to the 
similarities of the peptide A sequence to the signal peptides of these proteins. A multisequence alignment 
analysis showed a similarity between the signal peptides of the Sec-dependent proteins in general (See 
appendix VI).  
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still required to identify the mode of action of this product. A protein-function microarray might 
be helpful to investigate the specific binding of the signal sequence or the peptide constructs to 
the M domain of the fifty four homologue (Ffh protein) in the SRP that is binding to the signal 
peptide [137]. This is more important issue because of the promiscuity of the SRP, and because 
only one type of SRP is present in the bacteria, and this is processing all Sec destined proteins 
with their different secretion signal sequences. 
This approach might also be used for the optimization of binding affinities and the 
activity profile of the peptide constructs by investigating sequence modifications. Such a study 
could include generating combinatorial libraries of the successful signal peptides attached to a 
solid-phase and testing their specific binding to some known expressed cytosolic proteins. 
Following such a study, further successful structures might be candidates for drug discovery. 
The stability of the peptides in serum should further be addressed. This will determine the 
potential of such constructs to enter further clinical trials if they show promising stability and 
non-toxic effect against eukaryotic cells. Many drugs which exhibit promising pharmacological 
activities fail to show convincing effects in vivo. This is due to various reasons, including low 
stability or unexpected immunogenicity and toxicity. One main problem is that several 
therapeutic peptides and proteins exhibit a short plasma half-life time in the range of a few 
minutes to a few hours. Half-life times of only a few minutes are in most cases not effective in 
order to deliver sufficient drug amounts to the target tissue. Therefore, strategies to prolong the 
half-life of peptide A to enter clinical studies might require replacing some L-amino acids by D-
amino acids or other nonproteinogenic amino acids, to enhance the stability of the peptide 
towards degrading plasma enzymes. 
The utilizied CPPs are not specific for bacteria. They are known to internalize efficiently 
and rapidly into eukaryotic cells [83]. Thus, a rapid clearance of the serum from the peptide 
constructs can not only be expected because of degradation but also due to uptake into the host 
tissue. Before a pharmacological systemic application of such constructs can be considered, 
bacteria-specific CPPs need to be developed. So far those are not known.  
Since the L-amino acid construct of peptide A had no effect on bacterial growth, and the 
viability of the staphylococcal cells, it cannot be classified as a conventional antibiotic. 
Nevertheless, it might be useful as an anti-virulence agent that interferes with the Sec-system, 
thus, disarming the bacterial cells by competing secretion of virulence factors like V8 protease 
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and α-hemolysins. The non-toxic effect of peptide A on the bacterial cells provides a preliminary 
insight on a new strategy. This new strategy might create an in-vivo scenario that is similar to 
vaccination with a live, attenuated strain. The bacteria are eventually cleared by the host immune 
response, with little to no impact on the normal human microbiota (Figure 1.11). 
However, this approach, in targeting virulence, can introduce a new generation of potent drugs 
that principally consists of the cell penetrating peptides conjugated with chemical warheads, 
whose intervention with the bacterial virulence factors and mechanisms might slow the 
proceeding of the infection process. With this strategy, more chance can be given for the infected 
tissue to regulate its immune response clearing out the pathogen with less damage. The strategy 
of interfering with the secretion of pathogenicity factors rather than with the viability of the 
bacteria may impose weaker selective pressure for the development of antibiotic resistance 
relative to current antibiotics. Although all the advantages of such a novel strategy are highly 
desirable the results presented rather suggest that it would be extremely difficult to achieve drugs 
with clinical potential with this approach. 
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1 Appendix-I: Fmoc solid phase synthesis of the cell penetrating 
peptides 
As described in chapter IV, three peptide constructs were described in Rajarao et al. [87]. 
These peptides were chemically generated by the Fmoc solid phase approach. They are shown in 
table 5.1 
Table 5.1 List of the cell penetrating peptides synthesized by Fmoc solid phase peptide synthesis. 
Construct Sequence (labeled with F5M) Molar mass (monoisotopic) MALDI mass 
Peptide-1 VLTNENPFSDPC(fluor)-amide 1759.6 1760 
Peptide-2 RSNNPFRARC(fluor)-amide 1644.6 1645 
Peptide-3 YGRKKRRQRRRC(fluor)-amide 2087.9 2089 
1.1 Peptide-1 
Figure 1 The Fmoc deprotection profile shows the successful synthesis process of peptide-1 by the Pioneer 
peptide syntheisizer. 
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Figure 2 The HPLC chromatogram of the purified peptide-1 shows a major peak with some minor peaks. 
 
Figure 3 MALDI-TOF spectrum shows a measured mass of the purified peptide-1. 
  APPENDIX 
 116  
 
1.2 Peptide-2 
 
Figure 4 The Fmoc deprotection profile is an indication of successful synthesis of peptide-2 by the Pioneer 
peptide synthesizer. 
 
 
Figure 5 The HPLC chromatogram of the purified peptide-2 shows a major peak with two minor peaks. 
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Figure 6 The MALDI-TOF spectrum shows the expected molecular mass of peptide-2. 
1.3 Peptide-3 
 
Figure 7 The Fmoc deprotection protocol of the Pioneer peptide synthesizer indicates the coupling of the amino 
acids of peptide-3. 
. 
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Figure 8 HPLC chromatogram of the purified peptide-3 before labeling with fluorescein-5-maleimide (F5M). 
 
Figure 9 MALDI-TOF spectrum of peptide-3 (pure) before it was labeled with fluorescein-5-maleimide (F5M). 
Peptide-3 was purified and chemically coupled to fluorescein-5-maleimide (F5M), then it was 
purified by RP-HPLC. Further analysis and mass determination confirmed the successful 
synthesis of fluorescent peptides. See figures 10 and 11.  
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Figure 10  HPLC chromatogram of peptide-3 after labeling with fluorescein-5-maleimide. 
 
Figure 11 The MALDI-TOF spectrum shows the expected mass of the purified peptide-3. 
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2 Appendix-II: Fmoc solid phase synthesis of the potentially Sec-
interfering peptides 
Table 5.2 List of the potentially Sec- interfering peptides and their controls synthesized by Fmoc solid phase peptide 
synthesis. 
Construct Sequence monoisotopic 
mass 
Empirical 
mass 
Peptide A KGKFLKVSSLFVATLTTATLVSSPAANA-YGRKKRRQRRR-NH2 4362.5 4362 
Peptide B MKGKFLKVSSLFVATLTTATLVSSPAANA-YGRKKRRQRRR-NH2 4492.6 4493 
Peptide C For-MKGKFLKVSSLFVATLTTATLVSSPAANA-YGRKKRRQRRR-NH2 4520.6 4521 
Peptide D YGRKKRRQRRRC-NH2 1658.9 1662 
Peptide E KGKFLKVSSLFVATLTTATLVSSPAANA-NH2 2820.6 2821 
Peptide F MKGKFLKVSSLFVATLTTATLVSSPAANA-NH2 2951.7 2951 
Peptide G For-MKGKFLKVSSLFVATLTTATLVSSPAANA-NH2 2979.6 2980 
Peptide H AAMGNSFVLSTLTKTKPAFLTLVASASVK-YGRKKRRQRRR-NH2 4492.6 4494 
2.1 Peptide A 
 
Figure 12 The Fmoc deprotection protocol of the Pioneer peptide synthesizer indicates successful amino acid 
couplings of peptide A. 
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Figure 13 The HPLC chromatogram of the purified peptide A shows a single peak. 
 
 
Figure 14 The MALDI-TOF spectrum shows the expected mass of the purified peptide A, while the small peak 
at m/z 2181 is the double-charged mass of peptide A. 
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2.2 Peptide B 
 
Figure 15 The HPLC chromatogram of the purified peptide B shows a majorproduct peak with a late peak of 
unkown identity. 
 
 
Figure 16 The MALDI-TOF spectrum shows the expected mass of the purified peptide B, while the mass at m/z 
2247 is the double charged mass of peptide B. 
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2.3 Peptide C 
 
Figure 17 The HPLC chromatogram of the purified peptide C shows a single peak with a shoulder of a non-
separable byproduct. 
 
 
Figure 18 The MALDI-TOF spectrum shows a corresponding mass of the purified peptide C, while the peak at 
m/z 2261.86 is the double-charged mass of peptide C. 
. 
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3 Appendix-III: Fmoc solid phase synthesis of the control peptides 
3.1 Peptide D 
 
Figure 19 The Fmoc deprotection protocol of the Pioneer peptide synthesizerindicates a successful coupling of 
the amino acids of peptide D. 
 
 
Figure 20 The HPLC chromatogram of the purified peptide D shows a single peak. 
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Figure 21 The MALDI-TOF spectrum shows the expected meausred mass of the purified peptide D at m/z 1663. 
3.2 Peptide E 
 
Figure 22 The Fmoc deprotection protocol of the Pioneer peptide synthesizer indicates a successful coupling of 
the amino acids of peptide E. 
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Figure 23 The HPLC chromatogram of the purified peptide E shows a single peak. 
 
 
Figure 24 The MALDI-TOF spectrum shows the expected mass of the purified peptide E at m/z 2821 together 
with impurities. 
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3.3 Peptide F 
 
Figure 25 Fmoc deprotection protocol of the Pioneer peptide synthesizer: amino acid couplings of peptide F. 
 
 
Figure 26 The HPLC chromatogram of the purified peptide F shows a single peak. 
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Figure 27 The MALDI-TOF spectrum shows the expected mass of the purified peptide F at m/z 2952 together 
with impurities. 
3.4 Peptide G 
 
Figure 28 Fmoc deprotection protocol of the Pioneer peptide synthesizer: amino acid couplings of peptide G. 
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Figure 29 The HPLC chromatogram of the purified peptide G shows non-separable byproducts. 
 
Figure 30 The MALDI-TOF spectrum shows a major peak of the purified peptide G at m/z 2980. 
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3.5 Peptide H 
 
Figure 31 Fmoc deprotection protocol of the Pioneer peptide synthesizer: amino acid couplings of peptide H. 
 
 
Figure 32 The HPLC chromatogram of the purified scrambled sequence (peptide H) shows a single peak. 
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Figure Error! Use the Home tab to apply 0 to the text that you want to appear here.33 The MALDI-TOF spectrum 
shows a major peak of the purified peptide H at m/z 4494. 
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3.6 Peptide I  
 
Figure 34.The HPLC chromatogram of the purified peptide I shows a major peak. 
 
Figure 35 The MALDI-TOF spectrum shows the expected mass of the purified peptide I at m/z 4596, while the 
peak at m/z 2298 shows the double charged-mass of peptide I. 
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Figure 36 The HPLC chromatogram of the purified fluorescein-conjugated peptide B with added cysteine 
residue shows a major peak. 
 
Figure 37 The MALDI-TOF spectrum shows two peaks of the purified fluorescein-conjugated peptide B at m/z 
5043 and at m/z 2522 (double charged). 
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3.7 Peptide J (Peptide C with cysteine residue) 
 
Figure 38 The HPLC chromatogram of the purified fluorescein-conjugated peptide C with added cysteine 
residue shows a single major peak with non-separable byproducts. 
 
Figure 39 The MALDI-TOF spectrum shows a major mass of the purified peptide C with added cysteine residue 
together with impurities. 
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Figure 40 The HPLC chromatogram of the purified fluorescein-conjugated peptide C shows a major peak. 
 
Figure 41 The MALDI-TOF spectrum shows peaks of the mono and double charged mass at m/z 5073.356 and 
m/z 2535.78 of the purified fluorescein-conjugated peptide C with added cysteine residue. 
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4 Appendix-IV: Testing the peptide uptake by Staphylococcus aureus 
V8 strain 
A B C 
Figure 42 Images from the confocal laser microscope at a specific z-value. 
The images show the 3D distribution of the fluorescent peptide-3 in Staphylococcus aureus. A Staphylococcus aureus cells 
visible filter. B Staphylococcal cells under the fluorescence filter (at λ520 nm). C shows the pictures A and B superimposed. 
4.1 Fluorescence activated cell scanning (FACS) analysis: 
 
Figure 43 FACS analysis of staphylococcal cells incubated with peptide-1 and propidium iodide. 
A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). B: gated populations from the labeled cell vs, dead 
cells. C: visual quantification of the population for the counted cells in the gated area. Area 1: background. Area 2: the 
counted live cells. Area 3: counted dead cells. All dot plots were produced by FlowJo software. 
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Figure 44 FACS analysis of staphylococcal cells incubated with peptide-2 and propidium iodide. 
A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). B: gated populations from the labeled cell vs, dead 
cells. C: visual quantification of the population for the counted cells in the gated area. Area 1: background. Area 2: the 
counted live cells. Area 3: counted dead cells. All dot plots were produced by FlowJo software. 
 
Figure 45 FACS analysis of staphylococcal cells incubated with peptide-3 and propidium iodide. 
A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). B: gated populations from the labeled cell vs, dead 
cells. C: visual quantification of the population for the counted cells in the gated area. Area 1: background. Area 2: the 
counted live cells. Area 3: counted dead cells. All dot plots were produced by FlowJo software. 
 
Figure 46 FACS analysis of staphylococcal cells incubated with SYBR-green (all live cells). 
A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). B: gated populations from the labeled cell vs, dead 
cells. C: visual quantification of the population for the counted cells in the gated area. Area 1: background. Area 2: the 
counted live cells. Area 3: counted dead cells. All dot plots were produced by FlowJo software. 
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Figure 47 FACS analysis of staphylococcal cells incubated with propidium iodide (all dead cells). 
A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). B: gated populations from the labeled cell vs, dead 
cells. C: visual quantification of the population for the counted cells in the gated area. Area 1: background. Area 2: the 
counted live cells. Area 3: counted dead cells. All dot plots were produced by FlowJo software. 
 
Figure 48 FACS analysis of staphylococcal cells incubated with peptide-1 only. 
A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). B: gated populations from the labeled cell vs, dead 
cells. C: visual quantification of the population for the counted cells in the gated area. Area 1: background. Area 2: the 
counted live cells. Area 3: counted dead cells. All dot plots were produced by FlowJo software. 
 
Figure 49 FACS analysis of staphylococcal cells incubated with peptide-2 only. 
A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). B: gated populations from the labeled cell vs, dead 
cells. C: visual quantification of the population for the counted cells in the gated area. Area 1: background. Area 2: the 
counted live cells. Area 3: counted dead cells. All dot plots were produced by FlowJo software. 
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Figure 50 FACS analysis of staphylococcal cells incubated with peptide-3 only. 
A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). B: gated populations from the labeled cell vs, dead 
cells. C: visual quantification of the population for the counted cells in the gated area. Area 1: background. Area 2: the 
counted live cells. Area 3: counted dead cells. All dot plots were produced by FlowJo software. 
 
Figure 51 FACS analysis of staphylococcal cells incubated with SYBR-green (all cells). 
A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). B: gated populations from the labeled cell vs, dead 
cells. C: visual quantification of the population for the counted cells in the gated area. Area 1: background. Area 2: the 
counted live cells. Area 3: counted dead cells. All dot plots were produced by FlowJo software. 
 
Figure 52 FACS analysis of staphylococcal cells incubated with peptide-1 and propidium iodide. 
A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). B: gated populations from the labeled cell vs, dead 
cells. C: visual quantification of the population for the counted cells in the gated area. Area 1: background. Area 2: the 
counted live cells. Area 3: counted dead cells. All dot plots were produced by FlowJo software. 
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Figure 53 FACS analysis of staphylococcal cells incubated with peptide-2 and propidium iodide. 
A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). B: gated populations from the labeled cell vs, dead 
cells. C: visual quantification of the population for the counted cells in the gated area. Area 1: background. Area 2: the 
counted live cells. Area 3: counted dead cells. All dot plots were produced by FlowJo software. 
 
Figure 54 FACS analysis of staphylococcal cells incubated with peptide-3 and propidium iodide. 
A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). B: gated populations from the labeled cell vs, dead 
cells. C: visual quantification of the population for the counted cells in the gated area. Area 1: background. Area 2: the 
counted live cells. Area 3: counted dead cells. All dot plots were produced by FlowJo software. 
 
Figure 55 FACS analysis of staphylococcal cells incubated with peptide-J and propidium iodide. 
A: sideward fluorescence scattering (SSC) vs, forward scattering (FSC). B: gated populations from the labeled cell vs, dead 
cells. C: visual quantification of the population for the counted cells in the gated area. Area 1: background. Area 2: the 
counted live cells. Area 3: counted dead cells. All dot plots were produced by FlowJo software. 
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5 Appendix-V: Fluorogenic assay to detect V8 protease in the 
supernatant using the substrate ABz-AFAFEVFY(NO2)D 
 
Figure 56 The competitive inhibitory effect of the BHI contents on the cleavage rate of the substrate in the 
supernatant. 
 
Figure 57 Increased reactivity of the cleavage was associated with diluting the supernatant in the 
fluorogenic assay (BM medium). 
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Figure 58 The effect of the medium components on the rate of cleaving the fluorogenic substrate by the secreted 
V8 protease. 
The rate of cleavage of the fluorogenic substrate ABz-AFAFEVFY(NO2)D decreased when the culture 
supernatants were diluted with HEPES buffer (0: only Hepes buffer, 10: supernatants were diluted 1:9, 20: 
supernatants were diluted 2:8, 100: supernatant was not diluted with HEPES. Five culture media were used: 
BHI, BM, LB, T, and TSB. 
5.1 Studying the effect of the peptides on the secretion of the Sec-dependent 
protein (V8 protease) 
 
Figure 59 The reactivity of commercial V8 protease in the fluorogenic assay. 
The initial velocity was represented by the fluorescence increase in the first 10 min of the reaction. 
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Figure 60 WB analysis of the secreted V8 protease in the supernatants. 
The quantified bands of V8 protease in nine bacterial cultures non-treated/treated with 10 µM peptides A to H. 
The error bars represent the standard deviation values generated from three individual experiments. 
 
 
Figure 61 The reactivity of the secreted V8 protease in the supernatant as measured in the fluorogenic assay.  
The initial velocity is represented by the fluorescence increase in the first 10 min of the reaction. 
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6 Appendix-VI: Sequence alignment analysis of the Sec secretion 
signal peptides from Staphylococcus aureus 
The hallmark in the signal sequences of the Sec-dependent proteins is the Spase cleavage box 
AxAA at the C domain, in addition to the positively charged N domain and the hydrophobic H 
domain. 
N-domain H-Domain C-Domain 
 
Figure 62 Multiple alignments of staphylococcal secretion signal peptides. 
Multiple alignments of the staphylococcal secretion signal peptides are important tools in 
studying sequences. The basic information they provide is the identification of conserved 
sequence regions. This is very useful in designing experiments to test and modify the function of 
specific proteins, in predicting the function and structure of proteins and in identifying new 
members of protein families. By means of the software JALVIEW or the website 
http://www.ebi.ac.uk/Tools/sequence.html some useful parameters can be tested. The similarities 
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of the sequence alignment of both V8 protease and other staphylococcal signal peptides can be 
investigated as well. The multiple sequence alignment program ClustalW2 was used at the URL: 
http://www.ebi.ac.uk/Tools/msa/clustalw2/ 
 
Figure 63 Signal peptide alignment of 18 Sec-dependent proteins from Staphylococcus aureus.  
 
Figure 64 The similarity of hydrophobicity of the studied signal sequences. 
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Table 6.1 Analysis of signal peptide alignment of 18 Sec-dependent proteins known in S. aureus. 
The table compares the degree of similarity using the peptide alignment for eighteen secretion 
signal sequences from S. aureus. The score is ordered from the highest to the lowest value of 
similarity. The signal sequences of the Gly-hydrolase and the lipase show the highest score at 45.71. 
Sequence A Length Sequence B Length Score 
Gly-hydrolase 35 Lipase 37 45.7143 
Enterotoxin 22 Phos-phosphodiesterase 26 40.9091 
Staphylokinase 27 Staphopain 26 38.4615 
Glu-C-endoproteinase 29 IgG-binding-protein 29 37.931 
Immun-antigen-A 29 Enterotoxin 22 36.3636 
Serine-Protease-C 37 Staphopain 26 34.6154 
Beta-hemolysin 34 Phos-phosphodiesterase 26 34.6154 
Glu-C-endoproteinase 29 Beta-hemolysin 34 34.4828 
Serine-Protease-C 37 Immun-antigen-A 29 34.4828 
Gly-hydrolase 35 Aureolysin 28 32.1429 
Serine-Protease-A 35 Enterotoxin 22 31.8182 
Enterotoxin 22 Staphopain 26 31.8182 
Beta-hemolysin 34 IgG-binding-protein 29 31.0345 
IgG-binding-protein 29 Gly-hydrolase 35 31.0345 
EnterotoxineB 27 Staphopain 26 30.7692 
Immun-antigen-A 29 Phos-phosphodiesterase 26 30.7692 
Serine-Protease-A 35 Staphylokinase 27 29.6296 
Serine-Protease-A 35 Secretory 27 29.6296 
Aureolysin 28 Secretory 27 29.6296 
Glu-C-endoproteinase 29 Aureolysin 28 28.5714 
Serine-Protease-C 37 Aureolysin 28 28.5714 
Lipase 37 Aureolysin 28 28.5714 
EnterotoxineB 27 Enterotoxin 22 27.2727 
Beta-hemolysin 34 Enterotoxin 22 27.2727 
LeukotoxinD 26 Enterotoxin 22 27.2727 
Enterotoxin 22 Gly-hydrolase 35 27.2727 
Enterotoxin 22 Secretory 27 27.2727 
EnterotoxineB 27 LeukotoxinD 26 26.9231 
Glu-C-endoproteinase 29 Alpha-hemolysin 26 26.9231 
Glu-C-endoproteinase 29 Staphopain 26 26.9231 
Serine-Protease-A 35 Staphopain 26 26.9231 
Serine-Protease-C 37 LeukotoxinD 26 26.9231 
Alpha-hemolysin 26 Staphylokinase 27 26.9231 
Alpha-hemolysin 26 Secretory 27 26.9231 
Beta-hemolysin 34 LeukotoxinD 26 26.9231 
Beta-hemolysin 34 Staphopain 26 26.9231 
LeukotoxinD 26 Immun-antigen-A 29 26.9231 
LeukotoxinD 26 Autolysin 29 26.9231 
LeukotoxinD 26 Gly-hydrolase 35 26.9231 
LeukotoxinD 26 Aureolysin 28 26.9231 
LeukotoxinD 26 Staphopain 26 26.9231 
Immun-antigen-A 29 Staphopain 26 26.9231 
Aureolysin 28 Staphopain 26 26.9231 
Secretory 27 Phos-phosphodiesterase 26 26.9231 
EnterotoxineB 27 Staphylokinase 27 25.9259 
Glu-C-endoproteinase 29 Staphylokinase 27 25.9259 
Glu-C-endoproteinase 29 Secretory 27 25.9259 
Immun-antigen-A 29 Secretory 27 25.9259 
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Autolysin 29 Secretory 27 25.9259 
Beta-hemolysin 34 Aureolysin 28 25.0 
Autolysin 29 Aureolysin 28 25.0 
Glu-C-endoproteinase 29 Immun-antigen-A 29 24.1379 
Glu-C-endoproteinase 29 Autolysin 29 24.1379 
Glu-C-endoproteinase 29 Lipase 37 24.1379 
Serine-Protease-C 37 IgG-binding-protein 29 24.1379 
Beta-hemolysin 34 Immun-antigen-A 29 24.1379 
Immun-antigen-A 29 Autolysin 29 24.1379 
Immun-antigen-A 29 IgG-binding-protein 29 24.1379 
IgG-binding-protein 29 Lipase 37 24.1379 
EnterotoxineB 27 Alpha-hemolysin 26 23.0769 
Glu-C-endoproteinase 29 LeukotoxinD 26 23.0769 
Serine-Protease-C 37 Alpha-hemolysin 26 23.0769 
Serine-Protease-C 37 Phos-phosphodiesterase 26 23.0769 
Alpha-hemolysin 26 Beta-hemolysin 34 23.0769 
Alpha-hemolysin 26 Immun-antigen-A 29 23.0769 
Alpha-hemolysin 26 Aureolysin 28 23.0769 
Alpha-hemolysin 26 Staphopain 26 23.0769 
Alpha-hemolysin 26 Phos-phosphodiesterase 26 23.0769 
Autolysin 29 Phos-phosphodiesterase 26 23.0769 
Gly-hydrolase 35 Staphopain 26 23.0769 
Aureolysin 28 Phos-phosphodiesterase 26 23.0769 
Serine-Protease-A 35 Serine-Protease-C 37 22.8571 
Glu-C-endoproteinase 29 Enterotoxin 22 22.7273 
Serine-Protease-C 37 Enterotoxin 22 22.7273 
Alpha-hemolysin 26 Enterotoxin 22 22.7273 
Autolysin 29 Enterotoxin 22 22.7273 
Enterotoxin 22 IgG-binding-protein 29 22.7273 
Enterotoxin 22 Lipase 37 22.7273 
Enterotoxin 22 Staphylokinase 27 22.7273 
EnterotoxineB 27 Serine-Protease-C 37 22.2222 
EnterotoxineB 27 Autolysin 29 22.2222 
EnterotoxineB 27 Lipase 37 22.2222 
Serine-Protease-C 37 Secretory 27 22.2222 
Beta-hemolysin 34 Staphylokinase 27 22.2222 
Beta-hemolysin 34 Secretory 27 22.2222 
Autolysin 29 Staphylokinase 27 22.2222 
IgG-binding-protein 29 Secretory 27 22.2222 
Gly-hydrolase 35 Secretory 27 22.2222 
Serine-Protease-A 35 Aureolysin 28 21.4286 
Immun-antigen-A 29 Aureolysin 28 21.4286 
Glu-C-endoproteinase 29 Serine-Protease-A 35 20.6897 
Glu-C-endoproteinase 29 Serine-Protease-C 37 20.6897 
Glu-C-endoproteinase 29 Gly-hydrolase 35 20.6897 
Serine-Protease-A 35 Immun-antigen-A 29 20.6897 
Serine-Protease-A 35 Autolysin 29 20.6897 
Serine-Protease-C 37 Autolysin 29 20.6897 
Immun-antigen-A 29 Gly-hydrolase 35 20.6897 
Autolysin 29 IgG-binding-protein 29 20.6897 
Autolysin 29 Gly-hydrolase 35 20.6897 
Autolysin 29 Lipase 37 20.6897 
Glu-C-endoproteinase 29 Phos-phosphodiesterase 26 19.2308 
Serine-Protease-A 35 Alpha-hemolysin 26 19.2308 
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Serine-Protease-A 35 LeukotoxinD 26 19.2308 
Serine-Protease-A 35 Phos-phosphodiesterase 26 19.2308 
Alpha-hemolysin 26 LeukotoxinD 26 19.2308 
Alpha-hemolysin 26 Autolysin 29 19.2308 
Alpha-hemolysin 26 IgG-binding-protein 29 19.2308 
Alpha-hemolysin 26 Gly-hydrolase 35 19.2308 
Alpha-hemolysin 26 Lipase 37 19.2308 
LeukotoxinD 26 IgG-binding-protein 29 19.2308 
LeukotoxinD 26 Lipase 37 19.2308 
LeukotoxinD 26 Staphylokinase 27 19.2308 
LeukotoxinD 26 Secretory 27 19.2308 
LeukotoxinD 26 Phos-phosphodiesterase 26 19.2308 
Autolysin 29 Staphopain 26 19.2308 
IgG-binding-protein 29 Staphopain 26 19.2308 
Gly-hydrolase 35 Phos-phosphodiesterase 26 19.2308 
Lipase 37 Staphopain 26 19.2308 
Staphylokinase 27 Phos-phosphodiesterase 26 19.2308 
Staphopain 26 Phos-phosphodiesterase 26 19.2308 
EnterotoxineB 27 Glu-C-endoproteinase 29 18.5185 
EnterotoxineB 27 Serine-Protease-A 35 18.5185 
EnterotoxineB 27 Beta-hemolysin 34 18.5185 
EnterotoxineB 27 IgG-binding-protein 29 18.5185 
EnterotoxineB 27 Gly-hydrolase 35 18.5185 
EnterotoxineB 27 Aureolysin 28 18.5185 
EnterotoxineB 27 Secretory 27 18.5185 
Serine-Protease-C 37 Staphylokinase 27 18.5185 
Gly-hydrolase 35 Staphylokinase 27 18.5185 
Lipase 37 Secretory 27 18.5185 
Aureolysin 28 Staphylokinase 27 18.5185 
Enterotoxin 22 Aureolysin 28 18.1818 
IgG-binding-protein 29 Aureolysin 28 17.8571 
Serine-Protease-C 37 Beta-hemolysin 34 17.6471 
Beta-hemolysin 34 Gly-hydrolase 35 17.6471 
Serine-Protease-A 35 IgG-binding-protein 29 17.2414 
Beta-hemolysin 34 Autolysin 29 17.2414 
Immun-antigen-A 29 Lipase 37 17.2414 
Serine-Protease-C 37 Gly-hydrolase 35 17.1429 
Serine-Protease-C 37 Lipase 37 16.2162 
EnterotoxineB 27 Phos-phosphodiesterase 26 15.3846 
IgG-binding-protein 29 Phos-phosphodiesterase 26 15.3846 
Lipase 37 Phos-phosphodiesterase 26 15.3846 
Staphopain 26 Secretory 27 15.3846 
EnterotoxineB 27 Immun-antigen-A 29 14.8148 
Immun-antigen-A 29 Staphylokinase 27 14.8148 
IgG-binding-protein 29 Staphylokinase 27 14.8148 
Lipase 37 Staphylokinase 27 14.8148 
Staphylokinase 27 Secretory 27 14.8148 
Serine-Protease-A 35 Beta-hemolysin 34 14.7059 
Beta-hemolysin 34 Lipase 37 14.7059 
Serine-Protease-A 35 Gly-hydrolase 35 14.2857 
Serine-Protease-A 35 Lipase 37 14.2857 
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7 Appendix-VII: Comparison of the cellular proteomes in the presence 
and absence of peptide A. 
7.1 Supernatant proteins 
 
 
 
Figure 65 Comparison of the supernatant proteins between the peptide-treated and the non-treated cells. 
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7.2 Cell wall and periplasm proteins 
 
Figure 66 Comparison of the cell wall and periplasm proteins between the peptide-treated and the non-treated 
cells. 
7.3 Cytosolic proteins 
 
Figure 67 Comparison of the cytosolic proteins between the peptide-treated and the non-treated cells. 
7.4 Membrane proteins 
 
Figure 68 Comparison of the membrane proteins between the peptide-treated and the non-treated cells. 
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8 Appendix-VIII: Amino acids used in this study  
Three letter code One letter code Description Mw 
Ala A L-Alanine 89.09 
Arg R L-Arginine 174.2 
Asn N L-Asparagine 132.12 
Asp D L-Aspartic acid 133.1 
Cys C L-Cystein 121.16 
Gln Q L-Glutamine 146.15 
Glu E L-Glutamic acid 147.12 
Gly G L-Glycin 75.07 
His H L-Histidine 155.16 
Ile I L-Isoleucine 131.18 
Leu L L-Leucine 131.18 
Lys K L-Lysine 146.19 
Met M L-Methionine 149.21 
Phe F L-Phenylalanine 165.19 
Pro p L-Proline 115.13 
Ser S L-Serine 105.09 
Thr T L-Thrionine 119.12 
Trp W L-Tryptophane 204.23 
Tyr Y L-Tyrosine 181.19 
Val V L-Valine 117.15 
 
